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ABSTRACT 
 
This thesis describes the chemoenzymatic synthesis of three morphine alkaloids. The 
total synthesis of dihydrocodeine and hydrocodone was accomplished starting from 
bromobenzene in 16 and 17 steps, respectively. The key steps included a microbial 
oxidation of bromobenzene by E. coli JM109 (pDTG601A), a Kazmaier-Claisen 
rearrangement of glycinate ester to generate C-9 and C-14 stereo centers, a Johnson-
Claisen rearrangement to set the C-13 quaternary center, and a C-10/C-11 ring closure via 
a Friedel-Crafts reaction. 
In addition, the total synthesis of ent-hydromorphone starting from β-bromoethylbenzene 
in 12 steps is also described. The key reactions included the enzymatic dihydroxylation of 
β-bromoethylbenzene to the corresponding cis-cyclohexadienediol, a Mitsunobu reaction, 
and an oxidative dearomatization followed by an intramolecular [4+2] cycloaddition. 
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1. Introduction 
 
 Morphine (1), Figure 1, is a naturally occurring alkaloid found in opium, which is 
the latex of the poppy plant, Papaver somniferum, and is one of the oldest drugs known 
to man. It is the most abundant alkaloid found in opium along with other related alkaloids 
such as codeine (2), thebaine (3) and others. Morphine, along with its congeners and 
semi-synthetic derivatives, is one of the most potent and commonly used analgesics, and 
all these compounds used in the medicinal field are obtained from natural sources 
followed by semi synthesis.
1
  
 
 
 
Figure 1: Naturally occurring opiate alkaloids. 
More than 40 total and formal syntheses of morphinans are known so far but none of 
them meet the requirement of a truly practical synthesis. Although morphine does not 
present a highly complex structure, its unique pentacyclic core with five contiguous 
stereogenic centers makes it a challenging target for the synthetic chemist.
2
 The 
development of a practical route for the synthesis of morphine alkaloids has been a long 
standing goal in the Hudlický group. Our current approach begins with the enzymatic 
dihydroxylation of substituted benzenes to obtain the chiral cis-cyclohexadienediols, 
Figure 2. 
2 
 
 
Figure 2: Chemoenzymatic approach to morphine alkaloids. 
This thesis presents two approaches to these challenging targets. The first approach relies 
on two successive Claisen rearrangements: a Kazmaier-Claisen rearrangement
3
 and 
Johnson-Claisen rearrangement
4
. The Kazmaier-Claisen rearrangement involves a [3,3]- 
sigmatropic rearrangement of a chelated enolate 8, Figure 3, which will be useful to set 
the C-14 and C-9 stereocenters in morphine with remarkably high diastereoselectivity. A 
second Claisen rearrangement, the Johnson variant, will create the challenging C-13 
quaternary center at 11 through intermediate 10, Figure 3. This thesis presents the 
construction of this vital part of the molecule and further studies towards the completion 
of the synthesis of dihydrocodeine and hydrocodone. 
3 
 
  
Figure 3: Double Claisen approach towards morphine alkaloids. 
 
The second approach relies upon an unusual cycloaddition strategy, which  involves an 
enzymatic dihydroxylation of the β-bromoethylbenzene 5, to provide diene diol 7, Figure 
2, which will be tethered to the aromatic ring by a Mitsunobu reaction to access ether 13, 
Figure 4. Dearomatization of ether 13 will provide dienone 14, which will undergo a 
cycloaddition reaction to provide tetracycle 15, Figure 4. The rapid construction of the 
tetracyclic core of morphine including A, B, C and E rings and the completion of the 
synthesis of ent-hydromorphone 16, Figure 4, will be presented.  
 
 
 
4 
 
 
Figure 4: Dearomatization/cycloaddition approach towards morphine alkaloids. 
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2. Historical 
 
2.1 Microbial Oxidation of Arenes 
2.1.1 History of microbial oxidation of arenes 
The process of fermentation for the production of different kinds of food has been 
known to mankind for many centuries. The earliest evidence of mankind using this 
process dates back to 5400–5000 BC. Analysis of a pottery jar found in Iran‟s northern 
Zagros mountains suggested that Neolithic man fermented grapes to make wine.
5
 In 
1857, Louis Pasteur identified yeast as the organism responsible for alcoholic 
fermentation;
6
 he was successful in oxidising ethanol to acetic acid and was the first to 
show that the reason for this reaction is a living microorganism. The vital force behind 
these transformations was called „ferments‟, which were active only in living organisms.7  
Later in 1886, based on Pasteur‟s observations, Brown devised a series of  experiments 
and was able to oxidize different kinds of alcohols to the corresponding acids along with 
oxidation of dextrose to gluconic acid and mannitol to laevulose (fructose) using 
Bacterium aceti,
8
 which is credited as the first use of biocatalysis.
9
  
The study of enzymes dates back to 1833, when „diastase‟ (a substance isolated from malt 
extract) was found to degrade starch.
10
 The commonly used '-ase' suffix came from 
diastase, which is believed to be the first enzyme ever isolated. At the end of the 19
th
 
century, Fischer studied the metabolism of carbohydrates by yeast
11
 and also came up 
with a new theory for the action of enzymes, which is now well-known as the “lock and 
key” model.12 This model explains why enzymes can react specifically with some 
compounds, but this theory fails to explain the reactivity of the same functional group 
attached to different compounds with severe difference in size. Later in 1958, Daniel 
6 
 
Koshland amended this theory to an “induced fit” model, in which a conformational 
change was induced by the interaction between the enzyme and substrate.
13
 The credit for 
the first use of an isolated enzyme in chemistry goes to Dakin for the kinetic resolution of 
racemic ethyl mandelate by crude pig liver lipase.
14
 
The detailed study of the microbial metabolism of hydrocarbons started only in the 
beginning of the 20
th
 century.
15
 Consumption of toluene and xylene by the Bacillus 
hexacarbavorum bacterium was reported in 1908.
16
 Later studies by Söhngen revealed a 
bacterium, Bacillus pyocyaneum, that can survive various concentrations of benzene.
17
 In 
1935, trans-1,2-dihydroxy-1,2-dihydroanthracene, a product of mammalian metabolism 
of anthracene was isolated, which was the first dihydrodiol metabolite isolated.
18
 
Subsequent studies by Haccius and Helfrich with the organism Nocardia coralline 
determined that catechol was the major product from the fermentation of benzene.
19
 
Initially, it was postulated that a phenol was formed as an intermediate during this 
process. However, Marr and Stone argued that the formation of a trans-l,2-
dihydrocyclohexa-3,5-diene, resulting from hydrolysis of an epoxide is more favourable 
than the formation of a phenol intermediate. Their studies using two soil bacterial strains, 
P. aeruginosaand Mycobacterium rhodochrous, showed that both strains oxidized 
benzene to catechol, but did not oxidize phenols.
20
 These results, along with the studies 
by Young on naphthalene degradation in rats, in which he reported the isolation of the 
1,2-dihydronaphthalene-1,2-diol,
21
 gave  ample support to this hypothesis.  
In eukaryotic organisms, cytochromes oxidize aromatics to the corresponding arene 
oxides, which can be opened by different nucleophiles.
9
 However, in prokaryotic 
organisms, the dioxygen molecule bound to dioxygenase enzyme oxidises the aromatics 
7 
 
to the corresponding cis-dihydrodiols which are then further oxidised to catechols.
9
 In 
1968, Gibson reported the degradation of benzene, ethylbenzene and toluene by a strain 
of Pseudomonas putida.
22
 His studies found that all these aromatic hydrocarbons were 
oxidized at the same rate by the cell-extracts obtained from the organism. The incubation 
of the organism with both cis- and trans-cyclohexa-3,5-diene-1,2-diols revealed that the 
cis-isomer was oxidized approximately six times faster than its trans-isomer. This 
successful oxidation of cis-benzene glycol to catechol along with the absence of a phenol 
during this process led them to the conclusion that the first step of the oxidation is not the 
formation of an epoxide. Gibson proposed a mechanism for the oxidation of aromatics 
which involves a dioxetane 18, Figure 5.  
 
 
Figure 5: Gibson‟s proposed pathway for aromatic oxidation. 
 
Since the early 1950‟s a vast amount of research has been carried out on mechanistic 
studies aiming to elucidate the pathway(s) for the formation of diols and catechols from 
aromatic precursors. In 1960, Booth and co-workers incubated benzene and naphthalene 
with NADPH, 
18
O2 and rat liver microsomes.
23
 These studies showed incorporation of 
only one labelled atom of oxygen, which indicated the formation of an epoxide as an 
intermediate and the opening of the epoxide in a trans-diaxial fashion to obtain a trans-
1,2-dihydrodiol 27, Figure 7.  
8 
 
Gibson began to work on more diversely substituted intermediates to provide stronger 
evidence for the proposed dioxetane intermediate 18. In 1968, he was able to isolate the 
first stable cis-dihydrodiol [(+)-cis-4-chloro-2,3-dihydroxy-1-methylcyclohexa-4,6-diene] 
22, Figure 6, from p-chlorotoluene by the action of soil bacteria P. putida.
24
 The 
unknown compound obtained together with the catechol 23, Figure 6, was treated with 
acid, which gave them a mixture of phenols, 24 and 25, Figure 6. During these studies, he 
observed that the halogenated aromatics were metabolised at a slower rate with 
increasing size of the halogen, to give corresponding catechols.  
 
 
Figure 6: Degradation of p-chlorotoluene by soil bacteria P. putida. 
In 1970, Gibson proposed an iron-mediated reaction of molecular oxygen with aromatics 
for the formation of cis-dihydrodiols. Incubation of P. putida with benzene and 
18
O2 
provided cis-l,2-dihydrocyclohexa-3,5-diene 30, Figure 7, these isotopic labelling studies 
revealed that both oxygen atoms present in cis-dihydrodiol came from the same 
9 
 
molecule.
25
 These studies showed that the mechanism for the oxidation of aromatic 
compounds in microbes differed from those in mammalian systems.  
Cytochrome P450‟s are known to be responsible for the degradation of aromatic 
compounds in mammalian organism through an epoxide intermediate 26, Figure 7.
26
 This 
epoxide can be hydrolysed to yield an unstable trans-1,2-diydrodiol 27, which undergoes 
a dehydration reaction to give phenols 28 and 29. In dioxygenase enzymes
27
 two oxygen 
atoms are incorporated from dioxygen and further oxidation by a second enzyme called 
catechol dehydrogenase results in the formation of the final product as a catechol 31, 
Figure 7. 
 
 
Figure 7: Divergent pathways for the degradation of aromatics in microbes and 
mammalian systems. 
 
In 1970, Gibson reported the accumulation of cis-2,3-dihydroxy-l-methylcyclohexa-4,6-
dien 33, Figure 8, by the incubation of a mutant strain of P. putida 39/D with toluene. He 
10 
 
was able to generate the mutant strain of the parent organism by the incubation of the 
wild strains of the Pseudomonas putida with N-methyl-N-nitrosoguanidine. This mutant 
strain was devoid of the ability to carry out the second oxidation of the 1,2-dihydrodiene 
diol. The NMR data of 2,3-dihydroxy-l-methylcyclohexa-4,6-diene 33 was inconclusive, 
so a more rigid derivative was synthesized from the cis-dihydroarene diol 33, Figure 8. 
Compound 33 was acetylated, and the diester underwent a Diels-Alder reaction with 
maleic anhydride to provide cycloadduct 35, which was hydrogenated to obtain the 
saturated derivative 36. NMR analysis of this derivative proved the syn relationship 
between vicinal protons Ha and Hb. The formation of cis-dihydroarene diol 33 was 
confirmed by this spectroscopic evidence and the acid catalyzed dehydration of 33 to 
form o-cresol.
28
 
 
 
 
Figure 8: Degradation of toluene by mutant strain P. putida 39/D. 
 
11 
 
After establishing the relative stereochemistry of dihydrodiol 33, Gibson and co-workers 
turned their attention to confirm the absolute stereochemistry of 33. The absolute 
stereochemistry of the cis-dihydrodiol derived from naphthalene had already been 
confirmed by Gibson at that time by NMR studies and by conversion of the dihydrodiol 
to a known compound.
29
 To confirm the absolute stereochemistry of cis-dihydrodiol 33, it 
was hydrogenated to obtain a mixture of products 37, Figure 9, which were separated by 
silica gel chromatography as protected mono benzoates. NMR analysis of the major 
product showed it to be cis,cis-3-methylcyclohexane-l,2-diol 39, Figure 9. Further 
evidence was made available from the comparison between the minor isomer, cis,trans-3-
methylcyclohexane-l,2-diol 38, and a sample made from 3-methylcyclohexene 40, Figure 
9, via an oxidation using OsO4–H2O2, which is well known for the oxidation from the 
least hindered side. The major isomer cis,cis-3-methylcyclohexane-l,2-diol 39, was 
further oxidised to (-)-2(R)-methyladipic acid 41, Figure 9, (a compound with known 
absolute stereochemistry) using Jones reagent. This experiment established the absolute 
stereochemistry of the metabolite 2,3-dihydroxy-l-methylcyclohexa-4,6-diene 33, Figure 
9.
30
 
 
 
12 
 
 
Figure 9: Gibson‟s experiments for absolute stereochemistry proof of metabolite of 
toluene. 
Continuing research in the field of mutant strains resulted in determining the nucleotide 
sequence of the genes responsible for coding the toluene catabolic pathway.
31
 The 
knowledge of this gene sequence was used in the preparation of clones of Escherichia 
coli JM109. The first part of the catabolic pathway was effectively over-expressed in a 
recombinant organism JMl09 (pDTG601), which enables the production of cis-
dihydrodiols. Another recombinant organism JMl09 (pDTG602), which produces  
catechols from either arenes 42 or cis-dihydrodiols 43, Figure 9, was also developed.
31
 
The recombinant organism E. coli JMl09 (pDTG601) and the mutant strain P. putida 
39/D both lack the genes responsible for the oxidation of cis-dihydrodiols to the 
corresponding catechols. Toluene or chlorobenzene was required as an inducer for mutant 
strain P. putida 39/D, which resulted in the formation of mixture of products in the 
screening of new substrates. The recombinant organism JMl09 (pDTG601) uses 
isopropyl β-D-l-thiogalactopyranoside (IPTG) as an inducer, which solved the problem 
associated with the mutant strain P. putida 39/D. The third recombinant organism 
13 
 
developed, JMl09 (pDTG603), metabolized toluene to 2-hydroxy-6-oxo-2,4-
heptadienoate 45 (R = Me), Figure 10, by overexpressing the 1,2-catechol dioxygenase.
31
  
 
 
Figure 10: Comparison of the metabolism of aromatics by soil bacteria, blocked mutants, 
and recombinant strains. 
The mechanism for dihydroxylation using tolune dioxygenase (TDO) still remains 
uncertain. The mechanism proposed by Gibson (Figure 5) is highly unlikely because of 
the presence of high energy intermediates.
9
 Although the X-ray structure of naphthalene 
dioxygenase (NDO, an enzyme that metabolises fused aromatics) has been known since 
2003,
32
 the X-ray structure of TDO remains unknown. The exact mechanism is not 
known but some speculations are provided in Figure 11.  The first mechanism postulated 
by Gibson to explain the cis-stereochemistry of addition proposed the formation of an 
intermediate dioxetane 46, Figure 11, but the formation of such a species would require 
the considerably high-energy cycloaddition of a singlet oxygen species. Hence, another 
mechanism was suggested which involves a [3+2] cycloaddition of an iron (V) peroxide 
14 
 
57, Figure 11, to the aromatic substrate 42 to obtain 53, followed by reduction and 
migration of a hydroxyl group as a possible pathway for the production of cis-
dihydrodiols.
9, 33
 The indole dihydroxylation by NDO through an indole C-3 peroxide 
species  is already known from the work of Ramaswamy in 2000, which supports the iron 
mediated mechanism.
34
  
 
Figure 11: Postulated mechanisms for enzymatic dihydroxylation. 
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2.1.2 Application of aromatic metabolites in synthesis 
A wide variety of cis-dihydrodiols can be obtained from different aromatics using toluene 
dioxygenase and related enzymes. These dihydroxylations are highly regio-, stereo-, and 
enantioselective. A model for predicting the regio- and stereoselectivity was developed 
by Boyd in 1993 based on the results obtained from the cis-dihydroxylation of a series of 
1,4-disubstituted benzene.
35
 This model proposed that as the size difference between the 
substituent increases, regioselectivity and enantioselectivity also improve. 
 
 
Figure 12: Boyd‟s model for predicting the regio- and stereoselectivity of the oxidation 
of single ring aromatics. 
 
More than 400 substrates of toluene dioxygenase and related enzymes have been isolated 
so far, but only a few of these have been used by the synthetic community. The synthesis 
of polyphenylene 60, Figure 13, from the benzene derived cis-dihydrodiol 19, Figure 13, 
by researchers at Imperial Chemical Industries PLC in 1983 is the first known use of 
aromatic metabolites in synthesis.
36
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Figure 13: First application of an aromatic metabolite to synthesis. 
 
Shortly after this, Gibson illustrated another example of synthetic use of cis-dihydrodiols 
by the synthesis of indigo 61 by the dihydroxylation of indole 49, Figure 14, using 
NDO.
37
  
 
 
Figure 14: Synthesis of indigo. 
 
Later in 1987, the synthesis of (±)-pinitol 64 from benzene derived diol 19, Scheme 1, by 
Ley is considered to be the first true exploitation of aromatic metabolites in synthesis, 
which enticed the attention of many synthetic chemists.
38
 Protection of the hydroxyl 
groups of 19 as benzoates and epoxidation leads to a mixture of vinyl oxiranes 62 and 63, 
Scheme 1. Regioselective ring opening of epoxide 63 by MeOH, and a cis-
dihydroxylation using OsO4 followed by hydrolysis of the benzoate esters, provided (±)-
pinitol 64, Scheme 1. 
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Reagents and conditions: (a) BzCl, pyridine, DMAP, 0 °C; (b) mCPBA, DCE, phosphate 
buffer (pH 8); (c) MeOH, (+)-CSA; (d) OsO4, NMO, t-BuOH/THF/H2O (10:3:1); (e) 
Et3N/MeOH/H2O (1:5:1). 
Scheme 1: Ley‟s synthesis of (±)-pinitol. 
 
A year later, the same group reported a synthesis of the cellular secondary messenger 
inositol-1,4,5-trisphosphate (IP3) 66, starting from the benzene derived dihydrodiol 19, 
Figure 15.
39
  
 
 
Figure 15: Synthesis of inositol-1,4,5-trisphosphate IP3. 
 
In 1988, an enantioselective formal synthesis of PGE2α was reported by the Hudlický 
group.
40
 The cis-dihydrodiol 33 obtained from toluene was subjected to ozonolysis after 
protection of the diol functionality as an acetonide.  Concomitant reductive work up and 
neutral alumina-mediated cyclization provided known intermediate 68,
41
 thus completing 
a formal synthesis of PGE2α, Scheme 2. 
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Reagents and conditions: (a) 2,2-dimethoxypropane, p-TsOH, rt; (b) i) O3 (excess), 
EtOAc, –60 °C; ii) Me2S, 0 °C; (c) Al2O3 (neutral), DME, reflux. 
Scheme 2: Enantioselective formal total synthesis of PGE2α by Hudlický. 
 
After the successful synthesis of PGE2α, Hudlický and co-workers reported an 
enantioselective synthesis of (–)-zeylena.42 Enzymatic dihydroxylation of styrene 70, 
Figure 16, provided the corresponding cis-dihydrodiol 71, and a Mitsunobu inversion 
with cinnamic acid led to the intermediate 72. An intramolecular cycloaddition followed 
by further manipulation completed the total synthesis of (–)-zeylena 73, as shown in 
Figure 16. 
 
 
Figure 16: Total synthesis of (–)-zeylena. 
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In 1990, Hudlický and co-workers completed an enantiodivergent synthesis of pinitol 
starting from bromobenzene 4, Scheme 3. The bromo substituent at the C-1 position 
played a significant role in differentiating the double bonds in subsequent regioselective 
reactions.
43
 Protection of the cis-dihydrodiol provided the acetonide 74, which was 
followed by OsO4-mediated cis-dihydroxylation, dehalogenation, and epoxidation to give 
epoxide 75. The regioselective ring opening of the epoxide with MeOH and deprotection 
of the acetonide furnished (–)-pinitol 77. In a similar fashion, epoxidation, ring opening 
and dehalogenation of 74 provided 76; cis-dihydroxylation and deprotection of the 
acetonide yielded (+)-Pinitol 77. 
 
Reagents and conditions: (a) (i) E. coli JM 109 (pDTG601A); (ii) 2,2-dimethoxypropane, 
p-TsOH, rt;  (b) OsO4, NMO, H2O, acetone; (c) LiAIH4, THF; (d) mCPBA, CH2Cl2; (e) 
MeOH, Al2O3; (f) HCl, H2O, acetone. 
Scheme 3: Enantiodivergent synthesis of (+) and (–)-pinitol. 
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Since 1990, more than 50 natural products and their derivatives have been synthesized 
from the cis-dihydrodiol. The first few syntheses that used cis-dihydrodiols have been 
discussed; now only some noteworthy syntheses will be shown. A comprehensive listing 
of applications of cis-dihydrodiol in synthesis can be found in many reviews.
9, 44
 Another 
important application of the biocatalytic method to synthesis was shown by the Hudlický 
group by the elegant synthesis of (+)-lycoricidine 80, Scheme 4, in 1992.
45
 Lycoricidine, 
pancratistatin, and narciclasine are members of the Amaryllidaceae family and show 
considerable potential medicinal activity. Even though several synthetic routes for these 
compounds were developed at that time none of them were shorter than 15 steps. 
Hudlický‟s synthesis started from halobenzene 4, which underwent enzymatic 
dihydroxylation and protection of the diol functionality produced acetonide-protected 
diene 74, which was subjected to a hetero-Diels-Alder cycloaddition with a hetero-
dienophile, reduction of the N–O bond and protection of the alcohol functionality to yield 
compound 78. Acylation of 78 with 6-bromobenzo(1,3)dioxole-5-carbonyl chloride 
delivered imide 79; a modified Heck cyclization and global deprotection furnished (+)-
lycoricidine 80. Later in 1995, the first enantioselective synthesis of (+)-pancratistatin 
was accomplished by Hudlický.
46
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Reagents and conditions: (a) E. coli JM 109 (pDTG601A); (b) (ii) 2,2-dimethoxypropane, 
p-TsOH, rt; (c) benzyl hydroxycarbamate, Bu4NIO4, CH2Cl2; (d) Al(Hg), THF; (e) 
DMIPSCl, imidazole, CH2Cl2; (f) BuLi, THF, –78 °C, then 2-bromopiperonyloyl 
chloride; (g) Pd(OAc), Tl(OAc), DIPHOS, anisole; (h) Pd(C), cyclohexene, EtOH; (i) 
TFA, 0 °C. 
Scheme 4: Hudlický‟s synthesis of (+)-lycoricidine. 
 
Boyd has shown the versatility of cis-dihydrodiols by employing them in the synthesis of 
pseudosugars 85 and 86, Scheme 5.
47
 The metabolite of iodobenzene was converted to 82 
by acetonide protection, cis-dihydroxylation and carbonylation. The hydrogenation of 82 
afforded a mixture of diastereomers, which were separated as the benzoates to obtain 83 
and 84, Scheme 5. Reduction of esters and deprotection of acetonide provided carba-β-D-
altropyranose 85 and carba-α-L-galactopyranose 86, Scheme 5. 
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Reagents and conditions:  (a) 2,2-dimethoxypropane, pTsOH; (b) OsO4, NMO, Me2CO, 
H2O; (c) Pd(OAc)2, CO (1 atm) , NaOAc3H2O, MeOH; (d) 5% Rh/A12O3, EtOH, H2 (55 
psi); (e) BzCI, pyridine; (f) LiAIH4, THF, reflux; (g) TFA-THF-H2O (1:8:2), 50 °C. 
Scheme 5: Boyd‟s synthesis of pseudosugars. 
 
In 2004, Banwell employed the cis-dihydrodiol obtained from toluene in the synthesis of 
(–)-hirsutene 89, Figure 17.48 His synthesis includes 17 steps, and he employed a high 
pressure-induced Diels-Alder cycloaddition and an oxa-di-π-methane rearrangement as 
key steps.    
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Figure 17: Banwell‟s synthesis of (–)-hirsutene. 
 
In 2009, Hudlický and co-workers provided another application of the chemoenzymatic 
approach with their formal synthesis of oseltamivir (Tamiflu
®
) starting from 
ethylbenzoate 90, Scheme 6.
49
 The metabolite of 90, isolated after the biotransformation, 
was subjected to acetonide protection and then reacted with the N-hydroxy acetamide in 
the presence of NaIO4 to provide the bicyclic oxazine 91 by a hetero-Diels-Alder 
cycloaddition. Reduction of the N–O bond and SN2′ substitution of the allylic alcohol led 
to oxazoline 92. This was then hydrolysed to the acetamide and hydrogenation afforded 
the saturated ester that was then converted to azide 93. A base-induced collapse of the 
acetonide completed the formal synthesis of oseltamivir (95) via Fang‟s intermediate 94. 
In 2010, Hudlický reported a shorter, azide free synthesis of oseltamivir starting from the 
same starting material.
50
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Reagents and conditions:  (a) E. coli JM 109 (pDTG601A); (b) 2,2-dimethoxypropane, 
pTsOH; (c) CH3CONHOH, NaIO4, MeOH, rt; (d) Mo(CO)6, CH3CN/H2O (15:1), Δ; (e) 
MsCl, Et3N, DMAP, CH2Cl2, rt; (f) CaCO3, EtOH/H2O (1:1), Δ; (g) Rh/Al2O3 (5 mlo%), 
60 psi H2, 85% EtOH(aq); (h) (i) Ms2O, Et3N, CH2Cl2, rt; (ii) NaN3, acetone/H2O, rt; (i) 
DBU, CH2Cl2, rt. 
Scheme 6: Chemoenzymatic approach for the synthesis of oseltamivir. 
 
Another application of enzymatic dihydroxylation by Hudlický was his synthesis of (–)-
idesolide 101, Scheme 7.
51
 The synthesis began by converting benzoic acid 96 to the 
corresponding diol using a mutant strain R. eutrophus B9 developed by Reiner and 
Hegeman.
52
 The dihydroxylated acid was reacted with diazomethane to obtain methyl 
ester 97, which was reduced to a mixture of products, 98 and 99 with potassium 
azodicarboxylate (PAD). Oxidation and dimerization of the major isomer 98 led to the 
completion of the synthesis in five steps starting from benzoic acid. 
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Reagents and conditions:  (a) R. eutrophus B9; (b) CH2N2, THF, 0 °C; (c) PAD, AcOH, 
MeOH, 0 °C; (d) IBX, DMSO; (e) NaHCO3. 
Scheme 7: Chemoenzymatic synthesis of (–)-idesolide from benzoic acid. 
 
Another important application of aromatic metabolites involves the synthesis of morphine 
alkaloids and their derivatives. This topic will be covered in the following section. The 
aforementioned applications of metabolites constitute only a few of their many 
applications. These metabolites and their use in synthesis have been extensively 
reviewed.
9,44
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2.2 Morphine 
2.2.1 History and isolation of morphine alkaloids 
Opium has been used since ancient times; Sumerians were known to isolate opium from 
poppies 3000 years ago. They called opium “gill” which means “joy” and the poppy as 
“hul gill,” the “plant of joy,” 53 and it was used as a euphoriant in religious rituals.  It is 
believed that opium spread from Sumaria to other parts of the world.
53
 The word “opium” 
has been derived from the Greek word “opos” (juice) and “opion” (poppy juice). It has 
been used to produce euphoria, analgesia, sleep, and relief from cough and diarrhoea 
since ancient times.
54
 Opium was brought to India and China by Arab traders in eighth 
century and it reached all parts of Europe by the tenth to thirteenth century. Later, it was 
used as a natural anaesthetic/analgesic agent to relieve pain during surgery. The use of 
opium as a medicinal drug was exploited by the Swiss physician Paracelsus (1493-1541), 
who called it “laudanum” (a mixture of opium and wine which means “something to be 
praised” in Latin) and was used for all kinds of medical ailments. British physician 
Sydenham (1624-1689) used opium in alcohol as a cough suppressant and sleep aid. 
Manuscripts from the sixteenth century reported the abuse of this drug and developing of 
drug tolerance in Europe, and smoking of opium became the greatest social problem in 
China during the mid-seventeenth century, after the banning of tobacco smoking. 
Attempts to suppress the sale of opium in China failed because of the actions of British 
East India Company. Export of opium from India to China provided a large revenue for 
the East India Company at that time, which made India the largest opium producer in the 
world.
55
 Later, in 1913, British India stopped all opium shipments to China, after it had 
become less dependent on opium revenue.
56
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In the early nineteenth century (1805), the German pharmacist Friedrich Wilhelm 
Serturner isolated the active component of opium, which he named morphine (after 
Morpheus, the Greek God of dreams).
57
 This event plays an important role in the 
development of the fields of organic chemistry and pharmacology. Serturner developed a 
simple procedure for the isolation of morphine; trituration of Indian opium with hot water 
until the filtrate became colorless, then the filtrate was concentrated and saturated with 
ammonia to get a semi crystalline solid. It was further washed with water and was 
triturated with ethanol to provid pure morphine. 
The alkaloid content of crude opium constitutes more than forty different alkaloids. Raw 
opium contains 10-16% of morphine (1) by weight along with other alkaloids such as 
codeine (2) 1-3%, thebaine (3) 0.5-2%, papaverine (102) 0.8-1 %, traces of oripavine 
(103), and narcotine (104) 1-7%, as shown in Figure 18.  
 
 
Figure 18: Naturally occurring morphine alkaloids. 
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Opium is isolated by cutting the unripened poppy seed pods of Papaver somniferum 
about 98 days after development. The latex leaks out and is scraped off and further dried 
to obtain raw opium. This harvesting process can be repeated on a single seed pod for 
several days. The timing of the opium harvesting is also important as the ripened seed 
pod stops the alkaloid production. Alkaloids are abundant in the seed pods but thebaine 
can also be found in the roots of the opium poppy.
56, 58
 
In 1832, French chemist Robiquet isolated another naturally occurring opiate, codeine 
(2), Figure 18.  Thebaine 3 (1833) and papaverine 103 (1848) were later isolated from 
opium.
59
 Structural elucidation of morphine began soon after its isolation. Initial work 
was carried out by Liebig and later in 1847 Laurent deduced the correct empirical 
formula for morphine as C17H19NO3. 
60
 The use of morphine in minor surgeries and as an 
adjunct to general anaesthetics became common after the invention of the hypodermic 
syringe and hollow needle in 1853.
53
 Morphine also eventually replaced crude opium as 
the analgesic of choice. But very soon the addiction profile of morphine was revealed, 
which led to the search for a less addictive but still potent analgesic. In 1874, a more 
potent semisynthetic drug named heroin (105), Figure 19, was synthesized by an English 
chemist Wright at St. Mary‟s hospital in London by diacetylation of morphine (1).61 The 
name heroin came from “heroische”, which in German means “powerful” or “extreme”. 
Heroin was synthesised by refluxing morphine (1) and acetic anhydride to yield the bis-
acetyl derivative of morphine. Later in 1898, Friedrich Bayer and Company marketed 
heroin as a non-addictive morphine substitute and cough suppressant. Heroin is much 
faster at passing through the blood-brain barrier and is then metabolised to morphine in 
29 
 
the body, so it in fact exhibits a more addictive profile than morphine. This led to the 
withdrawal of heroin from the market by Bayer. Also, the addictive property made heroin 
a potential target for illicit use. Wright also played an important role in the elucidation of 
the oxygenation pattern in morphine.
62
  
 
 
Figure 19: Synthesis of heroin from morphine. 
 
The presence of the phenanthrene core in morphine was confirmed by von Gerichten in 
1881.
63
  About the same time, independent studies by Grimaux
64
 and Hesse
65
 proved the 
relationship between codeine and morphine by methylation of the phenolic hydroxyl 
group in morphine. After establishing the structural relationship between morphine and 
codeine, structural elucidation studies were performed on the more stable codeine. The 
presence of an oxygenated phenanthrene core was confirmed by experiments done by 
Hofmann, Knorr, and von Gerichten on morphine and codeine.
66
 The structure of 
morphine was fully elucidated by Robinson and Gulland in 1925, 120 years after its 
isolation.
67
 Later in 1952, the structure of morphine was confirmed by the first total 
synthesis by Gates.
68
 Final structural evidence was given by X-ray analysis by Mackay 
and Hodgkin in 1955.
69
 An excellent review by Hudlický and Butora covers the rich 
chemistry of structure elucidation of morphine.
70
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2.2.2 Biosynthesis of morphine alkaloids 
Morphine and related alkaloids are formed in P. somniferum through a series of 
benzylisoquinoline intermediates. The biosynthesis pathway begins with the conversion 
of L-tyrosine (106) to dopamine (110) and 4-hydroxyphenylacetaldehyde 109, Scheme 8. 
First, 106 is converted to 4-hydroxyphenylpyruvic acid 107 by transamination and then 
decarboxylated to 4-hydroxyphenylacetaldehyde 109. A second molecule of 106 is 
converted to dopamine 110 through an intermediate tyramine 108 by the action of two 
enzymes, L-tyrosine decarboxylase and phenolase. Condensation of 109 and 110 
catalysed by (S)-norcoclaurine synthase provides (S)-norcoclaurine (111), which is a 
common intermediate for the synthesis of many alkaloids.
71
 
 
Enzymes: (a) L-tyrosine transaminase; (b) p-hydroxyphenylpyruvate decarboxylase; (c) 
L-tyrosine decarboxylase; (d) phenolase; (e) (S)-norcoclaurine synthase. 
Scheme 8: Biosynthesis of (S)-norcoclaurine. 
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N-methyltransferase and norcoclaurine-6-O-methyltransferase-mediated
72
 mediated 
methylation of (S)-norcoclaurine 111 and P-450 mediated hydroxylation delivers (S)-3′-
hydroxy-N-methylcoclaurine 114,
73
 Scheme 9. It is converted to (S)-reticuline (115) by 
the 3′-hydroxy-N-methyl-(S)-coclaurine-4′-O-methyltransferase enzyme and is further 
transformed to its enantiomer (R)-reticuline (117) through a stereospecific reduction of an 
intermediate 116. An enzyme called dehydroreticuline catalyzes the formation of 116, 
Scheme 9, and the reduction involves the NADPH-dependent enzyme 1,2- 
dehydroreticuline reductase.
74
 A regioselective oxidative phenolic coupling of 117 
catalyzed by NADPH dependent cytochrome P450, salutaridine synthase provides 118.
75
 
The ketone functionality in 118 is stereoselectively reduced by an enzyme called 7-
oxidoreductase to provide (7S)-salutaridinol (119).
76
 
 
 
32 
 
 
Enzymes: (a) norcoclaurine-6-O-methyltransferase (b) N-methyltransferase; (c) P-450-
mediated hydroxylation; (d) 3′-hydroxy-N-methyl-(S)-coclaurine-4′-O-methyltransferase; 
(e) dehydroreticuline; (f) 1,2- dehydroreticuline reductase; (g) salutaridine synthase; (h) 
7-oxidoreductase. 
Scheme 9: Biosynthesis of (7S)-salutaridinol. 
 
(7S)-salutaridinol 119 is then acylated by (7S)-salutaridinol-7-O-acetyltransferase to 
obtain 120, Scheme 10.
77
 A non-enzymatic SN2′ displacement of acetate by phenolic 
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hydroxyl group yielded thebaine (3), as shown in Scheme 10. It is then converted to 
neopinone (121), Scheme 10, by thebaine-6-O-demethylase via demethylation.
78
 
Neopinone (121) exists in equilibrium with its conjugated isomer codeinone (122), 
Scheme 10, which then undergoes a reduction at the C-6 keto group by codeinone 
reductase to yield codeine (2).
79
 As a final step, demethylation of the phenolic ether by 
codeine-O-demethylase provides morphine (1), Scheme 10.
78
 
 
 
 
Enzymes: (a) (7S)-salutaridinol-7-O-acetyltransferase; (b) thebaine-6-O-demethylase; (c) 
codeinone reductase; (d) codeine-O-demethylase. 
Scheme 10: Biosynthesis of morphine. 
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An alternative pathway for the biosynthesis of morphine (1) from thebaine has been also 
proposed.
80
 This pathway involves the phenolic ether demethylation to oripavine (103), 
Scheme 11, which then undergoes 6-O-demethylation to provide morphinone (123). 
Stereoselective reduction of morphinone (123) provides morphine (1), Scheme 11.
78
 
 
 
Enzymes: (a) codeine-O-demethylase; (b) thebaine-6-O-demethylase; (c) codeinone 
reductase. 
Scheme 11: Alternative biosynthesis of morphine. 
2.2.3 Overview of selected morphine syntheses 
The milestone of the first total synthesis of morphine (1) was achieved by Gates and 
Tschudi in 1952;
68
 also, they confirmed the structure of morphine proposed by Robinson 
several years earlier.
81
 To date, more than 40 total and formal syntheses of morphine 
alkaloids have been reported, but none of them meets the requirement of a truly practical 
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synthesis. Although, morphine is not a highly complex structure, its unique pentacyclic 
core with five contiguous stereogenic centers, a quarternary carbon at C-13, a C-4, C-5 
ether linkage, and a completely dissonant relationship in morphine makes it a challenging 
target for synthetic chemists.
2
 The concept of dissonance/consonance was first introduced 
by Evans in 1973 and it was discussed in detail and was applied in the disconnection 
studies of morphine by Hudlický.
82 
 
 
 
Figure 20: Dissonant relationship in morphine. 
 
Some of the notable syntheses of morphine alkaloids will be mentioned here. 
Gates (1952) 
In 1952, the first total synthesis of morphine was achieved by Gates and Tschudi in 24 
steps with an overall yield of 0.01%, starting from 2,6-dihydroxy naphthalene 124, 
Scheme 12.
68, 83
 The synthesis began with a nitrosation/reduction/oxidation sequence to 
yield intermediate 127, which underwent Michael addition of ethyl cyanoacetate. Re-
oxidation of the catechol and a decarboxylation reaction yielded intermediate 128. A 
[4+2] cycloaddition reaction of butadiene with 128 provided 129 with correct C-13 
stereochemistry as had been shown in earlier model studies.
84
 The Diels-Alder 
cycloadduct 129 was converted to the keto lactam 130 through a reductive cyclization to 
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finish the D-ring. Unfortunately, this reaction led to the wrong stereochemistry at the C-
14 carbon atom. The credit for developing this cyclization goes to Woodward and 
Gates.
85
  
 
Reagents and conditions:  (a) (i) BzCl, pyridine, dioxane; (ii) NaNO2, AcOH; (iii) Pd/C, 
H2, AcOH, then FeCl3; (b) (i) SO2, MeOH; (ii) K2CO3, dimethylsulfite; (c) (i) KOH, 
MeOH; (ii) NaNO2, AcOH; (iii) Pd/C, H2, AcOH, then FeCl3; (d) (i) ethyl cyanoacetate, 
NEt3, then K3Fe(CN)6; (ii) KOH, MeOH, H2O; (e) butadiene, AcOH; (f) CuO/Cr2O, H2, 
150 °C. 
Scheme 12: Gates‟s synthesis of tetracyclic core of morphine via amide intermediate 
130. 
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A modified Wolff-Kishner reaction was used to reduce the keto group, followed by 
methylation of nitrogen and reduction of amide functionality provided d-β-Δ6-
dihydrodesoxycodeine (131), Scheme 13. At this stage, a resolution of 131 by 
crystallization of the tartrate salt of 131 provided the natural enantiomer which is 
epimeric at C-14. The hydroxyl group at C-6 was introduced by an acid-mediated 
hydration. The methyl ether at C-4 position was selectively removed followed by 
oxidation at C-6 delivered compound 133. After finishing compound 131, Gates turned 
his attention to epimerize the C-14 stereo centre. An α,β-unsaturated ketone intermediate 
was created by bromination and elimination of HBr, which was converted to hydrazone 
135.  
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Reagents and conditions:  (a) (i) KOH, N2H4; (ii) NaH, MeI; (iii) LiAlH4; (b) dil. H2SO4; 
(c) (i) KOH, ethylene glycol; (ii) tBuOK, Ph2CO; (d) Br2, AcOH; (e) 2,4-DNP; (f) HCl. 
Scheme 13: Epimerization of the C-14 stereocenter via hydrazone intermediate. 
 
The hydrazone formation led to the equilibration at C-14 stereogenic centre to provide 
137 through an intermediate 136, Scheme 13, because of the formation of the more stable 
cis-fused ring system. The hydrazone was then hydrolysed using acid to obtain 138. 
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Reagents and conditions:  (a) H2, PtO2; (b) (i) Br2, AcOH; (ii) 2,4-DNP; (c) HCl, acetone; 
(d) (i) LiAlH4; (ii) H2, Pd/C; (e) PyHCl, 220 °C. 
Scheme 14: Completion of the synthesis of (–)-morphine (1). 
 
The α,β-unsaturated ketone in 138 was hydrogenated and the final ring of morphine was 
constructed using a diphenyl furan ring formation between C-4 and C-5 carbon atoms to 
provide 140, Scheme 14. It was achieved by applying similar conditions that were used in 
the epimerization of C-14 stereo centre, which also led to the formation of unsaturation 
between C-7 and C-8. Acid-mediated hydrolysis of hydrazone and reduction of ketone 
functionality provided codeine (2). The first synthesis of morphine (1) was completed by 
demethylation of C-3 methyl ether using Rappoport‟s conditions.86 
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Rice (1980) 
Rice‟s synthesis of hydrocodone is known as the shortest and highest yielding synthesis 
of any morphine alkaloid to date. This biomimetic approach towards morphine alkaloid 
involves the isolation of only six intermediates and no column chromatography, and the 
final product was isolated in an overall yield of 29%.
87
 Rice‟s approach was inspired by 
the reports on Grewe-type electrophilic cyclization of benzylhexahydroisoquinoline 142, 
Figure 21.
88
 This reaction managed to provide dihydrothebainone 143, a precursor for 
codeine, in lower yields where the formation of isomeric compound 144 predominates in 
the reaction. 
 
 
Figure 21: Formation of dihydrothebainone via Grewe-type electrophilic cyclization. 
 
A mixture of amine 145, and acid 146, was heated to yield an amide intermediate, which 
underwent a Bischler-Napieralski cyclization to provide 147, Scheme 15. Formylation 
and Birch reduction of the more electron deficient aromatic ring provided intermediate 
148. A one pot reaction involving ketalization and regeoselective bromination provided 
149. 
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Reagents and conditions:  (a) (i) 200°C; (ii) POCl3, CH3CN; (iii) NaCNBH3, MeOH 
(86%); (b) (i) Li, NH3, THF, tBuOH; (ii) PhOCHO, EtOH; (c) (i) ethylene glycol, 
MeSO3H, THF; (ii) N-bromoacetamide (NBA). 
Scheme 15: Rice‟s synthesis of tricyclic core of morphine alkaloid. 
 
Acid-catalyzed hydrolysis of ketal followed by hydrogen fluoride-mediated Grewe-type 
cyclization provided dihydrothebainone derivative 151, Scheme 16. Amide 151 was 
hydrolysed under acidic conditions to obtain 152 and the bromine atom at C-1 was then 
removed by hydrogenation. Bromination at C-5 and base induced cyclization completed 
the pentacyclic core of morphine alkaloid. The synthesis of hydrocodone (153) was 
completed by the removal of the aryl bromide and methylation of nitrogen. Rice also 
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developed a method for resolution of compound 147, Scheme 15, which allowed access 
to both natural and unnatural series of morphine alkaloids. 
 
 
Reagents and conditions:  (a) (i) HCO2H, H2O; (ii) NH4F, HF, CF3SO3H; (b) HCl, 
MeOH; (c) (i) H2, Pd/C, AcOH, HCHO; (ii) Br2, AcOH; (iii) NaOH, CHCI3; (iv) H2, 
Pd/C, AcOH, HCHO. 
Scheme 16: Completion of synthesis of hydrocodone. 
 
Parker (1992, 2006) 
Parker and Fokas completed the racemic synthesis of dihydroisocodeine in 1992.
89
 The 
synthesis was completed in 11 steps and constituted a formal synthesis of morphine. 
Their approach to the construction of the morphine ring system was based on the tandem 
43 
 
cyclization of an ortho allyloxy aryl radical. Later, in 2006, the original synthesis was 
modified to result in an asymmetric synthesis of hydrocodone.
90
  
The synthesis started from commercially available m-methoxyphenethylamine 154, 
Scheme 17. Birch reduction of 154 followed by tosylation of amino functionality and 
hydrolysis of enol ether followed by methylation provided the enone 155. All attempts to 
perform an asymmetric reduction of 155 proved to be unsuccessful. This failure led to the 
bromination of 155 to obtain the 2-bromocyclohexenone derivative and the asymmetric 
reduction of this with (S)-oxazaborolidine -catechol borane reagent (CBS)
91
 provided the 
desired alcohol 156 in good yield and acceptable enantiomeric excess. Then the removal 
of halogen from the ring system and peroxy acid mediated epoxidation delivered the cis-
epoxy alcohol 157, Scheme 17. Treatment of the epoxy alcohol 157 with titanium 
isopropoxide resulted in the formation of cyclohexene diol which was silylated to obtain 
the compound 158, Scheme 17, C-ring fragment of morphine.  
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Reagents and conditions:  (a) (i) Li, NH3, tBuOH; (ii) TsCI, NEt3, HCl; (iii) MeI, 
K2CO3, acetone; (b) (i) Br2, NEt3; (ii) CBS, catechol borane; (c) (i) Na(Hg); THF-MeOH; 
(ii) mCPBA; (d) (i) Ti(OiPr)4; (ii) TBSCl, imidazole, DMF. 
Scheme 17: Synthesis of C-ring fragment. 
 
The key intermediate in the synthesis is compound 160, Scheme 18, which is the 
precursor for the radical cyclization reaction. It was formed through a Mitsunobu reaction 
between alcohol 158 and a highly substituted phenol 159, which was synthesized from 
isovanillin in two steps.
92
 The silyl protecting group was removed to obtain intermediate 
160; tributyltin hydride mediated homolytic cleavage of carbon halogen bond in 161 
generated the aryl radical 162. The dihydrofuran ring was generated by the radical 
cyclization of the aforementioned species, which led to the formation of another radical at 
the C-14 carbon atom. This unstable radical was trapped by the styrene bond to form a 
stabilized benzylic radical and also connected the C-14 and C-9 carbon atoms as shown 
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in intermediate 163, Scheme 18. Then, phenylthiolate radical was eliminated to afford 
164 as a single diastereomer with the correct configuration at C-13 and C-14 
stereocenters.  
 
 
 
Reagents and conditions:  (a) (i) PBu3, DEAD; (b) 10% HF, CH3CN; (c) nBu3SnH, 
AIBN, toluene; (d) Li, NH3, tBuOH; (e) DMSO, (COCI)2, NEt3. 
Scheme 18: Synthesis of hydrocodone via radical cyclization approach. 
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A reductive desulfonation using lithium in ammonia led to the cyclization of the final 
ring to obtain dihydroisocodeiene (165), Scheme 18, and Swern oxidation of the C-6 
hydroxy group effected the completion of the synthesis of hydrocodone (153), Scheme 
18. 
Overman (1993) 
The first published enantiodivergent synthesis of morphine is Overman‟s approach which 
involves no resolution of intermediates. 
93
 An iminium ion-allylsilane cyclization and a 
Heck reaction were the key reactions in his approach. 
The synthesis started from isovanillin by the protection of the phenol and aldehyde to 
obtain ketal 167, Scheme 19. Ortho-lithiation of 167 with n-BuLi and quenching the 
aryllithium with iodine followed by protecting group hydrolysis and reprotection of the 
phenol with a benzyl group provided compound 168. Homologation of the aldehyde was 
effected using dimethylsulfonium methylide and Lewis acid catalyzed rearrangement of 
the corresponding epoxide to provide the A-ring fragment 169. 
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Reagents and conditions:  (a) (i) HC(OMe)3, HCl; (ii) NaH, CICH2OMe; (b) (i) nBuLi, 
I2; (ii) 6N HCl; (iii) BnBr, K2CO3; (c) (i) CH2SMe2; (ii) BF3OEt2, THF. 
Scheme 19: Overman‟s synthesis of A-ring fragment. 
 
The synthesis of the C-ring fragment was started by enantioselective reduction of 2-
allylcyclohex-2-enone 170, Scheme 20, using catecholborane in the presence of a chiral 
catalyst to obtain 172. Condensation of this alcohol with phenyl isocyanate and 
dihydroxylation of the terminal olefin followed by protection provided the acetonide 173. 
SN2′ displacement of this allylic carbamate provided the allyl silane 174. Deprotection of 
the acetonide led to the formation of an aldehyde which was treated with 
dibenzosurberylamine (DBS-NH2) followed by reduction to provid the C-ring fragment 
175, Scheme 20. 
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Reagents and conditions:  (a) (i) 171, catechol borane; (b) (i) PhNCO; (ii) OsO4, acetone, 
HCI; (c) (i) nBuLi, THF, –30 °C; (ii) CuI (PPh3)2, 0 °C; (iii) PhMe2SiLi, 0 °C; (d) (i) 
pTsOH, MeOH, NaIO4; (ii) DBS-NH2, NaCNBH3. 
Scheme 20: Synthesis of C-ring fragment. 
 
Condensation of amine 175 and aldehyde 169 in the presence of ZnI2 led to the formation 
of iminium ion 176, which underwent an allylsilane cyclization to generate compound 
177, Scheme 21. An intramolecular Heck cyclization provided the tetracycle 178, 
Scheme 21, in which the crucial C-13 quaternary carbon center was established. 
Deprotection of the benzyl ether group and a tandem epoxidation etherification reaction 
resulted in the formation of the final ring of the morphine alkaloid to provide 179. 
Overman‟s synthesis was finished by oxidation of the C-6 alcohol to a ketone and 
hydrogenolysis of the DBS group in the presence of formaldehyde to provide 
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hydrocodone (153), Scheme 21. Hydrocodone was then converted to morphine as using 
the conditions described by Rice.
94
 
 
 
Reagents and conditions:  (a) (i) ZnI, EtOH, 60°C; (b) Pd(TFA)2(PPh3)2, 1,2,2,6,6- 
pentamethylpiperidine, toluene; (c) (i) BF3·OEt2, EtSH; (ii) CSA, 3,5-
dinitroperoxybenzoicacid; (d) (i) TPAP, NMO; (ii) H2 Pd(OH)2, HCHO. 
Scheme 21: Overman‟s synthesis of hydrocodone. 
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Trost (2002, 2005) 
Enantioselective synthesis of (–)-codeine (2) and morphine (1) was reported by Trost in 
2002. 
95
 Trost‟s synthesis involves an asymmetric allylic alkylation as a key step which 
connects the A and C rings of morphine in an enantioselective manner. Later, the 
dihydrofuran ring and B ring were created using two Heck cyclization sequence. 
The synthesis started with the asymmetric allylic alkylation of 2-bromoisovanillin 180 
and allylic ester 181, Scheme 22, leading to the formation of ether linkage between the 
top A ring and bottom C ring of the morphine alkaloids to provide compound 182, 
Scheme 22. The ester group was reduced to alcohol 184 after protection of the aldehyde 
functionality.   
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Reagents and conditions: cat. PdL, NEt3, CH2Cl2; b) p-TsOH, CH(OMe)3, MeOH; c) 
DIBALH, toluene, –78 °C. 
Scheme 22: Trost‟s synthesis of intermediate 184. 
 
A modified Mitsunobu reaction followed by acid mediated deprotection led to the 
formation of aldehyde 186, Scheme 23. The dihydrofuran ring and the quaternary C-13 
carbon center were generated in one step via an intramolecular Heck cyclization to 
provide the tricyclic intermediate 187. Aldehyde 187 was converted to 188 using a 
Corey-Fuchs homologation and a chemoselective reduction of the trans-vinyl bromide 
led to the formation of intermediate 189. This underwent a second intramolecular Heck 
cyclization to create the B ring in 190. Tetracycle 191 was generated via a selenium 
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dioxide mediated allylic oxidation and reduction of the corresponding enone. The nitrile 
group was then converted to an amine and it was immediately methylated to obtain 192, 
Scheme 23. 
 
Reagents and conditions: (a) (i) PPh3, acetonecyanohydrin, DIAD; (ii) p-TsOH, THF, 
H2O; (b) Pd(OAc)2, dppf, Ag2CO3, toluene; (c) CBr4, PPh3, CH2Cl2; (d) n-Bu3SnH, 
toluene; (e) Pd(OAc)2, dppp, Ag2CO3, toluene; (f) (i) SeO2, dioxane, sand; (ii) DIBALH, 
THF, Et2O; (g) DIBALH, CH2Cl2, Et2O, then NH4Br, MeNH2 followed by NaBH4. 
Scheme 23: Trost‟s synthesis of intermediate 192. 
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The pentacyclic core of morphine was made by generating the D ring through a 
hydroamination reaction to provide codeine (2) as shown in Scheme 24. Codeine (2) was 
then converted morphine (1) using Rice‟s existing method. 96 
 
 
 
Reagents and conditions: (a) LDA, THF, 150-W tungsten bulb. 
Scheme 24: Completion of synthesis of codeine. 
 
Fukuyama (2006, 2010) 
A racemic synthesis of morphine was reported by Fukuyama in 2006;
97
 his synthesis 
started with the convertion of isovanillin into the 2-iodo derivative using known 
protocols.
93, 98
 The acetal 193, Scheme 25, was hydrolysed under acidic conditions 
followed by a Wittig reaction and treatment with camphorsulfonic acid in MeOH 
provided the homologated phenol 194. One of the key steps in this synthesis was the 
coupling of phenol 194 with epoxide 195 by means of a Tsuji-Trost coupling.
99
 A 
Mitsunobu inversion of alcohol 196 followed by deprotection of the silyl ether and 
another Mitsunobu reaction provided the nitrile 197. 
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Reagents and conditions: (a) (i) AcOH, THF-H2O, 0 °C to rt; (ii) MeOCH2PPh3Cl, 
NaHMDS, THF, 0 °C to rt; (iii) HCl, MeOH, rt; (b) Pd2(dba)3, P(2-furyl)3, CH3CN, rt; (c) 
(i) p-nitrobenzoic acid, DEAD, PPh3, toluene, 0 °C; (ii) CSA, MeOH; (iii) 2-hydroxy-2-
methylpropanenitrile, DEAD, PPh3, toluene, 0 °C. 
Scheme 25: Synthesis of ether 197. 
 
Reduction of nitrile 197 followed by protection delivered carbamate 198, Scheme 26. An 
intramolecular Heck reaction was designed for the completion of tricyclic core to obtain a 
silyl enol ether which upon desillylation yielded ketone 200. The double cyclization was 
achieved under acidic condition via an intramolecular Mannich type reaction. The 
endgame involved the conversion of ketone to enone by the Ito-Saegusa method
100
 and 
epoxidation to obtain epoxide 201, Scheme 26. 
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Reagents and conditions: (a) (i) LiBH4, Et2O, MeOH, 0 °C; (ii) TBSCI, imidazole; (iii)  
DIBALH, CH2Cl2, -78 °C; (iv) ClCO2Me, K2CO3; (b) (i) Pd2(dba)3, P(o-tolyl)3, NEt3, 
MeCN; (ii) TBAF; (c) HCI, MeOH, reflux; (d) (i) TMSCI, LiHMDS, THF, 0 °C; (ii) 
Pd(OAc)2, MeCN; (iii) H2O2, H2O, NaOH, MeCN, 0 °C; (e) NaBH4, MeOH, CH2Cl2, 0 
°C.   
Scheme 26: Synthesis of intermediate 201. 
 
The ketone in 201, Scheme 26, was reduced from the less hindered face and the resulting 
alcohol 201 a was converted to thiocarbamate, which upon exposure to radical conditions 
resulted in the allylic alcohol 202, Scheme 27. C-6 stereochemistry was adjusted by a 
oxidation reduction sequence and the cleavage of the methyl ether was achieved 
following a known protocol to obtain racemic morphine (1).
96
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Reagents and conditions: (a) (ii) 1,1′-thiocarbonyl diimidazole,  DMAP, ClCH2CH2Cl, 60 
°C; (ii) Et3B, n-Bu3SnH, THF; (b) (i) Dess-Martin periodinane, CH2Cl2; (ii) LiAlH4, 
THF; (c) BBr3, CH2Cl2. 
Scheme 27: Completion of synthesis of morphine. 
 
Later in 2010, the same group reported an enantioselective synthesis of morphine based 
on the same approach.
101
 -Acetoxylation of cyclohexenone 203 followed by iodination 
provided iodoketone 204, Scheme 28. Enzyme-mediated chiral resolution and protection 
of the alcohol as silyl ether followed by Luche reduction yielded alcohol 205. Alcohol 
206 was prepared by the palladium-catalyzed Suzuki-Miyaura coupling of 205 and 212. 
A Mitsunobu reaction followed by intramolecular Heck cyclization delivered (+) or (-)- 
208. The carbamate was reduced and the secondary amine was protected using 2,4-
dinitrobenzene-sulfonyl chloride (DNSCl). After deprotection of the silyl ether, the 
alcohol was oxidised to enone and the C-9 hydroxyl was mesylated to 209.Treatment 
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with base led to substitution of the mesyl group for β-isomer and decomposition under 
much harsh conditions. DNS group was cleaved using mercapto acetic acid and Et3N 
which led to the formation of neopinone (210) and codeinone (211), Scheme 28. These 
mixtures were converted to pure codeinone under acid mediated conditions and reduction 
and cleavage of the methyl ether provided morphine (1), Scheme 28. 
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 Reagents and conditions: (a) (i) Pb(OAc)4, toluene, rt; (ii) I2, DMAP, py, CCl4; (b) (i) 
lipase AK, THF, phosphate buffer (pH 7.41); (ii) TBSOTf, 2, 6-lutidine; (iii) NaBH4, 
CeCl3, MeOH (c) 212, [PdCl2(dppf)], aq. NaOH, THF; (d) 194, n-Bu3P,DEAD, THF; (e) 
[Pd2(dba)3], P(o-tolyl)3, NEt3, CH3CN, rt; (f) (i) LiAlH4, THF, rt; (ii) aq. NaOH, DNsCl; 
(iii) CSA, MeOH; (iv) Dess-Martin periodinane; (v) aq. TFA, toluene, 50 °C; (vi) MsCl, 
iPr2NEt, 0 °C; (g) HSCH2CO2H, iPr2NEt, 0 °C; (h) (i) HCl, dioxane, CH2Cl2; (ii)  
NaBH4, MeOH; (iii) BBr3, CH2Cl2.  
Scheme 28: Fukuyama‟s synthesis of codeinone. 
 
 
59 
 
Chida (2008, 2013) 
In 2008, Chida reported a formal synthesis of morphine by intercepting 
dihydroisocodeine.
102
 The highlight of the synthesis was a cascade of Johnson-Claisen 
rearrangements to establish the C-13 and C-14 stereocenters. He had already employed 
this strategy in the synthesis of the Amaryllidaceae alkaloid galanthamine in 2007.
103
 
Synthesis of dihydroisocodeine started from commercially available tri-O-acetyl-D-glucal 
213, Scheme 29. The acetate group was hydrolysed under basic condition and was treated 
with p-anisaldehyde dimethylacetal before the C-6 hydroxyl group was protected as its 
silyl ether to provide 214. The primary alcohol was generated by DIBALH mediated 
reductive cleavage of 214, which was converted into the corresponding methyl glycoside 
and the primary alcohol was replaced by iodine to obtain compound 215. The resulting 
iodide was eliminated under basic condition‟s to generate the corresponding olefin that 
underwent a Ferrier‟s carbocyclization.  A subsequent β-elimination provided olefin 216, 
followed by 1,4-reduction and trapping of the intermediate enolate using Comin‟s reagent 
completed the synthesis of C-ring by delivering vinyl triflate 218. Suzuki coupling of 
vinyl triflate 218 with boronic acid 217 followed by clevage of the PMB ether provided 
allylic alcohol 220. 
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Reagents and conditions: (a) (i) NaOMe, MeOH; (ii) p-anisaldehyde dimethylacetal, 
PPTS, DMF, 45 °C; (iii) TBSCl, imidazole; (b) (i) DIBALH, toluene, –20 °C; (ii) Ph3P, 
HBr, MeOH, NaBr, DME, 0 °C; (iii) I2, imidazole, Ph3P; (c) (i) tBuOK, THF; (ii) 
Hg(OCOCF3)2, acetone, buffer; (iii) MsCl, NEt3, DMAP; (d) (i) L-Selectride, –78 °C; (ii) 
Comins‟ reagent; (e) Pd(OAc)2, Ph3P, aq .Na2CO3, 1, 4-dioxane; (f) DDQ. 
Scheme 29: Synthesis of intermediate 220. 
 
Allylic alcohol 220 was subjected to Johnson-Claisen conditions to provide ester 221, 
Scheme 30, with the requisite stereochemistry at C-14, in 87% yield. Removal of silyl 
protecting group and a second Claisen rearrangement provided the bis-ester 222, with the 
correct C-13 stereochemistry in 55% yield. A cascade Claisen rearrangement route is also 
possible after removing the silyl protecting group of the allylic alcohol 220. This reaction 
led to the product 222 in 36% yield. 
An epoxidation etherification reaction and protection of alcohol as silyl ether followed by 
reduction of esters provided tricycle 223, Scheme 30. Friedel-Crafts type cyclization 
61 
 
under acidic condition provided tetracycle 224, Scheme 30. Dehydration followed by 
reductive amination and protection delivered 225 that underwent a hydroamination 
reaction to provide dihydroisocodeine 226, Scheme 30. This formalised the synthesis as 
the conversion of 226 to morphine is already known. 
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Reagents and conditions: (a) EtCOOH, CH3C(OEt)3, 140 °C, 24 h; (b) Bu4NF, 2-
nitrophenol, CH3C(OEt)3, 140 °C, 120 h; (c) (i) m-CPBA; (ii) TBSCl, imidazole, CH2Cl2; 
(iii) DIBAL-H; (d) (i) montmorillonite K-10; (ii) TBSOTf, 2, 6-lutidine; (e) (i) MeNH2, 
MeNH3Cl, MS 3Å, 0 °C, then LiBH4; (ii) TsCl, DMAP, py, 80 °C; (f) (i) Bu4NF, THF; 
(ii) Li, tBuOH, NH3,THF, –78 °C; (g) (i) Swern oxidation; (ii) LiAlH4. 
Scheme 30: Chida‟s formal synthesis of morphine. 
 
Later in 2013, Chida group published another paper on the second generation synthesis of 
morphine using the same strategy.
104
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Hudlický (1992-present) 
One of the long standing goals in the Hudlický group is the synthesis of morphine and a 
wide range of unique strategies have been applied to the synthesis of morphine alkaloids 
over the last 20 years. All these approaches relied on the successful implementation of 
enzymatically derived cis-cyclohexadiene diols. A short discussion of Hudlický‟s 
approaches toward morphine alkaloids will be presented.  
Cycloaddition strategy 
One of the first approach towards morphine alkaloids from Hudlický group relied on the 
successful construction of the morphine core through an intramolecular 4+2 
cycloaddition. Both halves of morphine can be derived from cis-cyclohexadiene diol. 
These two subunits can be tethered and undergo cyclization to deliver the morphine core 
in a short sequence. To test this approach a series of model reactions was designed.  
 The first model study aims the formation of tricyclic core of morphine ring with 
all asymmetric centers, lacking only the aromatic ring and ethylamino bridge.
105
 This 
study started by preparing enantiomerically pure cis-cyclohexadiene diol 33 by the 
biotransformation of toluene 32, Scheme 31. Selective protection of the less hindered 
hydroxyl group as silyl ether and the diene functionality was attached by treatment with 
sorbyl bromide under basic conditions led to the formation of 229. An intramolecular 
cycloaddition of 229 can lead to two different products, but heating in CCl4 resulted in 
only in adduct 230 as observed in the synthesis of zeylena.
42
 A Cope rearrangement of 
this molecule can lead to the desired structure 228, but all attempts to carry out this 
reaction with 230 were unsuccessful. Deprotection of silyl ether followed by oxidation 
provided 231, which underwent the Cope rearrangement and delivered the expected 
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product after reduction of ketone to obtain 232 a, Scheme 31. A second approach was 
carried out that involved a diimide reduction and the aforementioned transformations to 
obtain 227, which underwent an intramolecular cycloaddition to deliver 228, Scheme 31, 
without any regiochemical issues. 
 
 
Reagents and conditions: (a) Pseudomaonas putida 39D; (b) (i) PAD, AcOH, MeOH; (ii) 
THSCl, imidazole, DMF, 0 °C, 18 h; (iii) NaH, sorbyl bromide, THF, 0 °Crt, 30 h; (c) 
toluene, 210 °C, 24 h; (d) (i) THSCl, imidazole, DMF, 0 °C, 18 h; (ii) NaH, sorbyl 
bromide, THF, 0 °Crt, 30 h; (e) CCl4, 77 °C, 7 h; (f) (i) Bu4NFH2O, THF; (ii) PCC, 
CH2Cl2, rt, 21 h; (g) (i) xylene, 250 °C, 22 h; (ii) NaBH4, CeCl37H2O, MeOH, rt, 15 min. 
Scheme 31: Cycloaddition approach towards the synthesis of tricyclic core of morphine. 
 
Later in 1998, a more advanced model study for the synthesis of the morphine core was 
published by Hudlický group.
106
 This work comprised the installation of 
ethylaminobridge and the stereochemical correction of previously reported compound 
228 to 232b, Scheme 31. The absolute stereochemistry of 232b was determined by X-ray 
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crystallography. Azidoethyl benzene 233, Scheme 32, was synthesised from 
commercially available bromoethyl benzene. Biooxidation of 233 afforded cis-
cyclohexadiene diol 234. Applying the same chemistry as discussed in previous 
synthesis, led to the formation of 235. Reaction with sorbyl bromide followed by 
reduction of the azide and protection as acetate provided 236, which is the key 
intermediate for the intramolecular [4+2] cycloaddition.  The cyclization provided a 
single stereoisomer 237 in moderate yield. The stereochemistry was confirmed through 
X-ray crystallographic analysis that suggested an exo transition state for the 
cycloaddition. 
 
 
Reagents and conditions: (a) E. coli JM109 (pDTG601); (b) (i) PAD, AcOH, MeOH, 0 
°C-rt, 14 h; (ii) THSCl, imidazole, DMF, 0 °C, 13 h; (c) (i) NaH, sorbyl bromide, THF, 0 
°C-rt, 14 h; (ii) PPh3, 0.4% H2O/THF, 45 °C, 18 h; (iii) Ac2O, pyridine, rt, 2 h; (d) 
toluene, sealed tube, 230 °C, 20 h; (e) HF/MeCN (5:95), rt, 3.5 h. 
Scheme 32:  Modified approach with revised stereochemistry. 
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Radical cyclizations 
Hudlický‟s work on radical cyclization approach was inspired by the work of Parker and 
he designed several generations of radical cyclization approaches. His first generation 
approach involved β-bromoethylbenzene as the starting material; enzymatic 
dihydroxylation generated the cis-cyclohaxadiene diol that underwent a diimide reduction 
followed by selective protection of distal hydroxyl group delivered 12, Scheme 33. 
Stereochemistry of C-5 hydroxyl group (morphine numbering) was inverted using 
Mitsunobu reaction and alkylation using oxazolidone followed by hydrolysis provided 
240. A second Mitsunobu installed the aromatic moiety of morphine also provided the 
correct C-5 stereocenter to deliver 241. It was subjected to radical cyclization conditions 
that gave a complex mixture, from which upon chromatography 243 was isolated as 
major product along with 242. 
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Reagents and conditions: (a) (i) Escherichia coli JM109 (pDTG601) (10g/L); (ii) PAD, 
AcOH, MeOH; (iii) TBSOTf, Hunig's base, CH2Cl2; (b) BzOH, n-Bu3P, DEAD, THF; (c) 
(i) NaOH; (ii) 2-oxazolidone, NaH, DMSO; (d) 2-bromo-6-methoxy phenol, n-Bu3P, 
DEAD, THF; (e) (TMS)3SiH, AIBN, benzene, 140 °C, sealed tube. 
Scheme 33: Hudlický‟s radical cyclization approach towards morphine. 
 
The second generation approach relied on two independent radical cyclization reactions 
that addressed the low yields and the lack of stereoselectivity of radical cyclization 
approach in the first synthesis.
107
 This approach used o-bromo-β-bromoethylbenzene 244, 
Scheme 34, as the substrate for biooxidation. Key intermediate 246 for the first radical 
cyclization was synthesised in straightforward steps. Exposure of 246 to radical 
cyclization conditions provided a mixture of diastereomers 247 and 248, in a ratio 1:2 
favouring epi-C9 configuration. After completing the synthesis of isoquinoline, the 
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chemistry was pursued with more abundant 248 that will lead to enantiomeric series of 
morphine. 
 
 
Reagents and conditions: (a) (i) Escherichia coli JMI09 (pDTG601) (0.2g/L); (ii) PAD, 
AcOH, MeOH; (iii) 2,2-dimethoxypropane, p-TsOH; (b) 2-oxazolidone, NaH, DMSO; 
(c) n-Bu3SnH, AIBN, benzene, reflux. 
Scheme 34: Second generation radical cyclization approach. 
 
The second part of the synthesis was started by removing the acetonide, protecting the 
distal hydroxyl and was subjected to a Mitsunobu reaction to provide 236, Scheme 35. It 
was subjected to radical cyclization conditions to provide 250 as a single diastereomer in 
49% yield. Reduction of oxazilidinone moiety provided 251 that upon oxidation and a 
Freidel-Crafts type cyclization furnished pentacyclic morphine core 253. The primary 
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alcohol in 251 was also transformed to a halide 254 and a C-10 to C-11 ring closure 
under Friedel-Crafts conditions provided morphinan 255. 
 
 
Reagents and conditions: (a) (i) Dowex 50X8-100, MeOH; (ii) TBSOTf, Hunig's base, 
CH2Cl2; (iii) 2-bromo-6-methoxy phenol, n-Bu3P, DEAD, THF; (b) n-Bu3SnH, AIBN, 
benzene,reflux; (c) DIBAL-H, DCM; (d) (i) TBAF, THF; (ii) (COCI)2, DMSO, NEt3, 
CH2Cl2; (e) CF3SO3H; (f) MsCI, NEt3; (g) AICl3, benzene. 
Scheme 35: Completion of synthesis of morphinan 255. 
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Heck cyclization 
Radical cyclization studies resulted in the wrong stereochemistry at C-14 carbon that 
prompted Hudlický‟s group to design another approach based on Heck cyclization 
reaction. This approach also used an isoquinoline system similar to radical cyclization 
approach. β-Bromoethylbenzene 5, Scheme 36, was used as the starting material for 
biooxidation, selective reduction and protection of both hydroxyl groups delivered 256. 
Displacement of bromine with oxazolidine-1,4-dione completed the synthesis of 257. 
More reactive amide carbonyl was selectively reduced and N-acyliminium ion–olefin 
cyclization provided 258, elimination of halide followed by hydrolysis of benzoate esters 
afforded 259.  Tosylation of distal hydroxyl group followed by Mitsunobu inversion 
generated 260 that upon hydrolysis of benzoate delivered the epoxide 261. 
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Reagents and conditions: (a) (i) Escherichia coli JM109 (pDTG601) (10g/L); (ii) PAD, 
AcOH, MeOH; (iii) benzoic acid, DCC, CH2Cl2; (b) oxazolidine-1,4-dione, 
tetramethylguanidine, THF; (c) (i) NaBH4, MeOH, THF; (ii) AlCl3, CH2Cl2 (cis: trans = 
3.7 : 1); (d) (i) DBU, DMSO; (ii) NaOMe, THF; (e) (i) TsCl, py, DMAP; (ii) benzoic 
acid, PPh3, DEAD, THF; (f) NaOMe, MeOH, THF. 
Scheme 36: Synthesis of epoxide 261. 
 
A regio- and stereoselective ring opening of 261 using the potassium salt of guaicol 262 
generated 263, Scheme 37 that already contains all carbon atoms of morphine with 
correct stereochemistry at C-5 and C-9. An intramolecular Heck cyclization was designed 
as the key step to generate the furan ring with a concomitant closure of the C-13 stereo 
center. A similar strategy was already known from previously reported procedures.
95, 108
 
Heck cyclization furnished pentacyclic carbamate 264 in good yield. Reduction of 
oxazilidinone using DIBAL-H furnished 265. Desilylation and hydrogenation followed 
by Swern oxidation provided aldehyde that underwent a Friedel-Crafts type cyclization to 
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obtain morphinan 266.
109
 The only problem encountered in this synthesis was the 
generation of epi-C-14 stereo center that originated from the hydrogenation of C-8/C-14 
olefin.  
 
 
Reagents and conditions: (a) (i) DME, 18-crown-6; (ii) TBSOTf, Hunig's base, CH2Cl2; 
(b) Pd(PPh3)4, Proton Sponge™, toluene; (c) DIBAL-H, CH2Cl2; (d) (i) TBAF, THF, 
H2O; (ii) H2, PtO2, AcOH; (iii) (COCI)2, DMSO, NEt3, CH2Cl2; (iv) CF3SO3H. 
Scheme 37: Synthesis of morphinan 266. 
 
In 2007, Hudlický designed an enantiodivergent route towards the synthesis of 
codeine.
110
 Setting the stereochemistry at C-5 carbon was the key part in this design as it 
controls all the subsequent bond-forming processes. The starting material chosen for both 
approaches is homochiral diene diol 7, Scheme 38, generated by the enzymatic oxidation 
of β-bromoethyl benzene. The diol was converted to Boc-protected amine 267 and was 
coupled with phenol 180 via a Mitsunobu reaction to provide 268 that has C-5 
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configuration opposite to the natural isomer. Intramolecular Heck cyclization was 
occurred syn to the C-5 substituent to provide 269. Vinyl bromide 270 was made via a 
Wittig reaction of aldehyde 269 and a second Heck cyclization using Trost‟s condition 
delivered 271 in low yields (44%) to complete the phenanthrene skeleton. Stereocenter at 
C-6 carbon was adjusted by an oxidation reduction sequence after deprotection of the 
silyl group. Oxymercuration of the styrene bond and an intramolecular trapping of the 
mercurium ion with amino group after removal of Boc-protecting group followed by 
reduction produced ent-codeine (272) to complete the synthesis in 14 steps from β-
bromoethylbenzene. The final transformation was plagued with low yields but all 
attempts to use Trost‟s photo stimulated protocol95a were unsuccessful.  
 
Reagents and conditions: (a) (i) PAD, AcOH, MeOH; (ii) Ac2O, NEt3, DMAP; (iii) 
MeNH2, K2CO3, –40 °C;  (iv) (Boc)2O, NEt3, MeOH; (v) TBSCl, imidazole, –78 °C; (b) 
n-Bu3P, DIAD, THF, 0 °C; (c) Pd(OAc)2, Ag2CO3, dppf, toluene, 110 °C; (d) 
PPh3CH2Br2, t-BuOK, THF, –60 °C; (e) Pd(OAc)2, Ag2CO3, dppp, toluene, 110 °C; (f) (i) 
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TBAF, THF; (ii) IBX, DMF; (iii) NaBH4, CeCl3, MeOH; (iv) TFA, CH2Cl2; (v) 
Hg(OAc)2, NEt3, THF;  LiAlH4 
Scheme 38: Second generation synthesis of ent-codiene via Heck cyclization reaction. 
 
Later in 2009, synthesis of natural codeine was completed using this enantiodivergent 
approach.
110-111
  A double Mitsunobu inversion was designed for the installation of the 
natural configuration at C-5 carbon center, but this route always led to poor yields. A 
modified approach was implemented in the synthesis of ether-bridge in 274, Figure 17; a 
regio and stereoselective opening of the epoxide 273 with a phenoxide delivered ether 
274; the completion of the synthesis was achieved by following the same sequences as 
those leading to the unnatural series. 
 
 
Figure 22: Enantiodivergent synthesis of (–)-codeine. 
 
A third generation approach for the synthesis of opiate alkaloids were designed based on 
similar Heck cyclization approach. A major variation in this route was the generation of 
B and D-rings. Three different routes were designed to attain these rings that include an 
aldol, Mannich or aza-Prins cyclization.  
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The synthesis of A-ring started from commercially available isovanillin 275, Figure 22, 
which was converted to acetal protected phenol 277 in 4 steps with an overall yield of 
48%.  
 
 
Figure 23: Synthesis of A-ring fragment. 
 
Synthesis of C-ring started from β-bromoethylbenzene 5, Figure 24, biooxidation and 
subsequent protection led to the formation of 278 that underwent displacement of halogen 
with amine functionality and further protection delivered allylic alcohol 279. Mitsunobu 
coupling of A and C-ring fragments and an intramolcular Heck cyclization as seen 
earlier, accomplished the synthesis of tricycle 280.  
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Figure 24: Synthesis of ent-neopinone. 
 
Initial attempts to generate the B-ring were unsuccessful. At this point a similar approach 
was published by Fukuyama;
101
 following his protocol, Boc-protecting group in 280, 
Figure 24, was removed and the amine was reprotected with 2,4-dinitrobenzenesulfonyl 
group and oxidation provided 281. Under acidic conditions, it underwent cyclization and 
the alcohol was protected with MsCl, generated mesylate 282a and dienone 282b. 
Removal of the protecting group with thioglycolic acid, 1,6-conjugate addition furnished 
the final molecule ent-neopinone (210b).
112
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Recent synthesis: A nitrone cycloaddition/radical cyclization approach 
A recent synthesis from Hudlický group studied the stereochemical outcomes of a nitrone 
cycloaddition or a radical cyclization.
113
 Previous work suggested that an intramolecular 
nitrone cycloaddition can be used to control the relative stereochemistry of C-9/C-14.
114
 
  The proposed synthesis begins with the biooxidation of 1-phenyl-2-acetoxyethane 
283, Figure 25; following the same chemical sequences as in earlier mentioned syntheses 
led to the formation of allylic alcohol 284. Mitsunobu inversion with a suitable aromatic 
partner accessed 285, a Heck cyclization attained tricycle 286.  
 
 
Figure 25: Synthesis of tricycle 286. 
 
Acid hydrolysis led to the formation of aldehyde 287, Scheme 39, and the in situ 
generated nitrone 288 underwent [2+3] cycloaddition to adduct 289. Surprisingly, the 
stereochemical outcome from the cycloaddition gave incorrect C-9/C-14 relationship. 
Hence, adduct 289 was converted to styrene 290 through a Hoffmann elimination of 
trialkyl ammonium salt resulted from treatment of 289 with Meerwein salt and LiAlH4. 
Oxidation of the primary alcohol and a reductive amination followed by Boc-protection 
resulted in the formation of ethyl amino side chain. Desilylation and oxidation with 
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concomitant elimination of amino alcohol delivered tetracycle 291; a known intermediate 
for the synthesis of ent-codienone and ent-codeiene. The [2+3] cycloadditon was repeated 
with nitrile oxide, but provided the same stereochemical outcome. 
 
 
 
Reagents and conditions: (a) 50% aqueous TFA, toluene, 50 °C, 92%; (b) 
NHMeOH·HCl, Hunig‟s base, toluene, reflux, 38%; (c) (i) Meerwein salt, CH2Cl2, then 
LiAlH4, THF, 76% over 2 steps; (ii) Dess–Martin periodinane, CH2Cl2, 75%; (d) (i) 
NH2Me·HCl, NEt3,Ti(i-PrO)4, MeOH, then NaBH4; (ii) (BOC)2O, EtOH, 66% over 3 
steps; (iii) TBAF, THF; (iv) Dess–Martin periodinane, CH2Cl2, 51% over 2 steps. 
Scheme 39: Nitrone cycloaddition approach for the formal synthesis of ent-codeine. 
 
A radical cyclization approach using SmI2 was also investigated; aldehyde 287, Scheme 
40, underwent radical cyclization to generate tetracycles 292 and 293. This mixture was 
hydrogenated to convert 292 to 293, which led to styrene 294 in two steps. An oxidation 
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of primary alcohol provided aldehyde 295, an intermediate that is already known, thus 
formalizing the synthesis of ent-hydrocodone. 
 
 
Reagents and conditions: (a) SmI2, HMPA, THF, 50%; (b) H2, Pd/C, MeOH, 92%; (c) (i) 
MsCl, NEt3, CH2Cl2 ; (ii) NaOH (aq), MeOH, 69% over 2 steps; (d) Dess–Martin 
periodinane, CH2Cl2, 72%.   
Scheme 40: Formal synthesis of ent-hydrocodone via a radical cyclization reaction.  
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3. Discussion 
 
3.1 Introduction 
Morphine is one of the oldest drugs known to man and it plays an important role as an 
analgesic for pain relief. All the unnatural derivatives of morphine alkaloids currently 
used in medicine are obtained by the semi synthesis of morphine alkaloids isolated from 
natural sources. Morphine is the principal constituent of opium (latex isolated from 
the poppy plant Pappaver somniferum) along with other alkaloids such as codeine, 
thebaine, papaverine etc.
56, 58
 A brief history of morphine has already been discussed in 
chapter two of this dissertation. The history of total synthesis of morphine alkaloids spans 
over 60 years since the first synthesis of morphine by Gates in 1952.
68
 The quest for a 
practical synthetic route that can compete with isolation from natural sources remains an 
unsolved problem. More than 40 total and formal syntheses of morphinans are known so 
far, but none of them meets the requirement of a truly practical synthesis. As we 
discussed earlier, it can result from a complete “dissonant relationship” present in 
morphine. 
82a
 The only notable synthesis was accomplished by Rice in 1980 that comes 
close to a practical synthesis of morphine.
87
  
One of the long standing goals in Hudlický‟s group is to develop an efficient route to 
morphine alkaloids. All of his approaches are based on the utilization of chiral cis-
cyclohexadienediols as the starting materials obtained by the enzyme mediated 
dihydroxylation of aromatics. This strategy has been effectively applied in many 
syntheses of morphine alkaloids by Hudlický and co-workers as discussed in the 
historical section of this thesis. 
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This chapter describes two different approaches to morphine alkaloids. The first section 
involves the synthesis of dihydrocodeine and hydrocodone starting from bromobenzene. 
The key steps involved in this synthesis are two Claisen rearrangements, an 
intramolecular amidation reaction, a Friedel-Crafts type cyclization and an etherification 
reaction through the opening of an epoxide.
115
 The second section describes the synthesis 
of ent-hydromorphone starting from β-bromoethyl benzene. A dearomatizive 
intramolecular cycloaddition/amination strategy was utilized for this efficient 
synthesis.
116
  
3.2 Total synthesis of dihydrocodeine and hydrocodone 
The pentacyclic core of the morphine alkaloid (1), Figure 26, can be generated through an 
intramolecular etherification reaction that resulted from the opening of an epoxide. The 
B-ring of the alkaloid can be generated form a Friedel-Crafts type ring closure reaction. 
Hydrolysis of oxazilidinone 11 and an intramolecular amidation followed by an oxidation 
will generate the aldehyde 297. The most difficult part of the synthesis is the installation 
of C-13 quaternary carbon center that can be formed through a [3,3]-sigmatropic 
rearrangement of alcohol 298, which can be generated through a coupling reaction 
between A- and C-ring fragments 299 and 9a respectively. Synthesis of C-ring fragment 
and the installation of C-9 and C-14 stereocenters can be attained through another [3,3]-
sigmatropic rearrangement of an intermediate derived from cyclohexadienediol 6 that can 
be obtained from bromobenzene 4 through enzymatic dihydroxylation. 
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Figure 26: Retrosynthetic analysis for the synthesis of morphine alkaloids. 
 
One of the key strategies in this approach is the generation of the key intermediate 9a, 
Figure 26, using Claisen rearrangement along with C-9 and C-14 stereo centers. Claisen 
reaction or [3,3]-sigmatropic rearrangement was reported by Ludwig Claisen in 1912 
where he described the transformation of phenylallyl ether 300, Figure 27, to 2-allyl 
phenol 303 through an intermediate 302.
117
 The oxygen can be replaced by its sulfur or 
nitrogen analogues. Many versions of Claisen rearrangements have been reported since 
the discovery made by Ludwig Claisen. These reactions can be effectively catalyzed 
under different conditions; these topics have been extensively reviewed in many 
publications.
118
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Figure 27: First reported [3,3]-sigmatropic rearrangement by Ludwig Claisen. 
 
[3,3]-Sigmatropic rearrangements of lithium enolates of allyl esters at lower temperatures 
were reported by Robert E. Ireland in 1972.
119
 He was able to prepare γ,δ-unsaturated 
acid 307, Figure 28, of corresponding allyl ester 304 under mild conditions. He also 
reported quenching of lithium enolates like 305 with trimethylsilyl chloride as 
advantageous for these reactions to obtain silylenol ethers of the type 306 that showed 
better stability compared to enolate ethers of the type 305. He also described the 
stereochemical control of [3,3]-sigmatropic rearrangement through stereoselective 
enolate formation.
120
 
 
 
Figure 28: [3,3]-sigmatropic rearrangement of lithium enolates. 
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The first synthesis of an amino acids by Claisen rearrangement was reported by Steglich 
in 1975.
121
 In 1982, Ireland-Claisen rearrangement of glycine allylic esters was reported 
by Bartlett and co-corkers.
122
 Another variation of the Ireland-Claisen reaction was 
reported by Uli Kazmaier in 1994, where he prepared γ,δ-unsaturated acids 309 and 310, 
Figure 29, from glycine allylester 308. This rearrangement occurs with high 
diastereoselectivity; trans-substituted allyl esters led to syn as the major product and cis-
allyl esters produced anti as major products. He proposed formation of a chelate-bridged 
metal enolate 311, which can undergo [3,3]-sigmatropic rearrangement at low 
temperatures.
3
 Addition of metal salts that would lead to chelation resulted in the 
formation of stable enolates that cannot decompose at higher temperatures. Stability and 
reactivity of these metal salts vary among which ZnCl2 provided best results. Kazmaier 
proposed the formation of a chelate-bridged stabilized carboxylate intermediate rather 
than the formation of a high energy ester enolate as the reason for the accelerated 
rearrangement. Replacement of the acidic amide proton with a methyl group resulted in 
complete loss of reactivity. Later, Kazmaier and co-workers developed chiral versions of 
these reactions by incorporating chiral ligands.
123
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Figure 29: Kazmaier-Claisen rearrangement. 
 
The early work by Hudlický group focused on the synthesis of 312, Figure 30, from 313, 
through a Kazmaier-Claisen rearrangement. The amino acid generated contains C-9 and 
C-14 stereocenters in the right configuration, and was the key intermediate for the 
synthesis of morphine. In order to test the viability of this methodology, different model 
compounds were prepared from enzymatically derived cis-cyclohexadienediols of the 
type 43.  
 
 
Figure 30: Synthesis of key intermediate from enzymatically derived 
cyclohexadienediols. 
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Different gycinate esters were prepared from diols (R = Cl, Me, aryl) and were tested for 
Kazmaier-Claisen rearrangement.
124
 Even though Kazmaier-Claisen rearrangement is 
known to proceed with high diastereoselectivity, this rearrangement provided a mixture 
of diastereomers at C-9 (morphine numbering) presumably because the rearrangement 
proceeded through both chair and boat transition states despite the fact that only the Z-
enolate species was generated from glycinates. It is known form Ireland‟s work that 
cyclohexenyl derivatives containing substituents on the ring frequently undergo the 
Ireland-Claisen rearrangement through both chair and boat transition states and therefore 
result in isomeric mixtures.
125
 During these model studies, formation of the undesired 
isomer predominates but still it was a proof of concept that Kazmaier-Claisen 
rearrangement can be used to set the C-9 and C-14 stereocenters. Also, the undesired 
isomer can be equilibrated to the required isomer under base catalyzed conditions. 
3.2.1 Synthesis of A and C-ring fragments  
Our synthetic studies started from the enzymatic dihydroxylation of bromobenzene 4, 
Scheme 41, with E. coli JM109 (pDTG601a)
31, 126
 to obtain diol 6 (X = Br).
43
 These 
biotransformations provide 15 g/L diol and each run provided 200-250 g product. The 
distal double bond that is less substituted was selectively reduced with diimide generated 
from potassium azodicarboxylate (PAD) to obtain compound 314 in 75-80% yield. Then 
the distal hydroxyl group was protected as silyl ether 315 with 93% yield. Then the 
proximal hydroxyl group was coupled with Boc-protected glycinate ester. Following a 
procedure that was already known,
127
 mixing Boc-glycine, DCC and DMAP before 
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adding the alcohol 315, led to mixture of compounds 316 and 317 that proved to be 
tedious in terms of separation. The 
13
C NMR spectra of 316 exhibited four carbonyl 
signals, a signal at δ 171.8 ppm corresponding to the ester carbonyl, a signal at δ 167.7 
ppm corresponding to the amide carbonyl, and two signals at δ 155.7 ppm, and δ 151.5 
ppm corresponding to the Boc carbamate groups; instead of two carbonyl signals (δ 169.6 
ppm, δ 155.3 ppm) exhibited by 317.  This problem was solved by adding the alcohol 
before mixing Boc-glycine, DCC and DMAP to obtain the desired product 317 in yields 
ranging from 88-92%. All these reactions described in this scheme proved to be efficient 
and scalable.  
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Reagents and conditions: (a) E.coli JM109 (pDTG 601a), 15 g/L; (b) PAD, AcOH, 
MeOH, 75-80%; (c) TDS-Cl, CH2Cl2, –78 °C  rt, 93%; (d) CH2Cl2, Boc-Gly, DCC, 
DMAP, 88-92%. 
Scheme 41: An efficient route for the synthesis of glycinate ester. 
 
The Boc-protected glycinate ester 317, Scheme 42, was subjected to Kazmaier-Claisen 
rearrangement conditions; two diastereomers of amino acid 319 were obtained via 
intermediate 318. It proved to be difficult to separate the amino acid diastereomers 320 
and 321, so the acid functionality in 319 was converted to methyl esters 9 a and 9 b with 
diazomethane. This reaction proved to be very challenging as slight variation in 
temperature led to inconsistent results. Best results were obtained when the reaction 
mixture was kept at –78 °C during the addition of LDA and then slowly warmed to room 
temperature over a period of 18 hours. Dropwise addition of LDA to a solution of 
glycinate ester 317 and ZnCl2 in THF at –78 °C followed by esterification resulted in the 
formation of amino acid with 44% yield and 3.4:1 isomeric ratio favoring the undesired 
diastereomer. Reversing the addition of reagents, namely dropwise addition of a solution 
of glycinate ester 317 and ZnCl2 to LDA in THF at –78 °C followed by esterification 
resulted in the formation of diastereomers 9 a and 9 b with 65% yield and 1.8:1 isomeric 
ratio favoring the undesired diastereomer. The undesired diastereomer 9 b was subjected 
to base-catalyzed equilibration to eventually provide pure 9 a with the correct absolute 
configuration at C-9 (morphine numbering). The separation of diastereomers was not 
economical in terms of the amount of silica gel, solvent, and time. This tedious column 
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chromatography problem was solved by using suction column chromatography as 
described by Hudlický.
128
 
 
 
Reagents and conditions: (a) ZnCl2, LDA, THF, –78 °C  rt; then quench with 1N HCl; 
(b) CH2N2, Et2O, 0 °C, 65% with 1.8:1 isomeric ratio after two steps; (c) DBU, THF, 
reflux, 39%. 
Scheme 42: Kazmaier-Claisen rearrangement of glycinate ester 294. 
 
The stereochemical outcome from the Kazmaier-Claisen rearrangement depends on the 
fixed enolate geometry arising from the chelation with the metal. The rearrangement can 
proceed through a chair or a boat like transition state.  Six-membered rings are known to 
prefer a boat like transition state during similar reactions.
129
 This is preferentially due to 
the steric interactions between the cyclohexenyl ring and the solvated metal in the chair 
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like transition state. But, studies by Ireland showed that rearranged product can be 
generated through both chair and boat transition state in silylketene acetals.
125
 Many 
previous results pointed out that the effect of bulky silylether is negligible in this 
rearrangement.
130
 As depicted in Figure 31, the bromine atom at the -position in the 
allylic carbon can lead to unfavourable interactions with the solvated metal in a boat like 
transition state 322, Figure 31, and the cyclohexenyl ring in a chair like transition state 
323. Because of these two steric interactions, both transition states have a very small 
energy difference. This led to the product formation by both pathways, therefore giving a 
mixture of diastereomers.
124
 
 
 
Figure 31: Origin of diastereomers in the Kazmaier-Claisen rearrangement of glycinate 
ester 317. 
The equilibration of the undesired isomer 324, Figure 32, to the desired isomer 325 
stopped after reaching 1:1 ratio. Such equilibration is possible because of a more stable, 
hydrogen bonded conformation in cases where X = Br, Cl, as shown in Figure 32. The 
ester functionality is axial in 326 a and equatorial in 326 b. In both orientations, it 
experiences steric hindrance (cyclohexene methylene in 326 a and Boc-group in 326 b) 
and hence equilibration of either diastereomer yields ~1:1 mixture, with eventual 
production of the required isomer by recycling. The corresponding isomeric mixtures 
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where X = methyl or aryl were not responsive to base catalyzed equilibration
131
 due to 
the absence of a hydrogen bonded conformation. This leads to a rigid conformation and a 
sterically crowded environment that reduces the availability of C-9 proton. 
 
 
Figure 32: Base-catalyzed equilibration of undesired isomer. 
3.2.2 Synthesis of tetracyclic core of morphine  
After successfully establishing the C-9 and C-14 stereocenters we turned our attention to 
connect the A- and C-ring fragments of morphine alkaloid. The A-ring fragment; 2,3-
dimethoxyboronic acid 299, Scheme 43, was synthesized starting from 2,3-dimethoxy 
benzene using a known procedure.
132
 Ester 9 a, Scheme 43, was subjected to Suzuki 
coupling with 2,3-diemthoxyboronic acid to produce cleanly compound 327, Scheme 43. 
No attempts were made at this point to elicit the C-10/C-11 closure of carboxylate 327 to 
a complete phenanthrene skeleton by creating the B-ring.  
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Reagents and conditions: (a)Pd(dppf)2Cl2, Cs2CO3, THF, reflux, 94-96%. 
Scheme 43: Coupling of A and C-rings. 
Studies by Gonzalez showed that attempts at the cyclization in 328, Figure 33, using 
either TsOH or PPA failed and resulted in acylation of C-13 to provide 329 instead of 
330.
124, 131
  
 
 
Figure 33: Previous attempts for the synthesis of B-ring via Friedel-Crafts cyclization. 
  
These results prompted us to focus on the installation of C-13 quaternary carbon before 
attempting the C-10/C-11 closure. Another [3,3]-sigmatropic rearrangement (Johnson-
Claisen rearrangement) was planned for the installation of this stereocenter that involves 
the chirality transfer from the C-6 carbon center.  
In 1970, Johnson developed another version of [3,3]-sigmatropic rearrangement which 
involved the formation of an olefinic ester from the allylic alcohol.
133
 Heating allylic 
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alcohol 334, Figure 34, with excess of ethyl orthoacetate 331 in the presence of a 
catalytic amount of acid resulted in mixed orthoacetate 335, which loses ethanol to form 
the ketene acetal 336. This acetal undergoes rearrangement to obtain the γ, δ-unsaturated 
ester 337. These reactions have been widely used in the synthesis of many natural and 
unnatural products since their discovery and are covered in many reviews.
118b, 118e, 134
 
 
 
Figure 34: Johnson-Claisen rearrangement for the synthesis of olefinic ester from allylic 
alcohol. 
 
In order to establish the correct stereochemistry, we decided to remove the silyl 
protecting group in 327, Scheme 44, and the C-6 hydroxyl group in alcohol 338 was 
subjected to the Mitsunobu inversion to obtain the benzoate ester 339. Earlier studies 
from our group showed that the hydrolysis of a benzoate ester to an alcohol and attempts 
to carry out Johnson-Claisen reaction were not fruitful.
127
 Reduction of benzoate ester 
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339 with LiAlH4 provided alcohol 340 in 74% yields over three steps.  The primary 
alcohol in 340 was converted to oxazilidinone 341 via an intramolecular cyclization.  
 
 
Reagents and conditions: (a) Bu4NF, THF, 92%; (b) n-Bu3P, DEAD, BzOH, THF, 0 
°Crt, 95%; (c) LiAlH4, THF, 0 °Crt, 84%; (d) NaH, DMF, 0 °Crt, 95%. 
Scheme 44: Synthesis of oxazilidinone 341. 
 
After synthesizing the oxazilidinone, we turned our attention towards the installation of 
C-13 quaternary carbon through Johnson-Claisen rearrangement. Our studies started by 
treating the alcohol 341, Table 1, with triethyl orthoacetate 332, Figure 34, under acid-
catalyzed conditions. Variety of acids was used for this purpose, but none of the reactions 
led to any satisfactory results. The results of several attempts are shown in Table 1. 
Mixing alcohol with large excess of triethyl orthoacetate and catalytic amount of 
propionic acid in sealed- tube and heating for 18 hours resulted in the formation of 
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propionate ester 342, Table 1. It prompted us to change the catalyst to o-nitro phenol in 
order to avoid the unwanted side reaction. But the reaction mixture was complex with no 
indication of product formation. Attempts to increase the temperature of the reaction 
mixture to 160 °C with a catalytic amount of propionic acid resulted in the formation of 
bridged compound 343 in low yields. These reactions were carried out on a small scale 
and only a milligram of compound 343 was isolated, making the complete 
characterization very difficult. Similar results were observed when the reactions were 
carried out in presence of phenol
135
 or I2-SiO2 as catalyst.
136
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Table 1: Screening of different conditions in Johnson-Claisen rearrangement. 
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We also investigated a modified version of Johnson-Claisen reaction that involved the 
formation of mixed orthoester 345, Figure 35, via the reaction of alcohol 341 and excess 
of diethylketene acetal 344 to obtain the intermediate 346. After formation of this 
intermediate, excess ketene acetal was evaporated and triisiobutylaluminium (TIBAL) 
was added to effect the [3,3]-sigmatropic rearrangement at room temperature.
137
 To our 
surprise, the resulting reaction mixture was quite complex and only alcohol 341 was 
recovered in 34% yield. 
 
 
Figure 35: A modified version of Johnson-Claisen reaction. 
 
The unsuccessful results obtained from the aforementioned reactions prompted us to 
investigate possibilities of other types of Claisen rearrangements for installing the C-13 
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quaternary carbon center. We decided to investigate Ireland-Claisen rearrangement; 
hence alcohol 341 was converted to acetate 348 and was subjected to Ireland-Claisen 
reaction conditions.
119-120, 138
 This reaction only resulted in the formation of alcohol 341 
possibly through an intermediate 348 a as shown in Figure 36. 
 
 
Figure 36: Attempts to generate the C-13 stereocenter via Ireland-Claisen reaction. 
 
The Eschenmoser-Claisen rearrangement
139
 was also investigated as an alternative to 
Johnson-Claisen rearrangement. Alcohol 341, Figure 37, was stirred with N,N-
dimethylacetamide dimethyl acetal 349 and was heated to reflux for several hours 
following a known protocol.
140
 This reaction also resulted in the formation of bridged 
product 343 in low yield in a complex mixture.  
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Figure 37: Eschenmoser-Claisen approach for the installation of C-13 quaternary carbon.  
 
At this point, we turned our attention to a different strategy to install the C-13 quaternary 
carbon center. This approach relied on a cycloaddition reaction of a diene 351, Figure 38, 
with a ketene dimethylacetal 352 to obtain 353 that can be eventually converted to the 
desired molecule 354. Burgess reagent
141
 is known as a mild reagent for effecting 
dehydration reactions; we decided to take advantage of this process that worked well in 
other projects in our group.
142
 Surprisingly, this reaction led to the formation of a bicyclic 
compound 350 in 77% yields. The IR spectrum of 350 did not exhibit any -NH or -OH 
streach, indicating a new C-N bond formation. 
1
H NMR signal exhibits only one alkene 
signal at δ 4.89 ppm. 13C NMR showed two carbonyl signals corresponding to ester 
carbonyl and amide carbonyl. This result along with our previous observations from 
Johnson-Claisen rearrangement confirmed that the nucleophilic character of the 
secondary amide nitrogen causing problems in installing the C-13 quaternary carbon 
center. 
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Figure 38: Unexpected formation of bicycle 350. 
 
Meanwhile, we decided to repeat Johnson-Claisen chemistry on a compound that was 
already known to give a successful result. In 2008, Chida and co-workers reported a 
formal synthesis of morphine.
102, 104
 There key strategy was a cascade Johnson-Claisen 
rearrangement to install both C-13 and C-14 stereocenters as we discussed in earlier 
chapter.
102, 104
 Repeating Chida‟s chemistry to install C-13 quaternary carbon center can 
be helpful to correct any technical errors associated with these reactions. In order to 
obtain the key intermediate to study the [3, 3]-sigmatropic rearrangement, we decided to 
proceed through a different route, much shorter than the one reported by Chida and co-
workers as shown in Scheme 45. Starting from the allylic alcohol 315, Scheme 45, which 
we have already used in the synthesis of our key intermediate, a Suzuki coupling with 
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boronic acid 299 attached both A- and C- ring fragments to produce 355. The alcohol 355 
was then treated with triethyl orthoacetate and catalytic amount of propionic acid to 
obtain the ester 356 through a [3,3]-sigmatropic rearrangement that set the C-14 
stereocenter. Deprotection of silyl protecting group delivered alcohol 357, a Mitsunobu 
inversion followed by selective hydrolysis of benzoyl group led to the formation of key 
intermediate 359. Then we decided to employ Chida‟s conditions for Johnson-Claisen 
rearrangement, led to the formation of diester 360 with the installation of C-13 quaternary 
carbon center. 
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Reagents and conditions: (a) Pd(dppf)2Cl2, Cs2CO3, THF, reflux, 80%; (b) CH3C(OEt)3, 
propionic acid (cat.), 140 °C, 52%; (c) Bu4NF, THF, 86%; (d) n-Bu3P, DEAD, BzOH, 
THF, 0 °Crt, 62%; (d) NaOMe/MeOH, 0 °Crt, 42%; (e) CH3C(OEt)3, o-nitro phenol 
(cat.), 140 °C, 33%. 
Scheme 45: Model reaction for installing C-13 and C-14 stereocenters. 
 
Chida‟s experience along with our previous results confirmed that the side reactions at 
either C-13 or C-6 emanating from the nucleophilic character of the secondary amide 
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nitrogen was causing difficulties in installing the C-13 quaternary carbon center and 
displacing the C-6 group. In order to avoid these side reactions, we decided to protect the 
amide nitrogen in 341, Scheme 46, with a methyl group that was planned to be installed 
at a later stage to provide 362 (56%) and 361 (31%). The formation of 361 was a result of 
the methylation of secondary alcohol along with amide nitrogen. We were quite excited 
to obtain the Claisen rearranged product 11 in 34% yields after heating the alcohol 362 
with triethyl orthoactate and catalytic amount of o-nitro phenol for seven days.  
 
 
Reagents and conditions: (a) NaH, MeI, THF, 0 °C, 56%; (b) CH3C(OEt)3, o-nitro phenol 
(cat.), 140 °C, 51%. 
Scheme 46: Successful implementation of Johnson-Claisen rearrangement for the 
installation of C-13 stereocenter. 
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The orthoester Claisen rearrangement was studied under different reaction conditions and 
the results are summarised in Table 2 shown below. Entry 2 was found to give the best 
results among different conditions studied. When ethanol formed in the reaction mixture 
was continuously removed from the reaction mixture, the yield was improved up to 51% 
and the reaction time was reduced substantially to four days. 
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Table 2: Screening of Johnson-Claisen reaction conditions for the generation of a C-13 
stereocenter. 
Compound 11, Scheme 47, was hydrolysed to acid 363 and was converted to the methyl 
ester 364 using a modified Fischer esterification protocol.
143
 The B-ring in 365 was 
formed through a cyclization reaction that involved an acid catalyzed intramolecular 
amidation. This two-step process was later modified to a single step operation by using 
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the coupling reagent O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium hexafluoropho- 
sphate (HBTU).
144
  
 
 
 Reagents and conditions: (a) 50% aq NaOH, MeOH, 80 °C; (b) TMSCl, MeOH; (c) 
Na2CO3; (d) cat. AcOH, EtOH, 39%; (e) HBTU, DIPEA, CH2Cl2, r.t., 76%. 
Scheme 47: Synthesis of D-ring via an intramolecular amidation reaction. 
 
Oxidation of the primary alcohol in 365 furnished the crucial substrate for the C-10/C-11 
closure, namely aldehyde 366, Scheme 48, in 58% yields over three steps. The C-10/C-11 
closure was studied using different conditions and we were pleased to obtain the desired 
cyclization product 367 under conditions employed by Evans.
145 
 We employed a known 
protocol for the reduction of the benzylic hydroxyl to furnish 369 in 50% over two 
steps.
146
 The one step deoxygenation proceeds through the initial formation of a 
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hydrodiphenylsilyl ether and generation of the oxonium complex 368 by the Lewis acid, 
followed by desiloxylation through the donation of a hydrogen atom.  
 
 
 Reagents and conditions: (a) DMP, CH2Cl2, 82%; (b) BF3·OEt2, CH2Cl2, –20 °Cr.t., 
76%; (c) Ph2SiHCl, cat.InCl3, DCE, reflux, 67%. 
Scheme 48: Synthesis of tetracyclic core of morphine. 
3.2.3 Completion of the synthesis 
Tetracycle 369, Scheme 49, was subjected to epoxidation and an intramolecular opening 
of epoxide 370 established the C-5 stereocenter in 371 with 54% overall yield according 
to the method previously published by Overman.
108a, 147
 Mulzer
148
 and Chida
102
 also used 
a similar strategy in their approaches towards morphine core. 
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Reagents and conditions: (a) m-CPBA, CH2Cl2, 0 °Cr.t.; (b) CSA, THF, reflux, 54% 
after two steps.  
Scheme 49: Synthesis of pentacyclic core of morphine via an intramolecular epoxide 
opening reaction. 
Alcohol 371, Scheme 50, was oxidized in 84% yield to ketoamide 372, from which 
several morphinan derivatives would be easily attained. Thus the full reduction of 372 
gave dihydrocodeine (373) in 71% yield with the correct absolute stereochemistry at C-6, 
which is known to result from the reduction of C-6 ketones already containing the 
dihydrofuran bridge.
94
 Such a process is used frequently to adjust C-6 stereochemistry.
90, 
97, 111, 149
 Finally, reduction of the amide moiety in 371 delivered dihydroisocodeine (226) 
followed by oxidation at the C-6 alcohol provided hydrocodone (153) in 58% yield over 
two steps.  Thus our synthetic efforts resulted in the total synthesis of dihydrocodeine 
(374) and hydrocodone (153), which formalized the synthesis of morphine. 
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Reagents and conditions: (a) DMP, CH2Cl2, 84%; (b) LiAlH4, dioxane, reflux, 71%. 
Scheme 50: Completion of the synthesis. 
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3.3 Total Synthesis of ent-Hydromorphone: An Oxidative Dearomatization/Intra- 
molecular [4+2] Cycloaddition/Amination Sequence 
3.3.1 Introduction 
Diels-Alder reaction is one of the most widely used reactions in organic chemistry. Since 
its discovery in 1928,
150
 Diels-Alder reaction plays an important role in building 
complexity and in the synthesis of fused polycyclic natural products. In 1951, Stork and 
co-workers published a synthesis of cantharidin using Diels-Alder reaction.
151
 A few 
months later, first total synthesis of morphine
68
 was reported by Gates which also utilised 
Diels-Alder reaction. Later, Woodward‟s work demonstrated the potential of this reaction 
by employing it in the synthesis of many complex natural products.
152
  
The application of Diels-Alder reaction is further demonstrated in intramolecular 
versions, which are known as the intramolecular Diels-Alder (IMDA) reactions. This can 
be further subdivided in to Type 1 and Type 2 IMDA reactions depending on the position 
that the dienophile is tethered (See Figure 39).  
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Figure 39: Type 1 and Type 2 IMDA reactions. 
The aforementioned reactions are widely studied and have been a topic for many reviews 
over the years. 
153
 
The second approach involves an advanced strategy to construct the morphine skeleton 
by an intramolecular [4+2] cycloaddition of dienone 380, Figure 40, produced by 
oxidative dearomatization of a phenol such as 379. Previous studies have demonstrated 
that the configuration at C-5 carbon controls the stereochemical outcome in subsequent 
cyclization reaction.
95, 111
 A toluene dioxygenase-mediated dihydroxylation of an 
appropriate arene will generate the homochiral portion 378 and a Mitsunobu reaction can 
be used to couple the phenolic fragment. An amine functionality at C-9 and a suitable 
leaving group at C-16 will lead to the incipient closure of the ethylamino bridge in 381 
(or its aromatized equivalent), as shown in Figure 40.  Completion of the synthesis can be 
achieved by a deprotection and oxidation sequence to obtain ent-hydromorphone (16). 
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Figure 40: Advanced strategy to access morphinans by cycloaddition protocol. 
 
A model study was designed to test the viability of this cycloaddition approach. Instead 
of using an advanced species, we decided to start our studies using simpler molecule such 
as 384, Figure 41, which did not contain the nucleophilic group Y or a leaving group X as 
in 380, Figure 40. The expected [4+2] cycloaddition would generate 383, then the known 
hydroamination methodology
95, 110-111
 would be used to set C-9 late in the synthesis.  
The retrosynthetic analysis involves an enzymatic dihydroxylation of the β-
bromoethylbenzene 5, Figure 41, which undergoes further chemical manipulations to 
provide allylic alcohol 12. This can be tethered to the phenolic ring via a Mitsunobu 
reaction to access ether 13; dearomatization of 13 to dienone 384 and a [4+2] 
cycloaddition reaction provides tetracycle 383 as shown in Figure 41. A late stage 
introduction of C-9 stereochemistry can be attained via a hydroamination reaction of a 
113 
 
rearomatized substrate such as 382 and a deprotection-oxidation sequence completes the 
synthesis of ent-hydromorphone (16).  
 
 
Figure 41: Retrosynthetic analysis for the synthesis of ent-hydromorphone. 
 
Only a few syntheses of opiate alkaloids utilized Diels-Alder reactions to construct the 
complexity in the morphine core. The first reported synthesis of morphine by Gates 
demonstrated the power of [4+2] cycloaddition reaction by constructing the C-ring.
68
 In 
2009, Stork reported the construction of B and D-rings through the application of IMDA 
reaction.
154
 But it has been used only once in a direct construction of ring B of morphine 
skeleton, namely in an intermolecular [4+2] approach by Tius.
155
 They envisioned an 
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intermolecular cycloaddition between a substituted benzoquinone 387, Figure 42, and a 
styrene 386 to develop the phenanthrene core of morphine (1) through the formation of 
B-ring as evidenced in 385. 
 
 
Figure 42: Diels-Alder approach for the construction of B-ring by Tius. 
Earlier work from our group demonstrated the construction of B-ring leading to 
morphinan substructure via an intramolecular Diels-Alder reaction.
105-106
 It has been 
already discussed in the historical section of this thesis. Even though the tricyclic core 
which contains B-C-E rings of morphine with five stereocenters was created, the 
installation of aromatic part still provided a challenging task (See Figure 43). An 
enantiomerically pure substrate like 388, Figure 43, is easily available by taking 
advantage of enzymatically derived cis-cyclohexadiene diol. But the construction of B-
ring via an IMDA reaction is rather difficult process in such a system due to the fact that 
high energy conditions is required to overcome the aromatic stabilization energy.  
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Figure 43: Initial ideas for the synthesis of phenanthrene core. 
The aforementioned statement is well evidenced from our initial model reactions to effect 
such a cycloaddition reaction. All attempts led to [3,3]-sigmatropic rearrangement to 
provide 391, Scheme 51, no evidence for the cycloaddition product was obtained. These 
results turned our attention to destroy the aromaticity of A-ring to generate a reactive 
diene moiety to effect the [4+2] cycloaddition. Many methods are available for the 
preparation of a dearomatized intermediate to effect the cycloaddition. The 
dearomatization reaction and its application in synthesis of complex natural products 
have been extensively reviewed.
156
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Reagents and conditions: (a) (i) 3-bromo-2-methylprop-1-ene, K2CO3, DMF, 76%; (ii)  
CH3PPh3Br, n-BuLi, THF, –78 °C  0 °C then reflux for 4 h, 95%; (b) m-xylene, sealed 
tube, reflux, 9 days, 18%. 
Scheme 51: Model reactions to effect a [4+2] intramolecular cycloaddition. 
A Diels-Alder/Cope sequence similar in concept to our model studies was published by 
Rodrigo in 1998.
157
 His studies include oxidative dearomatization of phenols
158
 and 
subsequent cycloaddition on structurally different substrates to various natural products. 
A recent work from his group showed a more advanced dearomatization/cyclization 
strategy to synthesize partial morphine skeleton that includes rings A-B-C-E.
159
 His 
synthetic studies involve dearomatization of phenol 392, Figure 44, led to a mixture of 
many products. One drawback of this approach was the quinone generated by 
dearomatization can act as a dienophile or diene to provide 393 or 394 successively. The 
formation of dimer (24%) was also observed during this process. The mixture of 393 and 
394 (obtained in 64% yield) can undergo Cope rearrangement to generate the required 
product. The tetracycle 393 is further elaborated to the natural product (–)-
indolinocodeine in six steps. 
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Figure 44: Rodrigo's synthesis of indolinocodeine. 
3.3.2 Synthesis of dearomatizive cyclization precursor  
The above precedents bode well for a successful approach, which we began with the 
synthesis of the two subunits required to join together. Our synthetic efforts began with 
synthesizing 400, Scheme 52, following a known protocol.
112
  The first step of the 
synthesis was the generation of homochiral diol 7 by dihydroxylation of 5 by whole-cell 
fermentation with E. coli JM 109 (pDTG601A).
31
 It was immediately subjected to a 
selective reduction with potassium azodicarboxylate to obtain 396, followed by 
protection of the diol to give acetonide 397. The amine functionality was introduced by 
displacement of bromine in 397 with methylamine to provide 398. A one-pot operation 
that includes hydrolysis of the acetonide and protection of the secondary amine as a Boc- 
carbamate delivered 399. A regioselective silylation of the distal hydroxyl group 
completed the synthesis of C-ring fragment 400. 
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Reagents and conditions: (a) E. coli JM 109 (pDTG601A), 10–15 gL–1; (b) potassium 
azodicarboxylate, AcOH, MeOH, 0 °C, 83%; (c) 2,2-dimethoxypropane, acetone, TsOH, 
80%; (d) MeNH2, K2CO3, THF, sealed tube, 93%; (e) (i) 3M HCl, EtOH; (ii) Boc2O, 
NaHCO3, EtOH, 74% (2 steps); (f) TBSCl, imidazole, CH2Cl2, –78 °C  RT, 92%; (g) 
(i) TFA, CH2Cl2; (ii) TsCl, Et3N, CH2Cl2, 0 °C RT. 
Scheme 52: Synthesis of C-ring fragment. 
The arene coupling partner 405, Scheme 53, was synthesized from 3,4-
dihydroxybenzaldehyde 402 by adjustment of a known protocol.
160
 A regioselective 
acetylation of 3,4-dihydroxybenzaldehyde 402 produced the mono-acetylated derivative 
403. Protection of the p-hydroxyl phenol with MOMCl under mild basic conditions 
afforded aldehyde 404; the required phenol 405 was attained after the hydrolysis of the 
acetyl group.  
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Reagents and conditions: (a) Ac2O, NaOH, THF, 0 °C, 82–85%; (b) MOMCl, K2CO3, 
DMF, 0 °C  RT, 76–80%; (c) K2CO3, MeOH, RT, 88–90%. 
Scheme 53: Synthesis of A-ring fragment.  
3.3.3 Synthesis of tetracyclic core through an intramolecular cycloaddition  
After successfully synthesizing the A and C-ring fragments, our next goal was to connect 
both fragments. We performed a Mitsunobu reaction between the phenol 405 and alcohol 
400, Scheme 54, which gave access to the ether 406; a Wittig reaction completed the 
synthesis of styrene 408. Next challenge in the synthesis was the selective removal of 
MOM-protecting group in the presence of other acidic labile protecting groups. It was 
achieved by applying a known protocol employed by Rawal and co-workers;
161
 under 
mild conditions phenol 13 was produced, and this is the key intermediate required for the 
cyclization studies. 
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Reagents and conditions: (a) TMAD, PBu3, THF, 0 °C  RT, 81–85%; (b) CH3PPh3Br, 
n-BuLi, THF, –78 °C  0 °C then reflux for 4 h, 82–88%; (c) ZnBr2, 
CH3(CH2)10CH2SH, CH2Cl2, RT, 10 min, 92%; (d) PhI(OAc)2, MeOH, reflux, 16 h, 50%; 
(e) TFA, CH2Cl2, Ac2O, 0 °C, 15 min. 
Scheme 54: Intramolecular [4+2] cycloaddition approach towards the synthesis of 
tetracyclic core of morphine. 
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Applying similar conditions to remove MOM group from tosylated compound 409, 
Scheme 55, did not provide any evidence of required product rather than undesired side 
products 413 (46%) and 414 (37%).  
 
 
Reagents and conditions: (a) ZnBr2, CH3(CH2)10CH2SH, CH2Cl2, RT. 
Scheme 55: Attempts to cleave MOM group in 409. 
Our dearomatization studies began with the exposure of phenol 13, Scheme 54, to 
diacetoxy iodobenzene (DAIB) in MeOH at room temperature and then under reflux 
conditions, led to tetracycle 411 via an intermediate 410. The intermediate 410 is 
supposed to be very reactive species but we did not observe any cyclized product without 
heating the reaction mixture. Even though, this result was exciting, re-aromatization of 
411 was proved to be a little challenging. Acid-mediated conditions can lead to a 
deprotection of Boc-group before re-aromatization, which can result in conjugate addition 
to dienone to produce unwanted side product. Following Rodrigo‟s protocol,159 treating 
411 with TFA in presence of acetic anhydride provided acetamide 412. Unfortunately this 
route led to the formation of acetamide; all our attempts to hydrolyze the acetamide were 
unsuccessful.  
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These results prompted us to investigate other reagents for the dearomatization reaction. 
Introducing a better leaving group than –OMe group can solve the problem of re-
aromatization reaction. Exposure of 13, Scheme 56, to lead tetraacetate in refluxing 
dichloroethane provided [4+2] adduct 416 in 50% isolated yield via an intermediate 
dienone 415. The reason for low yields of this reaction can be formation of two 
diastereomers during the generation of intermediate dienone 415 with only one 
diastereomer undergoing the cycloaddition.  
As only one cycloaddition product was observed in the reaction seems to indicate that 
dienone 415 underwent the cycloaddition exclusively at the site of the exocyclic diene; 
none of the dimerization product was observed in this reaction. The endocyclic 
cycloaddition product was detected only once in about 3-4% yield. Even though the 
endocyclic diene is quite reactive, the exclusive formation of 416 can be attributed to 
steric reasons, which deny the dienophile the proximity of the endocyclic diene. The 
13
C 
NMR spectrum of 416 exhibited three carbonyl signals; a signal at δ 188.2 corresponding 
to the enone, signal at δ 170.9 showed the presence of the ester carbonyl from the acetyl 
group, and the amide carbonyl appeared at δ 155.4. Even though 416 obtained as a single 
stereoisomer, assignment of stereochemistry at C-4/C-12 was complicated by the 
presence of rotamers. Also these stereocenters were immediately destroyed by re-
aromatization reaction. 
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Reagents and conditions: (a) Pb(OAc)4, DCE, reflux, 4 h, 50%; (b) TFA, CH2Cl2, 0 °C, 
15 min. 
Scheme 56: Synthesis of tetracycle 414 via re-aromatization.  
Dienone 416 was treated with trifluoroacetic acid to afford phenol 417 via re-
aromatization and the concomitant hydrolysis of the Boc carbamate. 
3.3.4 Synthesis of D-ring and completion of the synthesis  
Our next aim was to construct the D-ring to complete the synthesis. A hydroamination 
reaction of 417, Scheme 56, was designed; however, all our attempts failed to install the 
ethylamino bridge through an aminomercuration were unsuccessful. A similar strategy 
was successfully employed in our previous work;
110-111
 Hg(OAc)2 mediated 
oxymercuration and subsequent reductive work up with lithium aluminium hydride 
constructed D-ring successfully.  Analysis of the crude reaction mixture suggested some 
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evidence of hydroamination under the aforementioned conditions but the isolation of pure 
products from these reactions was not possible. The failure of the aminomercuartion was 
likely due to the instability of phenol 417.  
We also observed the formation of 418, Scheme 57, produced by the treatment of 416 
with trifluoroacetic acid for longer period of time. Both 417 and 418 converted to the 
corresponding tosyl amides 419 and 420 by treatment with excess tosyl chloride. This 
resulted in concomitant tosylation of the phenolic hydroxyl along with the amine in 45% 
yield, over two steps. Removal of the silyl group from 419 delivered 420 in good yields. 
The establishment of the ethylamino bridge was accomplished by a nitrogen-centered 
radical cyclization enabled by a dissolved-metal reduction of the tosyl amide according to 
conditions adapted from the work of Parker
89a
 and Chida.
104  
This reaction worked very 
efficiently on both protected (419) and unprotected (420) compounds. The reductive 
cyclization approach was superior to hydroamination conditions that previously 
employed in our group. Hydroamination of 419 produced pentacycle 421 in 82-86% 
yields. To our surprise, cyclization of free alcohol 420 gave 422 in 93% yields.  
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Reagents and conditions: (a) TFA, CH2Cl2, 0 °C, 15 min; (b) TsCl, Et3N, CH2Cl2, 0 °C 
RT, 45% over two steps; (c) TBAF, THF, RT, 86%; (d) Li, tBuOH, NH3(liq), THF, –
78 °C, 10 min [82–86% for 419 to 421; 93% for 420 to 422]; (e) tBuOK, PhCOPh, 
PhCH3/DME, 85 °C, 8 h, 44%. 
Scheme 57: Completion of the synthesis of ent-hydromorphone. 
 
Oxidation of 422, Scheme 57, to ent-hydromorphone (16) was accomplished with 
benzophenone and tBuOK in 44% yield (83% based on recovered starting material) using 
a modified procedure from Woodward and Rapoport.
162
 Because of poor solubility of 422 
in most of the solvents, the reaction did not proceed to completion, and starting material 
(53%) was recovered from the reaction. Another explanation for the low yield is the trans 
relationship between the C-5 and C-6 positions in the ent-dihydroisomorphine 422. 
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Rapoport has provided a reasonable explanation based on the pseudo-six-membered ring 
conformation involved in such oxidations.
162b
 
Thus we were able to synthesize ent-hydromorphone in 12 steps from β-
bromoethylbenzene 5 making it one of the shortest syntheses of a morphinan.  
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4. Conclusions and Future Work 
 
In the course of the present study, the total syntheses of dihydrocodeine, hydrocodone, 
and ent-hydromorphone were accomplished using chemoenzymatic methods. A [3,3]-
Sigmatropic rearrangement was effectively used to set the C-9, C-14, and C-13 
stereocenters in the synthesis of dihydrocodeine and hydrocodone. A successful oxidative 
dearomatization and cycloaddition strategy was developed to accomplish the first total 
synthesis of ent-hydromorphone in 12 steps starting from β-bromoethylbenzene. 
Future work may be divided in to two categories:  
a) Optimized synthesis of natural hydromorphone: An enantiodivergent synthesis is 
achievable through the modification of stereocenter at C-5 carbon, as this stereocenter 
controls the rest of the stereochemical outcomes in the subsequent reaction sequences. 
Control of the stereocenter at C-5 carbon has already been accomplished by previous 
work from our group.
111
 Epoxide 273, Scheme 58, was synthesised following a known 
protocol. This epoxide 273 was opened with phenol 405 to set the C-5 stereocenter in 423 
that gave C-5 configuration of natural series. Protection of the alcohol with a silyl group 
provided 428, which is the enantiomer of 406, Scheme 54. Following the same sequences 
as in the ent-series would deliver the natural hydromorphone (16a), thus completing the 
enantiodivergent syntheses. The oxidative dearomatization and subsequent cycloaddition 
can be also achieved through an anodic oxidation by electrochemistry as evidenced from 
Quideau‟s work.163 
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Reagents and conditions: (a) DME-DMF (1:1), 18-crown-6, 80 °C, 24 h, 68%; (b) 
TBSCl, imidazole, CH2Cl2, –78 °C  RT. 
Scheme 58: Proposed synthesis of natural hydromorphone. 
b) Advanced strategies for the synthesis of hydromorphone: An advanced approach 
towards hydromorphone is proposed via an enamine intermediate as discussed earlier in 
chapter 3. The viability of this approach was tested through a model synthesis of enamine 
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431, Scheme 59, in a simple system as shown in Scheme 59. Starting from vanillin 427, 
Scheme 59, enamine 431 was prepared in a four step, three pot operation. 
 
Reagents and conditions: (a) MOMCl, Hunig‟s base, CH2Cl2, 65%; (b) 
trimethylsulfonium methyl sulfate; 50% NaOH (aq), CH2Cl2, 87%; (c) BF3OEt2, CH2Cl2; 
(d) MeNHBOc, n-BuLi, THF, –78 °C  RT, 45% over two steps. 
Scheme 59: Model reactions for the synthesis of enamine. 
Following the successful outcome of the model reaction, we focused in synthesizing 
advanced enamine intermediate. Mitsunobu coupling of phenol 405, scheme 60, with 
various alcohols were studied, ether 434 was subjected to Corey-Chaykovsky reaction to 
obtain the epoxide 437. Rearrangement of epoxide 437 provided aldehyde 438 which was 
converted to enamine 439 without isolation of the aldehyde 438. Enamine 439 was 
isolated in low yield, but all our attempts to reproduce this step was unsucdessful. This 
reaction needs to be studied in more detail to optimize this step.  
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Reagents and conditions: (a) TMAD, PBu3, THF, 0 °C  RT; (b) trimethylsulfonium 
methyl sulfate; 50% NaOH (aq), CH2Cl2, 87%; (c) BF3OEt2, CH2Cl2; (d) MeNHBoc, n-
BuLi, THF, –78 °C  RT, 9% over two steps. 
Scheme 60: Approach towards ent-hydromorphone via an advanced enamine 
intermediate. 
Future work towards hydromorphone also includes oxidative dearoamtization of an ester 
441, Figure 45; cycloaddition followed by a Curtius rearrangement would install the 
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amine functionality as shown in 443. This approach will serve as an alternate route, if the 
enamine approach does not work. 
 
Figure 45: Proposed synthesis of hydromorphone from ester 441. 
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5. Experimental Section 
 
5.1 General Experimental Details 
All reagents were purchased from Aldrich, Fisher Scientific, Acros or Oakwood 
chemicals and used as received unless otherwise indicated. Reactions were carried out 
under inert atmosphere in flame dried glassware unless stated otherwise. Solvents were 
distilled: CH2Cl2, DMF, iPr2EtN, DCE and pyridine from CaH2; MeOH from magnesium 
methoxide; THF from Na/benzophenone; toluene from Na. All alkyllithium and lithium 
amide bases were titrated against N-benzylbenzamide
164
 to a blue endpoint. 
QualitativeTLC was done with pre-coated silica gel aluminium sheets (EMD silica gel 60 
F254); detection by UV or by spraying with "CAM" solution (5 g of 
(NH4)6Mo7O24.4H2O, 1 g of Ce(SO4)2, 100 ml of 10% H2SO4) or 0.5% aqueous KMnO4 
solution followed by heating. Column chromatography was performed using silica gel 
SiliaFlash P60 from Silicycle (40-66 µm). Optical rotation was measured in a 1dm cell at 
18-22 °C and 589 nm; concentration c in g/100 ml. FT-IR spectra were obtained as ca. 
2% solutions in CHCl3 and on Bruker ALPHA platinum ATR spectrometer as neat 
material. NMR spectra were obtained on a Bruker Avance 300, 400 or 600 MHz 
instrument and are referenced to the residual proton signal of the deuterated solvent for 
1
H spectra, and to the carbon multiplet of the deuterated solvent for 
13
C spectra according 
to published values.165 The chemical shifts are reported in ppm and the spectroscopic data 
are reported as follows: (multiplicity, number of protons, coupling constant), where s = 
singlet, d = doublet, t = triplet, q = quartet and dd = doublet of doublets. Mass spectra 
were recorded on Kratos/MsI Concept lS mass spectrometer at Brock University. 
Combustion analyses were performed by Atlantic Microlabs, Norcross, GA. 
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5.2 Detailed Experimental Procedures 
 
(–)-(1S,2S)-3-Bromocyclohex-3-ene-1,2-diol (314). 
 
 
 
A 3L three neck flask was charged with diol 6 (203 g, 1.06 mol) in MeOH (1L) and was 
cooled in freezing mixture. Potassium azodicarboxylate (PAD) (318 g, 1.59 mol) was 
added in four portions over 20 minutes followed by slow addition of AcOH (424 mL, 
7.42 mol) in MeOH (1.2 L). Reaction mixture was stirred for 18 h and the pH of the 
reaction mixture was neutralized with sat. NaHCO3. Product was extracted with EtOAc, 
washed with brine, dired over Na2SO4, and was evaporated under reduced pressure to 
obtain 314 as a white solid (198 g, 1.02, 96%). Data was matched with reported 
procedure.
127, 166
 
(–)-(1S,6S)-2-Bromo-6-(((2,3-dimethylbutan-2-yl)dimethylsilyl)oxy)cyclohex-2-enol 
(315). 
 
Diol 314 (112 g, 0.58 mol) and imidazole (47g, 0.69 mol) was dissolved in CH2Cl2 (400 
mL) and this mixture was cooled to –78 °C. A solution of TDSCl (114 g, 0.64 mol) in 
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CH2Cl2 (300 mL) was added to the raction mixture over a period of 15 min. The reaction 
mixture was allowed to warm to room temperature and was stirred for 48 h. White 
precipitate formed was dissolved in water and the organic phase was separated. It was 
then washed with 10% CuSO4 solution (200 mLx3), brine, dried over Na2SO4, and was 
evaporated under reduced pressure to obtain 315 (166 g, 0.49 mol, 85%) as a thick 
colorless oil. It was taken to next step without further purification.  
(–)-(1S,6S)-2-Bromo-6-(((2,3-dimethylbutan-2-yl)dimethylsilyl)oxy)cyclohex-2-en-1-
yl 2-((tert-butoxycarbonyl)amino)acetate (317).  
 
A solution of alcohol, 315 (125 g, 0.37 mol), DCC (84.6 g, 0.41 mol) and DMAP (4.5 g, 
0.037 mol) in CH2Cl2 (350 mL) was cooled to –20 °C under argon atmosphere and a 
solution of Boc-glycine (72.0 g, 0.41 mol) in CH2Cl2 (350 mL) was cannulated to this 
reaction mixture over a period of 15 minutes. The reaction mixture was stirred for 14 
hours warming to room temperature. Then the reaction mixture was diluted with Et2O 
(200 mL) to preciptate dicyclohexyl urea, which was removed by filtration. Then the 
solvent was removed under reduced pressure, and the resulting crude mixture was 
subjected to silica gel chromatography with hexanes/EtOAc (90:10) as eluent to isolate 
the product 317 (167 g, 0.34 mol, 92%) as colorless oil.  
317: Rf  = 0.31 [hexane/EtOAc (90:10)]; [α]
  
 
 = –64.0 (c = 1.0, MeOH); IR (neat) ν 3445, 
2958, 1755, 1715, 1511 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 6.27 (dd, J = 5.2, 3.1 Hz, 
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1H), 5.59 (d, J = 3.9 Hz, 1H), 5.00 (bs, 1H), 3.97 (m, 3H), 2.39-2.19 (m, IH), 2.15-2.09 
(m, IH), 1.85-1.62 (m, 2H), 1.43 (s, 9H), 0.84 (s, 3H), 0.82 (s, 3H), 0.77 (d, J = 1.9 Hz, 
6H), 0.07 (d, J = 4.6 Hz, 6H); 
13
C NMR (75 MHz, CDCl3) δ 169.6, 155.3, 134.8, 117.0, 
79.6, 73.9, 69.2, 42.3, 34.0, 28.2, 25.5, 24.7, 22.6, 20.0, 18.5, −3.10, −3.15; LRMS (EI) 
m/z (%) 171 (7), 157 (9), 136 (34), 121 (9), 79 (10), 28 (100); HRMS (EI) calcd for 
C2IH39NSiBrO5: 492.1781. Found 492.1806; Anal. Calcd for C2IH39NSiBrO5: C, 51.21; 
H, 7.78. Found C, 51.41; H, 7.75.  
(1S,6S)-2-Bromo-6-(((2,3-dimethylbutan-2-yl)dimethylsilyl)oxy)cyclohex-2-en-1-yl 2-
(N-(tert-butoxycarbonyl)-2-((tert-butoxycarbonyl)amino)acetamido)acetate (316). 
 
A solution of alcohol, 315 (16.0 g, 47.7 mmol), DCC (17.7 g, 85.9 mmol) and DMAP 
(0.9 g, 7.16 mmol) in CH2Cl2 (30 mL) was cooled to –20 °C under argon atmosphere and 
a solution of Boc-glycine (13.4 g, 76.3 mmol) in CH2Cl2 (30 mL) was cannulated to this 
reaction mixture over a period of 15 minutes. The reaction mixture was stirred for 14 
hours warming to room temperature. Then the reaction mixture was diluted with Et2O 
(100 mL) to preciptate dicyclohexyl urea, which was removed by filtration. Then the 
solvent was removed under reduced pressure, resulting crude mixture was subjected to 
silica gel chromatography using hexanes/EtOAc (90:10) as eluent to isolate the product 
316 (9.8 g, 15.1 mmol, 34%) as colorless oil.  
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316: Rf = 0.28 [hexane/EtOAc (90:10)]; [α]
  
 
 = –75.0 (c = 1.0, MeOH); IR (neat) ν 3448, 
2955, 1755, 1715, 1684, 1511 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 6.28 (dd, J = 4.8, 3.3 
Hz, 1H), 5.56 (d, J = 3.6 Hz, 1H), 5.30-5.27 (m, 1H), 4.70 (d, J = 17.4 Hz, 1H), 4.51 (d, J 
= 5.1 Hz, 2H), 4.39 (d, J = 17.4 Hz, 1H), 3.99-3.94 (m, 1H), 2.32-2.23 (m, 1H), 2.12-2.04 
(m, 1H), 1.86-1.63 (m, 2H), 1.62-1.55 (m, 1H), 1.52 (s, 9H), 1.45 (s, 9H), 0.88 (d, J = 2.4 
Hz, 3H), 0.85 (d, J = 2.4 Hz, 3H), 0.82 (s, 3H), 0.81 (s, 3H), 0.11 (s, 3H), 0.09 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 171.8, 167.7, 155.7, 151.5, 134.7, 117.1, 84.4, 79.2, 74.0, 
69.2, 46.7, 45.0, 33.9, 28.3, 27.8, 25.8, 25.6, 24.8, 20.1, 20.0, 18.5, 18.4, –3.0, –3.1;  
(–)-(S)-Methyl 2-((1S,4S)-2-bromo-4-(((2,3-dimethylbutan-2-yl)dimethylsilyl)oxy) 
cyclohex-2-en-1-yl)-2-((tert-butoxycarbonyl)amino)acetate (9a).  
 
A solution of glycinate ester 317 (55 g, 0.11 mol) in THF (200 mL) along with a solution 
of ZnCl2 (18.3 g, 0.13 mol) in THF (200 mL) was added dropwise to freshly prepared 
LDA (0.31 mol) in THF (400 mL) at –78 °C over a period of 2 hours. The reaction 
mixture was slowly warmed to room temperature and stirred for 18 hours. The reaction 
mixture was then diluted with Et2O (800 mL), quenched with H2O (25 mL), and the pH 
value was adjusted to approximately 2.5 using 1 N HCl at 0 °C. The organic layer was 
separated, aqueous layer was washed with Et2O (3 x 500 mL), combined organic washes 
were dried over Na2SO4, and the solvent was evaporated under reduced pressure to 
provide amino acid 319 as a mixture of two diastereomers. A solution of excess of 
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diazomethane in Et2O (generated from N,N-nitrosomethylurea and 50% aqueous KOH 
solution) was treated with the crude amino acid solution in Et2O at 0 °C, and the resulting 
diastereomeric mixture of esters was separated by column chromatography on silica gel 
with hexane/EtOAc (95:5) as eluent to yield 9a and 9b (36 g, 1:1.8 ratio, 0.07 mol, 65% 
combined yield) as a colorless oil. 
9a: Rf = 0.14 [hexane/EtOAc (95:5)]; [α]
  
 
 = –27.7 (c = 1.0, CHCl3); IR (CHCl3) ν 3443, 
2956, 2868, 1749, 1715, 1503 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 6.27 (dd, J = 5.6, 1.3 
Hz, 1H), 4.81-4.73 (m, 2H), 4.12-4.09 (m, 1H), 3.71 (s, 3H), 2.96 (bs, 1H), 1.86-1.76 (m, 
1H), 1.63-1.50 (m, 4H), 1.40 (s, 9H), 0.86 (d, J = 6.9 Hz, 6H), 0.80 (s, 6H), 0.06 (d, J = 
5.3 Hz, 6H); 
13
C NMR (75 MHz, CDCl3) δ 171.7, 155.4, 135.5, 127.9, 79.7, 65.4, 55.2, 
52.2, 43.7, 34.1, 29.5, 28.2, 24.8, 20.2, 19.9, 18.5, –2.6, –3.0; LRMS (EI) m/z (%) 370 
(13), 366 (38), 364 (37), 348 (16), 346 (15), 231 (24), 229 (24), 162 (95), 75 (100); 
HRMS (EI) calcd for C22H41NSiBrO5: 506.1920. Found 506.1937; Anal. Calcd for 
C22H41NSiBrO5: C, 52.16; H, 7.96. Found C, 52.34; H, 8.01. 
 
9b: colorless liquid; Rf  = 0.16 [hexane/EtOAc (95:5)]; [α]
  
 
 = –55.7 (c = 1.0, CHCl3); IR 
(CHCl3) ν 3439, 2955, 2867, 1753, 1720, 1498, 1365, 1251, 1164 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ 6.30 (dd, J = 5.6, 1.3 Hz, 1H), 5.21 (d, J = 8.6 Hz, 1H), 4.68 (dd, J = 
8.7, 2.3 Hz, 1H), 4.11-4.09 (m, 1H), 3.71 (s, 3H), 3.05 (bs, 1H), 1.86-1.78 (m, 2H), 1.63-
1.50 (m, 3H), 1.43 (s, 9H), 0.84 (d, J = 6.9 Hz, 6H), 0.80 (s, 6H), 0.05 (d, J = 5.3 Hz, 
138 
 
6H); 
13
C NMR (75 MHz, CDCl3) δ 171.8, 155.4, 136.3, 125.5, 80.0, 66.7, 55.9, 52.3, 
45.1, 34.1, 29.2, 28.3, 25.8, 24.7, 23.4, 20.2, 18.6, -2.7, -2.9; HRMS (EI) calcd for 
C20H36NSiBrO5: 506.1920. Found 506.1937; Anal. Calcd for C20H36NSiBrO5: C, 52.16; 
H, 7.96. Found C, 52.28; H, 8.06.  
To a solution of pure 9b (26.5 g, 0.52 mol) in THF (250 ml), DBU (4.01 g, 0.26 mol) was 
added and the reaction mixture was heated to reflux for 36 hours. Chromatographic 
separation on silica gel using hexane/EtOAc (95:5) as eluent yielded 9a as a colorless 
liquid (10 g, 0.02 mol, 39%) along with 9b (colorless liquid, 12.8 g, 0.025 mol, 49%). 
After separation (as above) this process was repeated to convert all of 9b into 9a. 
(+)-(S)-Methyl 2-((tert-butoxycarbonyl)amino)-2-((2R,5S)-5-(((2,3-dimethylbutan-2-
yl)dimethylsilyl)oxy)-2',3'-dimethoxy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-yl)acetate 
(337). 
 
Methyl ester 9a (8.2 g, 16.2 mmol) was taken in a flame dried flask with boronic acid
132
 
(3.54 g, 19.42 mmol), Cs2CO3 (7.92 g, 24.3 mmol) and Pd(dppf)2Cl2 (1.3 g, 1.62 mmol) 
was added and was immediately evacuated under vacuum for 20 minutes after connecting 
to a reflux condenser. The reaction flask was purged with argon, THF (100 mL) was 
added and the reaction mixture was heated to reflux for 12 hours. Then the reaction 
mixture was cooled to room temperature and was filtered through a pad of celite, washed 
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several times with CH2Cl2 and the dark brown solution obtained was evaporated under 
reduced pressure to obtain the crude product as black dense oil. Chromatographic 
separation of crude product on silica gel using [hexane/EtOAc (90:10) → hexane/EtOAc 
(80:20)] as eluent yielded 337 (9 g, 15.9 mmol, 98%) as a colorless liquid.  
337: Rf = 0.24 [hexane/EtOAc (80:20)]; [α]
  
 
 = +14.7 (c = 0.57, CHCl3); IR (neat) ν 
3449, 3019, 2956, 2401, 1748, 1716 cm
-1
; 
I
H NMR (300 MHz, CDCl3) δ 6.97 (t, J = 7.9 
Hz, 1H), 6.82 (dd, J  = 8.3, 1.1 Hz, 1H), 6.66 (d, J = 7.6 Hz, 1H), 5.77 (dd, J = 3.9, l.5 
Hz, 1H), 5.71 (d, J = 9.7 Hz, 1H), 4.33 (dd, J = 9.7, 2.3 Hz, 1H), 4.24 (m, 1H), 3.85 (s, 
6H), 3.23 (s, 1H), 1.74 (m, 2H), 1.74 (q, J = 6.9 Hz, 1H), 1.55 (bs, 4H), 1.42 (s, 9H), 0.91 
(dd, J = 6.8, 0.9 Hz, 6H), 0.85 (s, 7H), 0.10 (s, 6H); 
13
C
 
NMR (75 MHz, CDCl3) δ 172.6, 
155.2,152.3, 146.2, 139.5, 134.6, 132.5, 124.1, 122.0, 11l.8, 79.3, 63.4, 60.6, 55.7, 54.7, 
52.1, 38.4, 34.4, 30.1, 28.4, 24.9, 20.5, 18.7, 17.9, -2.3, -2.8; LRMS (FAB + NBA 
matrix) m/z (%) 404 (10), 375 (17), 287 (68), 227 (55); HRMS (FAB + NBA matrix) 
calcd for C30H49NO7Si: 506.2574. Found 506.2538.  
(+)-(S)-Methyl 2-((tert-butoxycarbonyl)amino)-2-((2R,5S)-5-hydroxy-2',3'-dimetho- 
xy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-yl)acetate (338). 
 
To a stirred solution of silylether 327 (9 g, 15.9 mmol) in THF (100 mL) was added tetra-
n-butylammonium fluoride (TBAF) (19.6 mL, 19.6 mmol, 1M solution in THF) dropwise 
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at room temperature. The resulting solution was stirred for 16 h and the solvent was 
evaporated under reduced pressure to obtain the crude product, which was separated by 
column chromatography on silica gel with hexane/EtOAc (50:50) as eluent to yield free 
alcohol 338 (6.2 g, 14.7 mmol, 92%) as a white solid.  
338: Rf  = 0.30 [hexane/EtOAc (50:50)]; mp 65-68 
o
C (EtOAc/hexane); [α]  
 
 = +39.2 (c = 
1.0, CHCl3); IR (neat) ν 3354,3015,2938, 1709, 1523 cm
-1
; 
I
H NMR (300 MHz, CDCl3) δ 
6.98 (t, J = 7.9 Hz, 1H), 6.83 (dd, J = 8.2, 1.4 Hz, 1H), 6.68 (d, J = 7.5 Hz, 1H), 5.89 (dd, 
J  = 3.9, 1.4 Hz, 1H), 5.56 (d, J = 9.7 Hz, 1H), 4.3 (dd, J = 9.7, 2.5 Hz, 1H), 4.28 (m, 1H), 
3.86 (s, 3H), 3.84 (s, 3H), 3.47 (q, J = 7.0 Hz, 1H), 3.37 (bs, 1H), 3.30 (s, 3H), 1.92 (m, 
4H), 1.42 (s, 9H); 
13
C NMR (CDCl3, 75 MHz) δ 172.7, 155.2, 152.2, 146.1, 141.7, 134.4, 
131.0, 124.0, 122.1, 112.0, 76.6, 63.5, 60.6, 55.8, 54.9, 52.1, 39.1, 30.0, 28.3, 18.8; 
LRMS (EI) m/z (%) 303 (13), 216 (100), 200 (24), 185 (9); HRMS (EI) Calcd. for 
C22H31NO7: 421.2101. Found: 421.2077.  Anal. Calcd for C22H31NO7: C, 62.69; H, 7.41. 
Found: C, 62.65; H, 7.46. 
 (+)-(3R,6R)-6-((S)-1-((tert-Butoxycarbonyl)amino)-2-methoxy-2-oxoethyl)-2',3'-dim 
ethoxy-3,4,5,6-tetrahydro-[1,1'-biphenyl]-3-yl benzoate (339). 
 
Mitsunobu reagent was prepared by the addition of diethyl azodicarboxylate (DEAD) 
(3.5 mL, 22.1 mmol) to PBu3 (5.5 mL, 22.1 mmol) in THF at 0 °c and was stirred for 15 
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minutes. It was then cannulated to a stirred solution of alcohol 338 (6.2 g, 14.7 mmol) 
and benzoic acid (2.2 g, 17.7 mmol) in THF at 0 °c and was stirred for 4 hours while the 
reaction mixture was allowed to warm to room temperature. Then the solvent was 
removed under reduced pressure and the resulting oil was separated by column 
chromatography on silica gel using hexane/EtOAc (80:20) as eluent to yield the product 
339 as a white solid (7.3 g, 13.9 mmol, 95%). 
339: Rf = 0.27 [hexane/EtOAc (70:30)]; mp 57-60 °C (EtOAc/hexane); [α]
  
 
 = +130.5 (c 
= 1.0, CHCl3); 
1
H NMR (300 MHz, CDCl3) δ 8.02 (d, J =7.2 Hz, 2H), 7.54 (t, J =7.4 Hz, 
1H), 7.42 (t, J  = 5.6 Hz, 2H), 6.98 (t, J = 7.9 Hz, 1H), 6.83 (dd, J = 1.5, 8.0 Hz, 1H) 6.70 
(dd, J = 1.1, 7.2 Hz, 1H), 5.9 (s, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.53 (s, 1H), 3.26 (s, 3H), 
2.22 (m, 2H), 1.86 (m, 2H), 1.55 (s, 2H), 1.45 (s, 9H); 
13
C NMR (75 MHz, CDCl3) δ 
171.8, 166.3, 156.2, 152.8, 146.2, 139.2, 135.1, 133.0, 129.7, 128.4, 123.8, 122.2, 112.1, 
61.4, 56.0, 51.8, 40.9, 28.5, 26.9, 24.8; LRMS (EI) m/z (%) 525 (3), 403 (8), 303 (21), 
260 (50), 216 (100); HRMS (EI) calcd for C29H35NO5: 525.2363. Found 525.2369; Anal. 
Calcd for C29H35NO5: C, 66.27; H, 6.71.  Found C, 65.76; H, 6.88. 
 (+)-tert-Butyl ((S)-2-hydroxy-1-((2R,5R)-5-hydroxy-2',3'-dimethoxy-2,3,4,5-tetrahyd 
ro-[1,1'-biphenyl]-2-yl)ethyl)carbamate (340). 
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To a suspension of lithium aluminum hydride (1.7 g, 45.66 mmol) in THF (200 mL) at 0 
°C was added a solution of ester 339 (7.3 g, 13.8 mmol) in THF (200 mL) in a dropwise 
manner. The reaction mixture was slowly warmed to room temperature and was stirred 
for 2 hours. The reaction mixture was again cooled to 0 °C and 1.5 mL of H2O was added 
followed by 1.5 mL of 15% of aqueous NaOH solution and 4.5 mL of H2O. The reaction 
mixture was filtered through a pad of Celite and washed several times with CH2Cl2. 
Solvent was evaporated under reduced pressure to provide the crude product, which was 
chromatographed on silica gel with [hexane/EtOAc (50:50) → EtOAc (100)] as eluent to 
yield the product 340 as a white solid (4.6 g, 11.7 mmol, 84%). 
340: Rf = 0.21 [hexane/EtOAc (20:80)]; mp 61-65 °C (EtOAc/hexane); [α]
  
 
 = +91.0 (c = 
1.0, CHCl3); IR (neat) ν 3384, 2938, 1696, 1577, 1472 cm
-1
; 
1
H NMR (300 MHz, CDCl3) 
δ 6.89 (s, 2H), 6.54 (dd, J = 6.4, 1.8 Hz, 1H), 6.00 (d, J = 8.7 Hz, 1H), 5.56 (s, 1H), 4.70 
(d, J = 5.3 Hz, 1H), 4.54 (t, J = 5.4 Hz, 1H), 4.18 (d, J = 3.7 Hz, 1H), 3.78 (s, 3H), 3.68 
(s, 3H), 3.16 (m, 4H), 1.97 (m, 1H), 1.74 (m, 1H), 1.32 (s, 9H), 1.12 (s, 2H); 
13
C NMR 
(75 MHz, CDCl3) δ 155.5, 152.1, 146.0, 139.9, 136.6,.135.4, 124.0, 122.3, 111.7, 77.7, 
66.0, 61.5, 60.2, 56.0, 53.0, 37.1, 32.0, 28.7, 20.2; LRMS (EI) m/z (%) 321 (5), 264 (20), 
244 (15), 216 (100); HRMS (EI) calcd for C21H29NO5: 375.2046. Found 375.2039; Anal. 
calcd for C21H29NO5: C, 64.10; H, 7.94. Found C, 63.83; H, 8.24. 
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 (–)-(S)-4-((2R,5R)-5-Hydroxy-2',3'-dimethoxy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-
yl)oxazolidin-2-one (341). 
 
A solution of NaH (0.7 g, 29.23 mmol) in DMF (30 mL) was cooled to 0 °C and a 
solution of alcohol 340 (4.6 g, 11.7 mmol) in DMF (30 mL) was added via a cannula. 
The reaction mixture was stirred for 30 minutes at 0 °C and was taken to room 
temperature and was stirred for 14 hours. The reaction mixture was diluted with brine 
solution (50 mL) and washed with a mixture of CHCl3/EtOH (3:1). The organic layer was 
then dried over Na2SO4 and the solvent was evaporated under reduced pressure to 
provide the crude product. Silica gel column chromatography of crude mixture using 
EtOAc provides the product 341 (3.7 g, 11.6 mmol) as an off white solid.  
341: Rf = 0.29 [EtOAc]; mp 63-65 °C (CH2Cl2/hexane); [α]
  
 
 = –46.2 (c = 1.8, CHCl3); 
IR (neat) ν 3368, 2936, 1747, 1576 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.06 (t, J = 7.9 
Hz, 1H), 6.89 (d, J = 8.2 Hz, 1H), 6.67 (dd, J = 7.6, 1.2 Hz, 1H), 5.87 (m, 1H), 4.41 (m, 
1H), 4.16 (m, 1H), 3.89 (s, 3H), 3.82 (s, 3H), 3.55 (t, J = 4.7 Hz, 1H), 2.76 (bs, 1H), 2.27 
(m, 1H), 1.67 (m, 1H), 1.59 (m, 1H), 1.40 (m, 1H); 
13
C NMR (75 MHz, CDCl3) δ 159.3, 
152.9, 145.7, 134.7, 124.8, 121.0, 111.7, 71.6, 71.1, 67.3, 67.0, 61.9, 61.4, 55.8, 53.3, 
42.1, 31.7, 31.2, 19.3, 14.2; LRMS (EI) m/z (%) 301 (4), 216 (49), 200 (14), 87 (87); 
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HRMS (EI) calcd for C17H21NO5: 301.1314. Found 301.1310; Anal. calcd for 
C17H21NO5: C, 63.94; H, 6.63. Found C, 62.21; H, 6,87 (C17H21NO5)2EtOAc. 
3-(2,3-Dimethoxyphenyl)-4-((S)-2-oxooxazolidin-4-yl)cyclohex-2-enylpropionate 
(342).  
 
A solution of alcohol 341 (100 mg, 0.31 mmol) and propanoic acid (0.20 mL) in triethyl 
orthoacetate (2 mL) was heated at 140 °C for 18 h under argon atmosphere. The solvent 
was removed in vacuo by heating in an oil bath, the crude reaction mixture obtained was 
purified by column chromatography on silica gel hexane/EtOAc/Et3N (70:29:1) to obtain 
342 (25 mg, 0.07 mmol, 21%) as a colorless oil.  
342: Rf = 0.46 [hexane/EtOAc (70:30)]; IR (CHCl3) ν 3456, 3005, 2942, 2829, 1755, 
1472 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 7.04 (t, J = 8.1 Hz, 1H), 6.88 (dd, J = 8.1, 1.2 
Hz, 1H), 6.63 (dd, J = 7.5, 1.2 Hz, 1H), 5.93 (dd, J = 4.5, 1.8 Hz, 1H), 5.39 (d, J = 3.3 
Hz, 1H), 5.31 (t, J = 3.9 Hz, 1H), 4.25 (t, J = 9.0 Hz, 1H), 4.11 (dd, J = 9.0, 5.1 Hz, 1H), 
3.87 (s, 3H), 3.79 (s, 1H), 3.75 (s, 3H), 2.65 (s, 1H), 2.36 (dd, J = 15.0, 7.5 Hz, 2H), 2.04-
2.01 (m, 1H), 1.90-1.85 (m, 2H), 1.69 (bs, 1H), 1.16 (t, J = 7.5 Hz, 3H); 
13
C NMR (150 
MHz, CDCl3) δ 174.3, 159.1, 152.9, 145.5, 141.6, 135.2, 130.6, 128.4, 124.9, 124.8, 
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120.9, 120.8, 111.9, 67.6, 66.2, 61.3, 55.8, 53.3, 53.1, 42.1, 41.9, 42.21, 41.9, 27.9, 26.7, 
17.1, 9.3; HRMS (EI) calcd for C20H25NO6: 375.1682. Found 375.1679. 
(1R)-3-(2,3-Dimethoxyphenyl)-4-((S)-2-oxooxazolidin-4-yl)cyclohex-2-enyl acetate 
(348). 
 
Alcohol 341 (210 mg, 0.66 mmol) and acetic anhydride (0.08 mL, 0.79 mmol) were taken 
in pyridine (4 mL) and DMAP (8.6 mg, 0.07 mmol) was added and stirred for 18 h. Then 
the raction mixture was diluted with CH2Cl2 and was washed with dilute acid. The 
organic layer was washed with sat. NaHCO3 solution, brine, and dried over Na2SO4. 
Solvent was evaporated under reduced pressure and was purified by silica gel column 
chromatography hexane/EtOAc (50:50) to obtain 348 (127 mg, 0.35 mmol, 53%) as a 
white solid. 
348: Rf  = 0.20 [hexane/EtOAc (50:50)]; mp 66-68 
°
C (EtOAc/hexane); [α]  
 
 = +12.3 (c = 
1.0, CHCl3); IR (CHCl3) ν 3454, 3027, 3008, 2937, 2871, 2838, 1753, 1469 cm
-1
; 
1
H 
NMR (300 MHz, CDCl3) δ 7.02 (t, J = 8.1 Hz, 1), 6.85 (dd, J = 8.4, 1.5 Hz, 1H), 6.66 
(dd, J = 7.5, 1.2 Hz, 1H), 5.79 (d, J = 9.9 Hz, 1H), 5.41-5.37 (m, 1H), 4.19-4.01 (m, 2H), 
3.85 (s, 3H), 3.77 (s, 3H), 3.75-3.72 (m, 1H), 2.79 (bs, 1H), 2.21 (t, J = 4.5 Hz, 1H), 2.05 
(m, 4H), 1.72-1.66 (m, 2H); 
13
C NMR (150 MHz, CDCl3) δ 170.6, 159.2, 152.9, 145.6, 
139.6, 135.0, 130.5, 124.8, 120.9, 111.9, 69.3, 67.3, 61.4, 55.8, 53.3, 41.8, 27.0, 21.3, 
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19.3; HRMS (EI) calcd for C19H23NO6: 361.1525. Found 361.1526; Anal. Calcd for 
C19H23NO6: C, 63.15; H, 6.41. Found C, 60.74; H, 6.39 ( C19H23NO6)7CHCl3. 
(3S)-2-tert-Butyl 3-methyl 5-(2, 3-dimethoxyphenyl)-2-azabicyclo [2.2.2] oct-5-ene-2, 
3-dicarboxylate (350). 
 
Compound 338 (50 mg, 0.12 mmol) was dissolved in CH2Cl2 (3 mL) and the temperature 
was lowered to −20 0C. Then Burgess reagent (34 mg, 0.14 mmol) was added and then 
the reaction was allowed to warm to room temperature. The reaction was stirred for 20h 
and then washed with NaHCO3, brine and dried with Na2SO4. Solvent was evaporated 
under reduced pressure to obtain crude product and pure product was separated by 
column chromatography on silica gel with hexane/EtOAc (50:50) as eluent to yield 350 
(37 mg, 0.09 mmol, 77%) as a white dense oil.  
350: Rf = 0.50 [hexane/EtOAc (50:50)]; IR (CHCl3) ν 3007, 2976, 2940, 2873, 2837, 
1749, 1684, 1470, 1400 cm
-1
; 
1
H NMR (300 MHz, CDCl3, rotameric) δ 7.01 (t, J = 7.8 
Hz, 1H) 6.89-6.86 (m, 1H), 6.81-6.78 (m, 1H), 6.56-6.53 (m, 1H), 4.89 (dd, J = 6.0, 3.0 
Hz, 0.7H), 4.75 (m, 0.3H), 4.11 (s, 0.3H), 4.05 (s, 0.7H), 3.87 (s, 3H), 3.81 (s, 3H), 3.74 
(s, 3H), 3.34 (s, 0.3H), 3.28 (s, 0.7H), 2.21-2.16 (m, 1H), 1.07-1.1.67 (m, 1H), 1.54-1.48 
(m, 2H), 1.38 (s, 9H); 
13
C NMR (150 MHz, CDCl3) δ 172.2, 171.7, 154.5, 154.1, 152.9, 
146.6, 146.5, 144.4, 144.3, 133.4, 130.5, 130.1, 124.0, 123.9, 121.1, 112.1, 79.9, 79.8, 
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60.6, 59.4, 58.9, 55.9, 52.0, 51.9, 47.2, 45.7, 38.7, 38.4, 30.9, 29.7, 28.5, 28.3, 25.8, 18.9, 
18.8; HRMS (EI) calcd for C22H29NO6: 403.1995. Found 403.1991. 
(–)-(1R,6S)-2-(2,3-Dimethoxyphenyl)-6-((2,3-dimethylbutan-2-yl)dimethyl silyloxy)- 
cyclohex-2-enol (355). 
 
 Compound 315 (1 g, 2.98 mmol), boronic acid (1.09 g, 5.96 mmol), Cs2CO3 (1.94 g, 
5.96 mmol) and Pd(dppf)2Cl2 (0.49 g, 0.60 mmol) were taken in THF (15 mL) and 
purged with argon and was heated to reflux. Reaction was stirred for 5 h and then solvent 
was evaporated on a rotary evaporator. Reaction mixture was diluted with CH2Cl2 and 
was passed through a pad of celite. Solvent was evaporated under educed pressure to 
obtain the crude product. Pure product was separated by column chromatography on 
silica gel with hexane/EtOAc (80:20) as eluent to yield 355 (0.87 g, 2.2 mmol, 80%) as a 
colorless oil. 
355: Rf = 0.37 [(hexane/EtOAc (80:20)]; [α]
  
 
 = −74.6 (c = 1.0, CHCl3); IR (CHCl3) ν 
3544, 3004, 2956, 2866, 2838, 1424 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 7.02 (t, J = 8.1 
Hz, 1H), 6.85 (d, J = 7.8 Hz, 2H), 5.88 (t, J = 3.6 Hz, 1H), 4.47 (t, J = 3.6 Hz, 1H), 4.04-
3.98 (m, 1H), 3.86 (s, 3H), 3.78 (s, 3H), 2.65 (d, J = 3.9 Hz, 1H), 2.39-2.18 (m, 2H), 
2.02-1.89 (m, 1H), 1.73-1.60 (m, 2H), 0.92-0.87 (m, 12H), 0.17 (d, J = 5.4 Hz, 6H); 
13
C 
NMR (150 MHz, CDCl3) δ 152.6, 146.4, 136.4, 136.0, 129.7, 123.9, 122.4, 11.4, 70.9, 
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69.3, 60.6, 55.8, 34.3, 25.5, 24.9, 24.3, 20.4, 20.2, 18.7, 18.6, -2.5, -2.9; HRMS (EI) calcd 
for C22H36O4Si: 392.2383. Found 392.2379; Anal. Calcd for C22H36O4Si: C, 67.30; H, 
9.24. Found C, 67.29; H, 9.27. 
 (+)-Ethyl 2-((1S,4S)-2-(2,3-dimethoxyphenyl)-4-((2,3-dimethylbutan-2-yl)dimethyl 
silyloxy)cyclohex-2-enyl)acetate (356).  
 
Compound 355 (40 mg, 0.10 mmol) was taken in triethyl ortho acetate (5 mL) and micro 
spatula of activated 4A
o
 molecular sieves were added along with catalytic amount of 
propionic acid (5 μL). The mixture was heated at 150 oC in a sealed tube filled with argon 
for two days. Then the reaction mixture was passed through a pad of celite and washed 
with EtOAc, 2 drops of triethyl amine was added to the filtrate and was evaporated. 
Solvent was removed by azeotropic distillation with toluene, product was separated by 
column chromatography on silica gel with hexane/EtOAc (90:10) as eluent afforded 356 
(23 mg, 0.05 mmol, 52%) as a colorless oil. 
356: Rf = 0.27 [hexane/EtOAc (90:10)]; [α]
  
 
 = +9.2 (c = 1.0, CHCl3); IR (CHCl3) ν 
3026, 2957, 2867, 2842, 1725, 1470 cm
-1
;  
1
H NMR (300 MHz, CDCl3) δ 6.99 (t, J = 7.8 
Hz, 1H), 6.83 (dd, J = 8.1, 1.2 Hz, 1H), 6.71 (dd, J = 7.8, 1.5 Hz, 1H), 5.69 (dd, J = 3.0, 
1.5 Hz, 1H), 4.32-4.27 (m, 1H), 4.02 (q, J = 7.2 Hz, 2H), 3.84 (s, 3H), 3.75 (s, 3H), 3.11 
(dd, J = 10.5, 5.1 Hz, 1H), 2.33-2.08 (m, 2H), 1.89-1.59 (m, 5H), 1.18 (t, J = 7.2 Hz, 3H), 
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0.89 (d, J = 6.9 Hz, 6H), 0.85 (s, 6H), 0.11 (s, 6H); 
13
C NMR (150 MHz, CDCl3) δ 172.9, 
152.7, 146.5, 140.4, 135.9, 131.9, 123.8, 122.2, 111.4, 66.5, 60.7, 60.1, 55.8, 38.2, 34.3, 
29.1, 24.9, 24.8, 20.4, 20.3, 18.6, 14.2, -2.5, -2.6; HRMS (EI) calcd for C26H42O5Si: 
462.2802. Found: 462.2798; Analysis Calcd for C26H42O5Si: C, 67.49; H, 9.15. Found C, 
67.61; H, 9.15. 
 (+)-Ethyl 2-((1S,4S)-2-(2,3-dimethoxyphenyl)-4-hydroxycyclohex-2-enyl)acetate 
(357).  
 
TBAF (0.24 mL, 0.24 mmol) in THF (1.5 mL) was added to a solution of 356 (88 mg, 
0.19 mmol) in THF (1.5 mL) at room temperature and was stirred for 18 h. Solvent was 
evaporated under reduced pressure and the product was purified by silicagel column 
chromatography using hexane/EtOAc (70:30) as eluent to yield 357 (52 mg, 0.16 mmol, 
86%) as a pale yellow oil.  
357: Rf = 0.45 [hexane/EtOAc (30:70)]; [α]
  
 
 = +50.2 (c = 1.0, CHCl3); IR (CHCl3) ν 
3607, 3007, 2935, 2868, 2837, 1723, 1467 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 6.97 (t, J 
= 7.8 Hz, 1H), 6.83 (dd, J = 8.4, 1.5 Hz, 1H), 6.68 (dd, J = 7.5, 1.5 Hz, 1H), 5.79 (dd, J = 
3.9, 1.5 Hz, 1H), 4.30 ( d, J = 4.2 Hz, 1H), 4.00 (q, J = 7.2 Hz, 2H), 3.84 (s, 3H), 3.77 (s, 
3H), 3.16-3.11 (m, 1H), 2.33-2.10 (m, 3H), 1.94-1.85 (m, 2H), 1.79-1.69 (m, 2H), 1.16 (t, 
J = 7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3) δ 172.7, 152.5, 146.2, 142.7, 135.7, 130.1, 
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123.9, 122.2, 111.6, 65.5, 60.7, 60.2, 55.8, 37.9, 34.2, 29.1, 24.2, 14.2; LRMS (EI) m/z 
(%) 320 (14), 289 (12), 232 (44), 215 (33), 214 (100), 199 (18), 160 (16), 175 (30); 
HRMS (EI) calcd for C18H24O5: 320.1624. Found 320.1618. 
 (3R,6S)-6-(2-Ethoxy-2-oxoethyl)-2',3'-dimethoxy-3,4,5,6-tetrahydro-[1,1'-biphenyl]-
3-yl benzoate (358). 
 
Mitsunobu reagent was prepared by the addition of diethyl azodicarboxylate (0.21 mL, 
1.30 mmol) to PBu3 (0.24 mL, 1.3 mmol) in THF (4 mL) at 0 °C and was stirred for 15 
minutes. It was then cannulated to a stirred solution of alcohol 357 (284 mg, 0.89 mmol) 
and benzoic acid (130 mg, 1.06 mmol) in THF (4 mL) at 0 °C and stirred for 2 hours 
during which the reaction mixture was allowed to warm to room temperature. The solvent 
was removed under reduced pressure and the resulting oil was purified by silica gel 
column chromatography using hexane/EtOAc (80:20) as eluent to yield the product 358 
(235 mg, 0.55 mmol, 62%) as colorless oil. 
358: Rf = 0.37 [hexane/EtOAc (80:20)]; [α]
  
 
 = +147.2 (c = 1.0, CHCl3); IR (neat) ν 
3025, 3004, 2939, 2870, 2836, 1711, 1600, 1578, 1470, 1270 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 8.04-8.02 (m, 2H), 7.57-7.51 (m, 1H), 7.45-7.39 (m, 2H), 7.00 (t, J = 8.1 Hz, 
1H); 6.85 (dd, J = 8.1, 1.5 Hz, 1H), 6.72 (dd, J = 7.8, 1.5 Hz, 1H), 5.87-5.85 (m, 1H), 
5.67-5.63 (m, 1H), 4.03 (q, J = 7.2 Hz, 2H), 3.86 (s, 3H), 3.81 (s, 3H), 3.36-3.31 (m, 1H), 
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2.37-2.32 (m, 1H), 2.26-2.08 (m,1H), 1.95-1.86 (m, 1H), 1.19 (t, J = 7.2 Hz, 3H); 
13
C 
NMR (75 MHz, CDCl3) δ 172.4, 166.2, 152.6, 146.2, 144.4, 135.6, 132.8, 130.6, 129.6, 
128.4, 128.3, 126.6, 124.0, 122.1, 111.8, 69.5, 60.8, 60.2, 55.8, 37.9, 34.3, 26.0, 25.1, 
14.2; LRMS (EI) m/z (%) 424 (2), 215 (21), 214 (74), 200 (11), 122 (15), 105 (100)77 
(20); HRMS (EI) calcd for C25H28O6: 424.1886. Found 424. 
Ethyl 2-((2S,5R)-5-hydroxy-2',3'-dimethoxy-2,3,4,5-tetrahydro-[1,1'-biphenyl]-2-
yl)acetate (359). 
 
A solution of NaOEt in EtOH (5 mL, 0.02 M) was added to a solution of benzoate 358 
(86 mg, 0.20 mmol) in EtOH (2 mL) at room temperature. The reaction mixture was 
stirred for 2 hours and then the reaction mixture was made neutral pH with acidic resin. 
Filtration and purification using silica gel column chromatography using hexane/EtOAc 
(50:50) as eluent to yield the product 359 (27 mg, 0.08 mmol, 42%) as colourless oil and 
the data was matched with the reported compound. 359: Rf = 0.28 [hexane/EtOAc 
(50:50)]; [α]  
 
 = +101.4 (c = 1.40, CHCl3) [lit
104
 [α]  
 
 = +94.4 (c = 1.37, CHCl3); 
1
H 
NMR (300 MHz, CDCl3) δ 6.99 (t, J = 8.1 Hz, 1H), 6.84 (dd, J = 8.1, 1.2 Hz, 1H), 6.68 
(dd, J = 7.8, 1.5 Hz,  1H), 5.77 (t, J = 2.4 Hz, 1H), 4.34 (bs, 1H), 4.01 (q, J = 7.2 Hz, 2H), 
3.89 (s, 3H), 3.79 (s, 3H), 3.24-3.19 (m, 1H), 2.30 (dd, J = 15.6, 3.9 Hz, 1H), 2.10-1.99 
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(m, 3H), 1.67-1.47 (m, 2H), 1.17 (t, J = 7.2 Hz, 3H); HRMS (EI) calcd for C18H24O5: 
320.1614. Found 320.1618.  
Diethyl 2,2'-((1R,2S)-2',3'-dimethoxy-1,2,3,4-tetrahydro-[1,1'-biphenyl]-1,2-diyl) 
diacetate (360). 
 
Alcohol 359 (25 mg, 0.08 mmol) was dissolved in triethyl orthoacetate (7 mL) and 2-
nitrophenol (0.5 mg, 0.004 mmol) was added in a sealed tube and was heated to 140 °C 
for 3 days. Then the reaction mixture was diluted with sat. NaHCO3 solution and dried 
over Na2SO4. Triethyl orthoacetate was removed by azeotropy with toluene to get the 
crude product which was purified by silica gel column chromatography using 
[hexane/EtOAc (90:10) → hexane/EtOAc (30:70)] as eluent to yield the product 360 (10 
mg, 0.03 mmol, 33%) as light yellow oil and the data was matched with the reported 
compound.
104
 
360: Rf = 0.28 [hexane/EtOAc (70:30)]; [α]
  
 
 = –69.3 (c = 0.48, CHCl3) [lit.
104
 [α]  
 
 = –
53.5 (c = 0.61, CHCl3); 6.96-6.81 (m, 3H), 6.13 (d, J = 10.5 Hz, 1H), 5.89-5.82 (m, 1H), 
4.02 (q, J = 7.2 Hz, 2H), 3.96-3.90 (m, 5 H), 3.84 (s, 3H), 3.64 (d, J = 15.0 Hz, 1H), 2.89 
(d, J = 15 Hz, 1H), 2.74-2.70 (m, 1H), 2.12-2.03 (m, 3H), 1.95-1.81 (m,1H), 1.58-1.52 
(m, 1H), 1.18 (t, J = 7.2 Hz, 3H), 1.03 (t, J = 7.2 Hz, 3H); HRMS (EI) calcd for 
C22H30O6: 390.2035. Found 390.2037.  
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(+)-(S)-4-((1R,4R)-2-(2,3-Dimethoxyphenyl)-4-hydroxycyclohex-2-enyl)-3-methyloxa 
zolidin-2-one (362). 
 
The alcohol 341 (2.2 g, 6.89 mmol) was added to a suspension of NaH (0.5 g, 20.67 
mmol) in THF (30 mL) at room temperature and stirred for 1 hour. Then MeI (64.7mg, 
0.46) was added in THF (30 mL) via an addition funnel and was stirred overnight. Then 
the reaction was quenched with water, acidified to neutral pH, extracted with CH2Cl2, 
dried over Na2SO4, evaporated on a rotary evaporator and dried under reduced pressure to 
obtain the crude product, which was purified by flash column chromatography (EtOAc) 
to provide 362 (1.28 g, 3.8 mmol, 56%) as a light yellow solid along with 361 (0.75 g, 
2.16 mmol, 31%) as white solid. 
362: Rf = 0.14 [hexane/EtOAc (70:30)]; mp 60-62 °C (EtOAc/hexane); [α]
  
 
 = +92.2 (c = 
1.0, CHCl3); IR (CHCl3) ν 3603, 3012, 2961, 2939, 2866, 2836, 1744, 1576, 1473, 1451, 
1264, 1236 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 7.05 (t, J = 8.1 Hz, 1H), 6.88 (d, J = 7.8 
Hz, 1H), 6.73 (dd, J = 7.5, 1.2 Hz, 1H), 5.89 (s, 1H), 4.39-4.34 (m, 1H), 4.26 (t, J = 9.0 
Hz, 1H), 4.00-3.95 (m, 1H), 3.87 (s, 3H), 3.78-3.72 (m, 1H), 3.69 (s, 3H), 3.19-3.15 (m, 
1H), 2.63 (s, 3H), 2.18 (t, J = 5.4 Hz, 1H), 2.03-1.97 (m, 2H), 1.64-1.60 (m, 1H), 1.48-
1.39 (m, 1H); 
13
C NMR (150 MHz, CDCl3) δ 158.6, 152.6, 145.6, 140.1, 135.0, 134.4, 
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124.9, 121.9, 111.8, 67.5, 65.8, 60.4, 57.9, 55.8, 40.2, 31.4, 30.1, 20.3; LRMS (EI) m/z 
(%) 333 (4), 216 (19), 101 (16), 100 (100), 85 (50), 83 (74); HRMS (EI) calcd for 
C18H23NO5: 333.1576. Found 333.1579; Anal. Calcd for C18H23NO5: C, 64.85; H, 6.95. 
Found C, 64.67; H, 6.96. 
 (4S)-4-((4R)-2-(2,3-Dimethoxyphenyl)-4-methoxycyclohex-2-enyl)-3-methyloxazoli-
din-2-one (361). 
 
361: Rf = 0.25 [hexane/EtOAc (70:30)]; mp 144-146 °C (CH2Cl2/hexane); [α]
  
 
 = +127.8 
(c = 1.0, CHCl3); IR (CHCl3) ν 3008, 2931, 2866, 2827, 1744, 1468, 1267 cm
-1
;  
1
H 
NMR (300 MHz, CDCl3) δ 7.06 (t, J = 7.8 Hz, 1H), 6.88 (dd, J = 8.4, 1.2 Hz, 1H), 6.75 
(dd, J = 7.8, 1.5 Hz, 1H), 5.94 (d, J = 0.9 Hz, 1H), 4.26 ( t, J = 9.0 Hz, 1H), 3.94-3.91 (m, 
2H), 3.90 (s, 3H), 3.87-3.71 (m, 1H), 3.70 (s, 3H), 3.43 (s, 3H), 3.21-3.17 (m, 1H), 2.64 
(s, 3H), 2.25-2.21 (m, 1H), 2.06-2.01 (m, 1H), 1.67-1.55 (m, 1H), 1.47-1.38 (m, 1H); 
13
C 
NMR (150 MHz, CDCl3): δ 158.7, 152.5, 145.6, 140.3, 135.2, 132.1, 124.9, 121.9, 111.7, 
76.2, 65.9, 65.8, 60.5, 57.9, 55.9, 55.8, 40.4, 30.1, 27.5, 20.2, 15.3; LRMS (EI) m/z (%) 
347 (4), 210 (12), 179 (38), 100 (100), 56 (21); HRMS (EI) calcd for C19H25NO5: 
347.1733. Found 347.1728; Anal. Calcd for C19H25NO5: C, 65.69; H, 7.25. Found C, 
65.75; H, 7.11. 
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 (+)-Ethyl2-((1S,6R)-1-(2,3-dimethoxyphenyl)-6-((S)-3-methyl-2-oxooxazolidin-4-yl)- 
cyclohex-2-enyl)acetate (11).  
 
A solution of alcohol 362 (1 g, 2.99 mmol) and 2-nitrophenol (20 mg, 0.14 mmol) in 
triethyl orthoacetate (60 ml) was heated at 130 °C for 6 d under argon with continuous 
removal of EtOH. The reaction mixture was diluted with EtOAc, washed with 1N HCl, 
satd NaHCO3 solution, brine, dried over Na2SO4 and solvent was evaporated under 
reduced pressure to yield the crude product, which was purified by column 
chromatography on silica gel [hexane/EtOAc (50:50) → hexane/EtOAc (30:70)] to obtain 
11 (618 mg, 1.53 mmol, 51%) as a viscous yellow liquid.  
11: Rf = 0.30 [hexane/EtOAc (40:60)]; [α]
  
 
 = +25.6 (c = 1.0, CHCl3); IR (CHCl3) ν 
3008, 2978, 2939, 2836, 1737, 1466, 1425, 1264, 1230 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 7.01-6.96 (m, 1H), 6.90-6.86 (m, 1H), 5.98-5.89 (m, 2H), 4.39 (t, J = 8.7 Hz, 
1H), 4.13-4.08 (m, 1H), 4.03 (q, J = 7.2 Hz, 2H), 3.93-3.81 (m, 7H), 3.14 (dd, J = 19.2, 
14.4 Hz, 2H), 2.4-2.36 (m, 1H), 2.20-2.09 (m, 2H), 2.02 (s, 3H), 1.79-1.69 (m, 1H), 1.58-
1.45 (m, 1H), 1.16 (t, J = 7.2 Hz, 3H); 
13
C NMR (75 MHz, CDCl3) δ 171.5, 159.8, 153.5, 
148.4, 134.2, 133.1, 127.3, 123.9, 123.0, 112.0, 69.4, 60.7, 60.1, 56.9, 55.8, 47.9, 45.5, 
45.2, 30.9, 24.7, 18.5, 14.2; LRMS (EI) m/z (%) 403 (2), 100 (22), 83 (100), 47 (34), 43 
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(29); HRMS (EI) calcd for C22H29NO6: 403.1995. Found 403.2006; Anal. Calcd for 
C22H29NO6: C, 65.49; H, 7.24. Found C, 65.78; H, 7.32. 
Methyl2-((1S,6R)-1-(2,3-dimethoxyphenyl)-6-((S)-2-hydroxy-1-(methylamino)ethyl) 
cyclohe- x-2-enyl)acetate hydrochloride (364a). 
 
 To a solution of 11 (115 mg, 0.29 mmol) in MeOH (6 mL), 50% NaOH (aq) (3 mL) was 
added and the reaction mixture was heated for 4 hours. It was cooled to room temperature 
and was diluted with brine solution; pH of the reaction mixture was adjusted to ca. 3 
using con. HCl, and was extracted using CHCl3: EtOH (3:1). The organic phase was dried 
with Na2SO4 and the solvent was evaporated under reduced pressure to obtain the crude 
product 363 (105 mg, 0.29 mmol) as a light brown solid. This crude product was taken to 
next step without further purification. 
To a stirred solution of 363 (100 mg, 0.29 mmol) in MeOH (10 mL), TMSCl (156 mg, 
1.43 mmol) was added. The reaction mixture was stirred 48 hours, then the solvent was 
evaporated on a rotary evaporator and was dried under vacuum to get 364a (120 mg, 0.29 
mmol) as light brown compound.  
364a: Rf = 0.12 [CH2Cl2/MeOH (80:20)]; IR (CHCl3) ν 3632, 3605, 3354, 3246, 2969, 
2954, 2842, 1738, 1601, 1577, 1467, 1438, 1426, 1264, 1164 cm
-1
; 
1
H NMR (300 MHz, 
D2O) δ 7.18-7.11 (m, 3H), 6.02 (d, J = 10.2 Hz, 1H), 5.95-5.88 (m, 1H), 3.90 (s, 3H), 
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3.88-3.80 (m, 5H), 3.68 (d, J = 5.4 Hz, 1H), 3.64 (s, 3H), 3.45 (d, J = 15.9 Hz, 1H), 3.12 
(d, J = 15.9 Hz, 1H), 2.48 (d, J = 9.3 Hz, 1H), 2.37 (s, 3H), 2.19 (s, 2H), 1.72-1.69 (m, 
1H), 1.55-1.48 (m, 1H); 
13
C NMR (150 MHz, D2O) δ 174.4, 153.2, 147.2, 132.7, 132.1, 
127.8, 124.3, 123.9, 113.6, 60.9, 60.3, 55.9, 51.8, 48.8, 44.8, 43.7, 43.1, 32.9, 24.1, 17.9; 
HRMS (FAB/NBA matrix) calcd for C20H29NO5: 363.2124. Found 364.2071. 
Methyl 2-((1R,2R)-1-(2,3-dimethoxyphenyl)-2-((S)-2-hydroxy-1-(methylamino) eth- 
yl)cyclohexyl)acetate (364). 
 
 
The hydrochloride salt 364a (120 mg) was washed with saturated Na2CO3 (aq) solution 
and was extracted with CH2Cl2 at least three times. The combined organic layers were 
washed with brine, dried over Na2SO4 and was evaporated to get the crude product 364 
(109 mg, 0.29 mmol) as light yellow oil. It was taken to the next step without further 
purification. 
364: Rf = 0.6 [CH2Cl2/MeOH (90:10)]; [α]
  
 
 = +39.0 (c = 0.15, CHCl3); IR (CHCl3) ν 
3369, 3250, 3075, 3009, 2951, 2838, 2803, 1736, 1596, 1579, 1466, 1265 cm
-1
; 
1
H NMR 
(300 MHz, CDCl3): δ 7.03-6.96 (m, 2H), 6.86 (dd, J = 6.9, 2.7 Hz, 1H), 6.06 (d, J = 10.2 
Hz, 1H), 5.96-5.90 (m, 1H), 3.85 (s, 3H), 3.83 (s, 3H), 3.64 (bs, 1H), 3.56-3.52 (m, 4H), 
3.43-3.35 (m, 2H), 3.13 (d, J = 15 Hz, 1H), 2.69 (d, J = 6.3 Hz, 1H), 2.36 (d, J = 4.2 Hz, 
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1H), 2.24-2.17 (m, 1H), 2.08-2.03 (m, 2H), 1.81 (s, 3H), 1.77-1.66 (m, 2H); 
13
C NMR 
(150 MHz, CDCl3) δ 172.5, 153.1, 148.6, 135.0, 133.7, 127.7, 122.8, 122.7, 111.5, 62.5, 
60.5, 60.4, 55.8, 51.1, 45.2, 45.0, 34.6, 25.1, 18.8; LRMS (EI) m/z (%) 332 (16), 227 
(12), 88 (23), 86 (100), 84 (87), 74 (39); HRMS (EI) calcd for C20H31NO5: 363.2046. 
Found 363.2037. 
(+)-(1S,4aS,8aR)-4a-(2,3-Dimethoxyphenyl)-1-(hydroxymethyl)-2-methyl-1,4,4a,7,8, 
8a-hexahydroisoquinolin-3(2H)-one (365).  
 
The free amine 364 (10mg, 0.028 mmol) was heated to reflux with catalytic amount 
(0.12mg, 10 mol %) of acetic acid in EtOH. After 5 days of heating, solvent was 
evaporated, diluted with CH2Cl2 and was washed with sat. NaHCO3 solution. The organic 
layer was dried with Na2SO4 and was evaporated to get the crude product. Column 
chromatography on silica gel with CH2Cl2/ MeOH (95:5) as eluent provided 365 (3.6mg, 
0.011 mmol) as a light brown solid (39%), along with 20% recovered starting material.  
or 
To a solution of amino acid 1 (784 mg, 2.24 mmol) and DIPEA (2.03 g, 15.68 mmol) in 
CH2Cl2/CH3CN (3:1, 20 ml), HBTU (808.4 mg, 2.13 mmol) was added and stirred for 4 
hours. Then the reaction mixture was diluted with CH2Cl2 (60 ml), washed with dil. HCl 
(3 x 15 ml), satd solution of NaHCO3 (2 x 10 ml), brine (2 x 10 ml), dried over Na2SO4, 
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filtered and solvent evaporated to provide crude product. Column chromatography on 
silica gel using CH2Cl2/ MeOH (95:5) as eluent provided the amide 365 (567 mg, 1.7 
mmol, 76%) as a light brown solid.  
365: Rf  = 0.39 [CH2Cl2/ MeOH (95:5)]; mp = 69-72 °C (CH2Cl2/hexane); [α]
  
 
 = +236 (c 
= 0.2, CHCl3); IR (CHCl3) ν 3625, 3028, 3007, 2964, 2941, 2839, 1620, 1578, 1464, 
1423, 1310, 1225 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 6.98-6.83 (m, 3H), 5.83-5.77 (m, 
1H), 5.55 (d, J = 9.9 Hz, 1H), 3.85 (s, 3H), 3.79 (s, 3H), 3.34 (d, J = 3.9 Hz, 1H), 3.14 
(bs, 1H), 3.08 (s, 3H), 3.04-2.92 (m, 3H), 2.42-2.34 (m, 4H), 1.96-1.93 (m, 1H); 
13
C 
NMR (75 MHz, CDCl3) δ 169.8, 125.4, 122.6, 111.7, 66.8, 61.3, 61.1, 55.9, 45.3, 34.7, 
26.2, 20.7; LRMS (FAB/NBA matrix) m/z (%) 332 (100), 301 (21), 300 (46), 178 (21), 
165 (30), 152 (35), 128 (29), 115 (39), 105 (33), 91 (49), 89 (69), 77 (90); HRMS (EI) 
calcd for C18H22NO3 (M–CH2OH): 300.1594. Found 300.1596; Anal. Calcd for 
C19H25NO4: C, 68.86; H, 7.60. Found C, 68.07; H, 7.59.  
 (+)-(1S,4aS,8aR)-4a-(2,3-Dimethoxyphenyl)-2-methyl-3-oxo-1,2,3,4,4a,7,8,8a-octahy 
droisoquinoline-1-carbaldehyde (366).  
 
To a solution of amide 365 (224 mg, 0.67 mmol) in CH2Cl2 (5 ml), DessMartin 
periodinane (428 mg, 1.01 mmol) was added at 0 °C and was stirred for 30 minutes. Then 
the mixture was warmed up to room temperature and stirred for another 30 minutes. The 
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reaction mixture was diluted with CH2Cl2, stirred with 1:1 mixture of 10% Na2S2O3 and 
saturatedd solution of NaHCO3 for 10 minutes. Then organic layer was separated and 
washed with satd solution of NaHCO3, brine and dried over Na2SO4. Solvent was 
evaporated under reduced pressure to yield 366 (181 mg, 0.55 mmol, 82%) as a white 
glassy solid. It was taken to next step without further purification.  
366: Rf  = 0.29 [CH2Cl2/ MeOH (95:5)]; [α]
  
 
 = +169 (c = 0.45, CHCl3); IR (CHCl3) ν 
3006, 2962, 2929, 2875, 2855, 1721, 1633, 1579, 1465, 1441, 1424, 1398, 1302, 1262, 
1220 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 9.02 (s, 1H), 6.94-6.86 (m, 3H), 5.84-5.80 (m, 
1H), 5.57 (d, J = 9.9 Hz, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 3.53 (dd, J = 5.7, 1.8 Hz, 1H), 
3.02 (s, 3H), 2.49-2.43 (m, 2H), 2.34-2.31 (m, 2H), 2.04-1.91 (m, 1H), 1.79-1.62 (m, 
2H); 
13
C NMR (75 MHz, CDCl3,) δ 201.4, 170.0, 153.9, 149.1, 136.1, 133.9, 132.7, 
125.7, 124.8, 122.6, 112.3, 70.9, 61.2, 55.8, 47.4, 45.5, 41.9, 34.8, 29.7, 25.7, 19.9; 
LRMS (EI) m/z (%) 329 (19), 301 (20), 300 (100), 248 (10), 229 (38), 180 (45); HRMS 
(EI) calcd for C18H21NO4: 329.1627. Found 329.1623. 
 (+)-(4bS,8aR,9S)-3,4-Dimethoxy-11-methyl-8,8a,9,10-tetrahydro-7H-9,4b-(epiminoe 
thano)phenanthren-10-ol (367).  
 
Aldehyde 366 (50 mg, 0.15 mmol) was dissolved in CH2Cl2 (2 ml) and cooled to –10 °C, 
then BF3OEt2 (54 mg, 0.38 mmol) was added. The reaction mixture was stirred for 3 h, 
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then quenched with water and diluted with CH2Cl2. The reaction mixture was then 
washed with H2O, brine and dried over Na2SO4. The solvent was evaporated under 
reduced pressure and the crude product was purified by column chromatography on silica 
gel with CH2Cl2/MeOH (95:5) as eluent to furnish the intermediate alcohol 367 (38 mg, 
0.12 mmol, 76%) as a colourless liquid. 
367: Rf = 0.20 [CH2Cl2/MeOH (95:5)]; [α]
  
 
 = +48.7 (c = 1.5, CHCl3); IR (CHCl3) ν 
3583, 3004, 2940, 2840, 1626, 1484, 1415, 1399, 1320, 1279, 1096, 1054, 1029, 978 cm
-
1
; 
1
H NMR (300 MHz, CDCl3) δ 7.26 (d, J = 8.7 Hz, 1H), 6.85 (d, J = 8.7 Hz, 1H), 6.41 
(d, J = 10.2 Hz, 1H), 5.69-5.65 (m, 1H), 4.89 (d, J = 3.9 Hz, 1H), 3.83 (s, 3H), 3.81 (s, 
3H), 3.61 (t, J = 1.8 Hz, 1H), 3.13 (s, 3H), 2.88 (d, J = 17.7 Hz, 1H), 2.40 (d, J = 17.7 Hz, 
1H), 2.14-2.04 (m, 3H), 1.77-1.72 (m, 1H), 1.50-1.36 (m, 1H); 
13
C NMR (75 MHz, 
CDCl3) δ 170.5, 153.0, 147.4, 134.9, 133.9, 127.8, 125.7, 122.6, 112.0, 70.2, 63.0, 60.2, 
55.8, 46.1, 41.5, 38.2, 38.0, 25.4, 23.0; LRMS (FAB) m/z (%) 330 (81), 270 (20), 226 
(20), 165 (28), 115 (40), 89 (68), 77 (100); HRMS (EI) calcd for C19H23NO4: 329.1627. 
Found 329.1627; Anal. Calcd for C19H23NO4: C, 62.28; H, 7.04. Found C, 61.61; H, 7.66.  
 
(+)-(4bS)-3,4-Dimethoxy-11-methyl-8,8a,9,10-tetrahydro-7H-9,4b- (epiminoethano) 
phenanthren-12-one (369).  
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To a solution of the intermediate alcohol 367 (40 mg, 0.12 mmol) in 1,2-dichloroethane 
(2 ml), chlorodiphenylsilane (66.4 mg, 0.3 mmol) was added and the mixture was heated 
for 1 h; then catalytic InCl3 (5.3 mg, 0.02 mmol) was added and the mixture was heated 
to reflux for another 20 hours. After complete consumption of starting material (vide 
TLC), the reaction mixture was diluted with CH2Cl2, washed with H2O, brine and dried 
over Na2SO4. Solvent was evaporated under reduced pressure to obtain the crude product 
and column chromatography on silica gel with EtOAc as eluent afforded amide 369 (25 
mg, 0.08 mmol, 67%) as a white solid. 
369: Rf = 0.24 [EtOAc]; mp 55–58 °C (EtOAc/hexane); [α]
  
 
 = +48.7 (c = 1.5, CHCl3); 
IR (CHCl3) ν 3000, 2938, 2840, 1623, 1485, 1275, 1219, 1051 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 6.78-6.75 (m, 2H), 6.45 (d, J = 10.2 Hz, 1H), 5.67 (d, J = 9.9 Hz, 1H), 3.84 (s, 
3H), 3.81 (s, 3H), 3.58 (s, 1H), 2.99-2.94 (m, 4H), 2.83 (d, J = 16.8 Hz, 2H), 2.37 (d, J = 
17.4 Hz, 1H), 2.09-2.04 (m, 3H), 1.69-1.66 (m, 1H), 1.57-1.43 (m, 1H); 
13
C NMR (75 
MHz, CDCl3) δ 169.6, 151.9, 148.6, 134.7, 133.9,  125.5, 124.8, 123.7, 111.8, 60.1, 58.4, 
55.9, 46.1, 40.2, 37.8, 33.4, 29.5, 25.2, 23.1; LRMS (EI) m/z (%) 313 (100), 240 (37), 
225 (22), 192 (71), 85 (53), 83 (79); HRMS (EI) calcd for C19H23NO3: 313.1677. Found 
313.1673; Anal. Calcd for C19H23NO3: C, 72.82; H, 7.40. Found C, 72.57; H, 7.46.  
(–)-(1aR,3aR,4R,9bS,9cS)-8,9-Dimethoxy-12-methyl-2,3,3a,4,5,9c-hexahydro-1aH-
4,9b-(epiminoethano)phenanthro[3,4-b]oxiren-11-one (370).  
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To a solution of 369 (40 mg, 0.13 mmol) in CH2Cl2 (2 ml) at 0 °C, mCPBA (26.4 mg, 
0.15 mmol) was added in one portion and the reaction was warmed to room temperature. 
Stirring was continued for another 12 hours, then the reaction mixture was diluted with 
CH2Cl2, washed with a 1:1 mixture of 10% Na2S2O3, satd solution of NH4Cl, satd 
solution of NaHCO3, brine and was dried over Na2SO4. Solvent was evaporated under 
reduced pressure to obtain crude product as a colourless liquid. It was taken to next step 
without further purification.  
370: Rf = 0.30 [CH2Cl2/MeOH (95:5), double run]; [α]
  
 
 = –20.0 (c = 1.5, CHCl3); IR 
(CHCl3) ν 3023, 3003, 2937, 1626, 1483, 1416, 1277, 1261, 1037 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ 6.85 (d, J = 4.2 Hz, 1H), 6.81 (d, J = 3.9 Hz, 1H), 4.55 (d, J = 1.5 Hz, 
1H), 3.91 (s, 3H), 3.87 (s, 3H), 3.49 (s, 1H), 3.28 (1H), 2.97-2.87 (m, 4H), 2.84-2.80 (m, 
2H), 2.28 (d, J = 3.0 Hz, 1H), 2.04-1.94 (m, 2H), 1.37-1.34 (m, 1H), 1.34-1.22 (m, 2H); 
13
C NMR (75 MHz, CDCl3) δ 169.3, 151.8, 149.3, 130.1, 125.2, 125.1, 112.3, 60.7, 57.3, 
56.6, 55.9, 54.9, 43.4, 38.6, 33.9, 33.4, 29.7, 29.4, 22.4, 21.6; LRMS (EI) m/z (%) 329 
(14), 192 (8), 123 (10), 111 (18), 109 (15), 97 (23), 95 (20), 85 (28), 83 (26), 71 (38), 57 
(54), 55 (36), 44 (100), 43 (49); HRMS (EI) calcd for C19H23NO3: 329.16271 found 
329.1633.  
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(–)-(4R,4aR,7R,7aR,12bS)-7-Hydroxy-9-methoxy-3-methyl-4,4a,5,6,7,7a-hexahydro-
1H-4,12-methanobenzofuro[3,2-e]isoquinolin-2(3H)-one (371).  
  
The crude epoxide 370 (36 mg, 0.11) in THF (1ml) was treated with camphor sulphonic 
acid (CSA) (30.5 mg, 0.13) and heated to reflux for 24 hours. The reaction mixture was 
then diluted with CH2Cl2, washed with saturatedd solution of NaHCO3, brine and was 
dried over Na2SO4.The solvent was evaporated under reduced pressure to provide the 
crude product. Column chromatography on silica gel using CH2Cl2/MeOH (95:5) as 
eluent afforded 371 (22 mg, 0.07 mmol, 54% after two steps) as a colourless oil. This 
data was matched with reported compound.
149a
 
371: Rf = 0.16 [CH2Cl2/MeOH (95:5)]; [α]
  
 
 = –114.8 (c = 0.6, CHCl3); IR (CHCl3) ν 
3592, 3004, 2932, 1633, 1504, 1440, 1400, 1323, 1282, 1266, 1124, 1095 cm
-1
; 
1
H NMR 
(300 MHz, CDCl3) δ 6.75 (d, J = 8.1 Hz, 1H), 6.62 (d, J = 8.1 Hz, 1H), 4.33 (d, J = 6.9 
Hz, 1H), 3.86 (s, 3H), 3.74-3.71 (m, 1H), 3.42-3.34 (m, 1H), 2.99 (s, 3H), 2.97-2.92 (m, 
1H), 2.72-2.52 (m, 4H), 2.38-2.33 (m, 1H), 1.89-1.74 (m, 2H), 1.45-1.32 (m, 1H), 1.11-
1.00 (m, 1H); 
13
C NMR (75 MHz, CDCl3) δ 168.2, 144.5, 144.2, 130.3, 121.3, 121.2, 
114.6, 96.8, 72.1, 58.8, 56.6, 44.7, 42.7, 39.0, 34.1, 29.2, 26.6, 22.9. 
 
165 
 
 (–)-(7aR,12bS)-9-Methoxy-3-methyl-4,4a,5,6-tetrahydro-1H-4,12-methanobenzo 
furo[3,2-e]isoquinoline-2,7(3H,7aH)-dione (372).  
 
To a solution of 371 (12 mg, 0.038 mmol) in CH2Cl2 (1 ml), Dess-Martin periodinane (32 
mg, 0.08 mmol) was added at 0 °C and the mixture was stirred for 30 minutes whereupon 
it was allowed to warm to room temperature and stirred for another 5 hours. The reaction 
mixture was diluted with CH2Cl2, stirred with a 1:1 mixture of 10% Na2S2O3 and satd 
NaHCO3 solution during 10 minutes. The organic layer was separated and washed with 
satd NaHCO3 solution, brine and was dried over Na2SO4. The solvent was evaporated 
under reduced pressure and the crude product was purified by column chromatography on 
silica gel with CH2Cl2/MeOH (98:2) as eluent to provide 372 (10 mg, 0.03 mmol, 84%) 
as colorless oil.  
372: Rf = 0.15 [CH2Cl2/MeOH (95:5)]; [α]
  
 
 = –178.0 (c = 0.17, CHCl3); IR (CHCl3) ν 
3005, 2933, 1735, 1636, 1507, 1439, 1400, 1279, 1157 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 6.75 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 4.70 (s, 1H), 3.90 (s, 3H), 
3.80-3.79 (m,1H), 3.04 (s, 3H), 3.01-2.95 (m, 1H), 2.80-2.77 (m, 3H), 2.62 (dd, J = 18.0, 
3.9 Hz, 1H), 2.47-2.42 (m, 2H), 2.08-2.02 (m, 1H), 1.39-1.30 (m, 1H); 
13
C NMR (75 
MHz, CDCl3) δ 206.1, 167.6, 146.1, 143.6, 127.1, 121.9, 121.1, 115.8, 91.5, 58.8, 57.2, 
46.7, 44.5, 38.9, 34.3, 30.0, 26.8, 25.2; LRMS (EI) m/z (%) 313 (21), 248 (100), 231 (59), 
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203 (18), 156 (18), 149 (13), 139 (18), 127 (10), 111 (16), 105 (13); HRMS (EI) calcd for 
C18H19NO4: 313.1314. Found 313.1308. 
(–)-(4R,4aR,7S,7aR,12bS)-9-Methoxy-3-methyl-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-
methanobenzofuro[3,2-e]isoquinolin-7-ol (373), dihydrocodeine.  
 
To a stirred suspension of LiAlH4 (3 mg, 0.079 mmol) in dioxane (0.5 ml) was added a 
solution of 372 (5 mg, 0.016 mmol) in dioxane (0.5 ml), and the mixture was heated to 
reflux for 6 hours. Then the reaction mixture was cooled to room temperature, quenched 
by the addition of two drops of water followed by the addition of two drops of 15% 
NaOH solution and six more drops of water. The white suspension formed was filtered 
through a pad of celite, washed with CH2Cl2, solvent was evaporated under reduced 
pressure and the crude product was purified by column chromatography on silica gel with 
EtOAc/Et2NH (20:1) as eluent to provide 373 (3.4 mg, 0.011 mmol, 71%) as a white 
glassy solid which provided crystalline dihydrocodeine 373 upon trituration with CH2Cl2.  
373: Rf = 0.16 [EtOAc/Et2NH (20:1)]; mp 110-112 °C (CH2Cl2) [lit.
167
 mp 111-112 °C]; 
[α]  
 
 = –212 (c = 0.11, 1,4-dioxane) [lit.168 [α]  
 
 = –220 (c = 0.246, 1,4-dioxane)]; IR 
(CHCl3) ν 3590, 3010, 2936, 2909, 1504, 1449, 1440, 1322, 1278, 1157 cm
-1
; 
1
H NMR 
(300 MHz, CDCl3) δ 6.73 (d, J = 8.1 Hz, 1H), 6.64 (d, J = 8.1 Hz, 1H), 4.61 (d, J = 5.4 
Hz, 1H), 4.05 (bs, 1H), 3.87 (s, 3H), 3.14 (bs, 1H), 3.01 (d, J = 18.3 Hz, 1H), 2.55-2.52 
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(m, 1H), 2.32 (s, 4H), 2.32-2.28 (m, 2H), 2.05-1.84 (m, 2H), 1.73-1.69 (m, 1H), 1.60-
1.54 (m, 1H), 1.51-1.40 (m, 2H), 1.18-1.12 (m, 1H); 
13
C NMR (75 MHz, CDCl3) δ 146.2, 
141.7, 130.0, 126.5, 119.2, 113.3, 90.3, 67.1, 60.0, 56.4, 47.0, 42.8, 41.9, 40.4, 37.0, 27.2, 
20.2, 18.9; MS (EI) m/z (%) 301 (100), 286 (10), 244 (18), 242 (13), 199 (28), 185 (10), 
164 (20), 91 (18), 73 (16), 60 (21), 58 (32), 45 (61), 44 (54); HRMS (EI) calcd for 
C18H23NO3: 301.1678. Found 301.1674. 
 (–)-(4R,4aR,7aR,12bS)-9-Methoxy-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-metha 
nobenzofuro[3,2-e]isoquinolin-7(7aH)-one (153), hydrocodone.  
 
To a solution of 373 (3.5 mg, 0.012 mmol) in CH2Cl2 (0.6 ml), Dess-Martin periodinane 
(7.4 mg, 0.017 mmol) was added at 0 °C and the reaction mixture was stirred for 30 
minutes whereupon it was allowed to warm to room temperature and stirred for another 2 
h. The reaction mixture was diluted with CH2Cl2, stirred with a 1:1 mixture of 10% 
Na2S2O3 and saturated NaHCO3 solution during 10 min. Then organic layer was 
separated and washed with saturated NaHCO3 solution, brine and dried over Na2SO4. The 
solvent was evaporated under reduced pressure and the crude product was purified by 
column chromatography on silica gel with EtOAc/Et2NH (20:1) as eluent to provide 153 
(2.9 mg, 0.01 mmol, 83%) as a white glassy solid. Trituration with ether provided 
crystalline hydrocodone (153). 
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153: Rf = 0.21 [EtOAc/Et2NH (20:1)]; mp 191-194 °C (Et2O) [lit.
169
 mp = 194-197 °C]; 
[α]  
 
 = –195 (c = 0.11, CHCl3) [lit. [α]
  
 
 = –207 (c = 1.0, CHCl3)]; IR (CHCl3) ν 3007, 
2936, 1728, 1504, 1439, 1278, 1157, 1058 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 6.70 (d, J 
= 8.1 Hz, 1H), 6.63 (d, J = 8.1 Hz, 1H), 4.66 (s, 1H), 3.90 (s, 3H), 3.20-3.17 (m, 1H), 
3.03 (d, J = 18.3 Hz, 1H), 2.60-2.54 (m, 2H), 2.43-2.40 (m, 4H), 2.37-2.31 (m, 1H), 2.28-
2.15 (m, 2H), 2.11-2.02 (m, 1H), 1.89-1.79 (m, 2H), 1.33-1.19 (m, 1H); 
13
C NMR (75 
MHz, CDCl3) δ 207.8, 145.6, 142.9, 127.3, 126.3, 119.8, 114.6, 91.4, 59.2, 56.8, 46.9, 
46.8, 42.9, 42.8, 40.2, 35.6, 25.6, 19.9; MS (EI) m/z (%) 299 (100), 284 (14), 256 (11), 
243 (29), 242 (47), 214 (19), 212 (18), 161 (12), 188 (14), 185 (20), 96 (26), 86 (17), 84 
(24), 70 (18), 59 (30), 42 (15); HRMS (EI) calcd for C18H21NO3: 299.1521. Found 
299.1518. 
4-Methoxy-3-(2-methylallyloxy) benzaldehyde (390a). 
 
To a suspension of 166 (5.0 g, 32.8 mmol) and K2CO3 (6.8 g, 49.3 mmol) in DMF (30 
mL) was added 2-methyl bromo propene (3.6 mL, 39.4 mmol) at room temperature and 
was stirred for 5 hours. Then the reaction was quenched with water, diluted with ether 
and washed with water and extracted with ether. Then the organic layers were combined 
and washed with brine and dried over Na2SO4 and solvent was evaporated to get the pure 
product 390a (5.0 g, 24.3 mmol, 76%).  
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390a: Rf = 0.50 [hexane/EtOAc (50:50)]; IR (CHCl3) ν 3083, 3022, 2977, 2937, 2843, 
2758, 2735, 1685, 1596, 1587, 1510, 1441, 1435, 1269, 1134 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 9.83 (s, 1H), 7.46 (dd, J = 8.1, 1.5 Hz, 1H), 7.39 (d, J = 1.5 Hz, 1H), 6.98 (d, J 
= 8.4 Hz, 1H), 5.07 (d, J = 3.2 Hz, 2H), 4.57 (s, 2H), 3.96 (s, 3H), 1.84 (s, 3H); 
13
C NMR 
(150 MHz, CDCl3) δ 190.9, 154.9, 148.7, 140.1, 130.0, 126.8, 113.3, 111.2, 110.8, 72.5, 
56.3, 19.4; LRMS (EI) calcd for C12H14O3: 206. Found 206. 
1-Methoxy-2-(2-methylallyloxy)-4-vinylbenzene (390). 
 
To a solution of Wittig salt (2.94 g, 7.3 mmol) in THF (30 mL) at −78 oC n-BuLi (3.01 
ml, 6.78 mmol) was added drop wise and stirred for 15 minutes. Then the reaction 
mixture was warmed to 0 
o
C and 390a (1 g, 4.8 mmol) was added in THF (10 mL) via a 
canula. Then the suspension was heated to reflux for 2 hours, cooled to room 
temperature, diluted with EtOAc, washed with water and re-extracted with EtOAc. Then 
the organic layers were combined and washed with brine and dried over Na2SO4 and 
solvent was evaporated to get the crude product. It was the purified by flash column 
chromatography on silica gel using [hexane/EtOAc (90:10) → (80:20)] to get 390 (0.95 
g, 4.7 mmol, 95%) as a colorless oil. 
390: Rf = 0.54 [hexane/EtOAc (70:30)]; IR (CHCl3) ν 3088, 3012, 2980, 2935, 2913, 
2840, 1512, 1261, 1137 cm
-1
;
 1
H NMR (300 MHz, CDCl3) δ 6.99-6.94 (m, 2H), 6.83 (d, J 
= 8.1 Hz, 1H), 6.63 (dd, J = 17.4, 10.8 Hz, 1H), 5.58 (d, J = 17.4 Hz, 1H), 5.13 (d, J = 
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10.5 Hz, 2H), 5.00 (s, 1H), 4.54 (s, 2H), 3.88 (s, 3H), 1.85 (s, 3H); 
13
C NMR (150 MHz, 
CDCl3) δ 149.6, 148.4, 140.9, 136.6, 130.7, 119.9, 112.9, 111.8, 111.7, 111.1, 72.8, 
56.21, 19.5; LRMS (EI) calcd for C13H16O2: 204. Found 204. 
6-Methoxy-2-(2-methylallyl)-3-vinylphenol (391). 
 
 A solution of (100 mg, 0.49 mmol) was heated to reflux in m-xylene (2 mL) for 9 days 
under argon atmosphere in a sealed tube. It was then purified by column chromatography 
hexane/EtOAc (95:5) to obtain 391 (18 mg, 0.09 mmol, 18%) as a colorless oil. Only a 
part of the compound was isolated as pure product, rest came as a mixture of product with 
starting material. 
391: Rf = 0.24 [hexane/EtOAc (90:10)]; IR (CHCl3) ν 3541, 3086, 3011, 2972, 2943, 
2843, 1650, 1614, 1579, 1489, 1462, 1441, 1278, 1246 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 7.07 (d, J = 8.4 Hz, 1H), 6.88-6.75 (m, 2H), 5.69 (s, 1H), 5.54 (dd, J = 17.1, 1.2 
Hz, 1H), 5.17 (dd, J = 11.1, 1.2 Hz, 1H), 4.77 (s, 1H), 4.44 (s, 1H), 3.89 (s, 3H), 3.44 (s, 
2H), 1.82 (s, 2H); 
13
C NMR (150 MHz, CDCl3) δ 145.9, 144.1, 143.7, 134.7, 131.6, 
123.5, 116.9, 114.1, 110.6, 108.8, 56.1, 33.7, 23.2; LRMS (EI) calcd for C13H16O2: 204. 
Found 204. 
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4-Formyl-2-hydroxyphenyl acetate (403).  
 
 Aldehyde 402 
[1]
 (3.9 g, 28 mmol) was dissolved in THF (20 mL) and the solution was 
cooled to 0 
°
C. Then a solution of NaOH in water (2N, 70 mmol) was added dropwise 
followed by the addition of acetic anhydride (3.2 mL, 34 mmol).The reaction mixture 
was stirred for 20 minutes, diluted with EtOAc, made acidic with con. HCl (2.5 mL) and 
phosphate buffer (20 mL, pH = 2.5). Then it was filtered through a pad of Celite and 
organic phase was separated. The aqueous phase was washed 3 times with EtOAc, 
organic washes were combined, washed with brine, dried over Na2SO4 and solvent was 
evaporated under reduced pressure to obtain the crude product, which was purified by 
suction filtration chromatography on silica gel with [CH2Cl2/MeOH (98:2) → 
CH2Cl2/MeOH (95:5)] as eluent to provide 403 as a light yellow solid (4.2 g, 23.3 mmol, 
84%). It was recrystallized from ether to provide colourless crystals. 
403: Rf = 0.33 [CH2Cl2/MeOH (98:2)]; mp 88–91 
o
C (ether), [lit.
[2]
 87-89 °C (ether- light 
petrol)]; IR (CHCl3)ν3564, 3374, 3028, 2838, 2737, 1773, 1696, 1607, 1509, 1441, 
1371, 1296, 1277, 1172 cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 9.78 (s, 1H), 7.69 (dd, J = 
8.4, 1.8 Hz, 1H), 7.58 (d, J = 2.1 Hz, 1H), 7.07 (d, J = 8.4 Hz, 1H), 4.95 (bs, 1H), 2.33 (s, 
3H); 
13
C NMR (150 MHz, CDCl3) δ 191.8, 169.3, 155.4, 139.1, 129.6, 129.1, 124.0, 
116.7, 19.2; LRMS (EI) m/z (%) 180 (11), 138 (65), 137 (55), 43 (100); HRMS (EI) calcd 
for C9H8O4: 180.0423. Found 180.0427; Anal. Calcd for C9H8O4: C, 60.00; H, 4.48. 
Found C, 60.24; H, 4.59. 
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3-Hydroxy-4-(methoxymethoxy)benzaldehyde (405).   
 
To a suspension of K2CO3 (2.3 g, 16.8 mmol) in DMF (30 mL) at 0 °C was added 
MOMCl (0.84 mL, 2 mmol) dropwise. Then a solution of 403 (1.0 g, 5.6 mmol) in DMF 
(30 mL) was added dropwise through an addition funnel. The reaction mixture was 
allowed to stir for another 30 minutes and was diluted with H2O (100 mL). It was then 
extracted three times with Et2O (75 mL), organic washes were combined, washed with 
brine solution, dried over Na2SO4, and the solvent was evaporated under reduced pressure 
to provide the crude acetate 404 which was taken to next step without further purification. 
A saturated solution of K2CO3 in MeOH (15 mL) was added to a solution of acetate 404 
in MeOH (10 mL) at room temperature. The reaction mixture was stirred at room 
temperature for 40 minutes, then the pH of the reaction mixture was adjusted to 7 using 1 
N HCl and NH4Cl (sat.) solution. The aqueous layer was extracted with CH2Cl2 (3x100 
mL), washed with brine, dried over Na2SO4, and the volatiles were removed in vacuo to 
provide crude product, which was filtered through a plug of silica using EtOAc to yield 
405 (0.72 g, 3.95 mmol, 71% over two steps) as a colourless liquid.  
405: Rf  = 0.15 [hexane/EtOAc (80:20)]; IR (CHCl3) ν 3615, 3028, 3007, 2964, 2740, 
1705, 1578, 1464 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) δ 9.79 (s, 1H), 7.42 (d, J = 1.8 Hz, 
1H), 7.35 (dd, J = 8.4, 1.8 Hz, 1H), 7.17 (d, J = 8.4 Hz, 1H), 6.54 (s, 1H), 5.26 (s, 2H), 
3.47 (s, 3H); 
13
C NMR (CDCl3, 75 MHz) δ 191.4, 149.8, 146.7, 131.4, 124.3, 114.9, 
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114.3, 95.2, 56.6; LRMS (EI) m/z (%) 182 (13), 45 (100); HRMS (EI) calcd for C9H10O4: 
182.0579. Found 182.0576. 
(+)-2-((3aR,7aS)-2,2-dimethyl-3a,6,7,7a-tetrahydrobenzo[d][1,3]dioxol-4-yl)-N-meth 
ylethanamine (398). 
 
A solution of diol 396 (15 g, 67.8 mmol) in acetone (130 mL) was treated with 2,2,-
dimethoxypropane (12.5 mL, 101.8 mmol) and pTsOH. The reaction was stirred for 4 h 
at room temperature, whereupon the solvent was evaporated. The residue was diluted 
with H2O (50 mL) and extracted with CH2Cl2 (3 × 80 mL). The combined organic layers 
were washed with saturated aqueous Na2CO3 solution (2 × 10 mL), and brine, then dried 
(Na2SO4), filtered, and evaporated to yield bromide 397 (15.6 g) as a clear colorless oil, 
which was used without further purification. Bromide 397 (17.8 g, 68.2 mmol) was 
dissolved in THF (70 mL) and transferred to a 200 mL thick-walled reaction vessel 
containing K2CO3 (4.74 g, 34.1 mmol) and a magnetic stirring bar. The reaction vessel 
was cooled to –40 °C, and the solution was saturated with methylamine by passing 
gaseous methylamine from a lecture bottle through the solution for 15 min. The reaction 
vessel was sealed, and the mixture was stirred at 25 °C for 18 h. The mixture was cooled 
to –40 °C before the vessel was opened. Potassium salts were removed by filtration and 
rinsed with CH2Cl2. The solvent was evaporated to obtain amine 398 (13.6 g, 64.3 mmol, 
94%) as a pale yellow oil, which was used without further purification. Data was matched 
with reported procedure.
112
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(–)-tert-Butyl (2-((5S,6R)-5,6-dihydroxycyclohex-1-en-1-yl)ethyl)(methyl)carbamate 
(399). 
 
A solution of acetonide 398 (16.0 g, 75.7 mmol) in EtOH (91 mL) and H2O (9 mL) was 
treated with 3 mol L–
1
 HCl (38.0 mL, 113.6 mmol). The reaction mixture was stirred for 4 
h, treated with NaHCO3 (96 g), and stirred vigorously for 1 h. Then Boc anhydride (24.8 
g, 113.6 mmol) was added, reaction mixture was stirred for additional 4 h, filtered, and 
evaporated. The residue was diluted with H2O (40 mL) and extracted with CH2Cl2 (3 × 
30 mL). The combined organic layers were washed with saturated aqueous NH4Cl 
solution (2 × 10 mL), brine, dried (Na2SO4), filtered, and evaporated. Column 
chromatography on silica gel using [hexane/EtOAc (70:30)  hexane/EtOAc (30:70)] 
provided 399 (14.8 g, 54.8 mmol, 74%) as a light yellow oil. Data was matched with 
reported procedure.
112
 
(–)-tert-Butyl (2-((5S,6R)-5-((tert-butyldimethylsilyl)oxy)-6-hydroxycyclohex-1-en-1-
yl)ethyl)(methyl)carbamate (400). 
 
A solution of carbamate 399 (15 g, 55.2 mmol) and imidazole (7.5 g, 110.4 mmol) in 
CH2Cl2 (75 mL) was treated with TBSCl (9.16 g, 60.7 mmol) at –78 °C, the reaction 
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mixture was left to warm slowly to 25 °C overnight and treated with saturated aqueous 
NH4Cl solution (40 mL). After extraction with CH2Cl2 (3 × 100 mL), the combined 
organic layers were washed with saturated aqueous NaHCO3 solution (50 mL), brine (50 
mL), dried over Na2SO4, filtered, and evaporated. Column chromatography on silica gel 
using [hexane/EtOAc (90:10)  hexane/EtOAc (60:40)] provided 400 (19.5 g, 50.6 
mmol, 92%) as a light yellow oil. Data was matched with reported procedure.
112
  
 (–)-N-(2-((5S,6R)-5-((tert-Butyldimethylsilyl)oxy)-6-hydroxycyclohex-1-en-1-yl)eth- 
yl)-N,4-dimethylbenzenesulfonamide (401). 
 
To a solution of 400 (1.0 g, 2.59 mmol) in CH2Cl2 at 0 °C was added TFA (4.0 mL, 32 
mmol) and was stirred for 20 minutes. Then the reaction mixture was diluted with CH2Cl2 
(60 mL), then saturated NaHCO3 solution was added and pH was adjusted to 9. Organic 
layer was separated and the aqueous layer was washed with CH2Cl2 (3 x 30 mL), organic 
washes were combined and was washed with brine solution, dried over Na2SO4 and 
solvent was evaporated under reduced pressure to provide crude product (540 mg). Then 
the aqueous phase was saturated with NaCl and was washed with CHCl3:EtOH (3:1) (3 x 
30 mL), dried over Na2SO4 and solvent was evaporated under reduced pressure to 
provide another 200 mg of crude product. The crude material was taken to next step 
without further purification.  
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To a solution of crude product (740 mg, 2.6 mmol) in CH2Cl2 at 0 °C was added Et3N 
(0.47 mL, 3.37 mmol) followed by TsCl (593 mg, 3.1 mmol). The reaction mixture was 
slowly warmed to room temperature and was stirred for 3 hours. Then the solvent was 
evaporated under reduced pressure and column chromatography on silica gel using 
[hexane/EtOAc (90:10)  hexane/EtOAc (70:30)] provided 401 (979 mg, 2.2 mmol, 
86%) as a clear liquid.  
401: Rf  = 0.12 [hexane/EtOAc (70:30)]; [α]
  
 
 = –30.0 (c = 1.15, CHCl3); IR (CHCl3) ν 
3550, 3028, 3008, 2954, 2930, 2885, 2859, 1690, 1598, 1462, 1373, 1339, 1160, 1088 
cm
-1
; 
1
H NMR (CDCl3, 300 MHz) δ 7.64 (d, J = 8.1 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 
5.58 (bs, 1H), 3.92 (d, J = 3.6 Hz, 1H), 3.83-3.78 (m, 1H), 3.35-3.26 (m, 1H), 3.00-2.93 
(m, 1H), 2.70 (s, 3H), 2.39 (s, 4H), 2.30-2.23 (m, 1H), 2.21-1.88 (m, 3H), 1.80-1.67 (m, 
1H), 1.56-1.52 (m, 1H), 0.89 (s, 9H), 0.14-0.09 (m, 6H); 
13
C NMR (CDCl3, 75 MHz) δ 
143.1, 134.8, 134.0, 129.6, 127.3, 127.2, 70.7, 68.7, 49.1, 34.6, 33.1, 25.8, 25.5, 23.9, 
21.4, 18.0, −4.5, −4.9; LRMS (EI) m/z (%) 382 (4),  324 (8), 200 (10), 199 (25), 198 
(100), 197 (86), 155 (67), 140 (21), 105 (15), 91 (58), 77 (13), 75 (81), 73 (30), 57 (16), 
44 (35); HRMS (EI) calcd for C22H37NO4SSi (M
+–C4H9): 382.1508. Found 382.1496; 
Anal. Calcd for C22H37NO4SSi: C, 60.10; H, 8.48. Found C, 59.92; H, 8.28. 
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 (–)-tert-Butyl(2-((5S,6S)-5-((tert-butyldimethylsilyl)oxy)-6-(5-formyl-2-(methoxyme 
thoxy)phenoxy)cyclohex-1-en-1-yl)ethyl)(methyl) carbamate (406). 
 
To a solution of alcohol 400 (3.19 g, 8.28 mmol) and phenol 405 (1.66 g, 9.11 mmol) in 
THF (30 mL) at −10 °C was added PBu3 (2.9 mL, 11.59 mmol) followed by 
tetramethylazodicarboxamide (TMAD) (1.9 g, 10.76 mmol). The reaction mixture was 
slowly warmed to room temperature and was stirred for 18 hours. Solvent was evaporated 
under reduced pressure and purified by flash column chromatography on silica gel using 
[hexane/EtOAc (90:10)] as eluent to isolate product 406 (3.7 g, 6.7 mmol, 81%) as a clear 
oil.  
406: Rf  = 0.39 [hexane/EtOAc (70:30)]; [α]
  
 
 = –27.6 (c = 1.48, CHCl3); IR (CHCl3) ν 
3681, 3009, 2931, 1726, 1682, 1582, 1506, 1394, 1271, 1159 cm
-1
; 
1
H NMR (CDCl3, 300 
MHz) δ 9.86 (s, 1H), 7.70 (s, 1H), 7.44 (dd, J = 8.1, 1.5 Hz, 1H), 7.28-7.24 (m, 1H), 5.69 
(s, 1H), 5.29 (s, 2H), 4.75 (s, 1H), 4.11-4.06 (m, 1H), 3.49 (s, 3H), 3.25-3.17 (m, 2H), 
2.72 (s, 3H), 2.35-2.04 (m, 4H), 1.93-1.86 (m, 1H), 1.79-1.70 (m, 1H), 1.41 (s, 9H), 0.81 
(s, 9H), 0.00 (s, 3H), −0.09 (s, 3H); 13C NMR (CDCl3, 75 MHz, rotameric) δ 190.8, 
155.7, 152.7, 149.8, 132.4, 131.1, 128.6, 125.8, 125.2, 115.5, 94.8, 80.3, 79.3, 70.4, 60.5, 
56.5, 48.5, 34.5, 32.3, 31.7, 28.5, 25.8, 22.8, 18.0, −4.7, −4.8; LRMS (EI) m/z (%) 312 
(37), 268 (50), 237 (29), 136 (34), 57 (51), 44 (100); HRMS (EI) calcd for C29H47NO7Si: 
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549.3122. Found 549.3115; Anal. Calcd for C29H47NO7Si: C, 63.36; H, 8.62. Found C, 
63.02; H, 8.61.  
(–)-N-(2-((5S,6S)-5-((Tert-butyldimethylsilyl)oxy)-6-(5-formyl-2- (methoxymethoxy) 
phenoxy) cyclohex-1-en-1-yl)ethyl)-N,4-dimethylbenzenesulfonamide (407). 
 
To a solution of alcohol 401 (190 mg, 0.43 mmol) and phenol 405 (102 mg, 0.56 mmol) 
in THF (6 mL) at −10 °C was added PBu3 (0.15 mL, 0.65 mmol) followed by 
tetramethylazodicarboxamide (TMAD) (111 mg, 0.65 mmol). The reaction mixture was 
slowly warmed to room temperature and was stirred for 22 hours. Solvent was evaporated 
under reduced pressure and purified by flash column chromatography on silica gel using 
[hexane/EtOAc (80:20) hexane/EtOAc (50:50)] as eluent to isolate product 407 (130 
mg, 0.22 mmol, 50%) as a clear oil. 
407: Rf  = 0.34 [hexane/EtOAc (70:30)]; [α]
  
 
 = –21.1 (c = 1.5, CHCl3); IR (CHCl3) ν
3028, 3009, 2954, 2930, 2857, 1688, 1596, 1584, 1505, 1463, 1339, 1264, 1160, 1126, 
1084 cm
-1
; 
1
H NMR (CDCl3, 300 MHz) δ 9.87 (s, 1H), 7.69 (d, J = 1.2 Hz, 1H), 7.55-
7.45 (m, 3H), 7.28-7.23 (m, 3H), 5.75 (s, 1H), 5.31-5.26 (m, 2H), 4.72 (d, J = 4.8 Hz, 
1H), 4.14-4.05 (m, 1H), 3.48 (s, 3H), 3.05-3.01 (m, 1H), 2.94-2.88 (m, 1H), 2.62 (s, 3H), 
2.50-2.40 (m, 4H), 2.36-2.26 (m, 1H), 2.19-2.13 (m, 2H), 1.89-1.87 (m, 1H), 1.85-1.83 
(m, 1H), 0.80 (s, 9H), −0.00 (s, 3H), −0.11 (s, 3H); 13C NMR (CDCl3, 75 MHz, 
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rotameric) δ 190.9, 152.8, 150.1, 149.4, 143.1, 134.6, 131.8, 130.9, 129.6, 128.9, 127.3, 
125.4, 115.4, 115.1, 94.8, 79.9, 70.2, 60.4, 56.5, 49.4, 34.9, 32.4, 28.0, 25.7, 22.7, 21.5, 
17.9, −4.9, −5.0; LRMS (EI) m/z (%) 546 (2), 199 (12), 198 (100), 155 (44), 91 (47), 75 
(67), 45 (77); HRMS (EI) calcd for C31H45NO7SSi (M
+–C4H9): 546.1982. Found 
546.1976. 
 (–)-tert-Butyl(2-((5S,6S)-5-((tert-butyldimethylsilyl)oxy)-6-(2-(methoxy-methoxy)-5-
vinylphenoxy)cyclohex-1-en-1-yl)ethyl)(methyl)carbamate (408).  
 
To a suspension of Wittig salt CH3P
+
Ph3Br
–
(2.26 g, 6.3 mmol) in THF (20 mL) at -78 °C, 
nBuLi (2.9 mL, 5.8 mmol) was added and the resulting yellow solution was stirred for 15 
minutes. It was then warmed to 0 °C, and aldehyde 406 (1.58 g, 2.9 mmol) in THF (20 
mL) was cannulated into the reaction mixture, which was stirred for another 10 minutes 
at 0 °C. The resulting yellow suspension was heated to reflux for 4 hours whereupon the 
solvent was evaporated under reduced pressure and column chromatography on silica gel 
using hexane/EtOAc (80:20) provided 408 (1.3 g, 2.37 mmol, 82%) as a colourless 
liquid.  
408: Rf  = 0.57 [hexane/EtOAc (70:30)]; [α]
  
 
 = –9.4 (c = 0.17, CHCl3); IR (CHCl3) ν 
3009, 2954, 2930, 2898, 2857, 1683, 1601, 1577, 1506, 1261 cm
-1
; 
1
H NMR (CDCl3, 300 
MHz, rotameric) δ 7.21-7.20 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.01-6.93 (m, 1H), 6.67-
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6.57 (m, 1H), 5.67-5.58 (m, 2H), 5.20-5.13 (m, 3H), 4.57 (bs, 1H), 4.08 (bs, 1H), 3.48 (s, 
3H), 3.20-3.16 (m, 2H), 2.73 (bs, 3H), 2.36-2.04 (m, 4H), 1.89-1.86 (m, 1H), 1.74-1.67 
(m, 1H), 1.42 (s, 9H), 0.83 (s, 9H), −0.01 (s, 3H), −0.08 (s, 3H); 13C NMR (CDCl3, 75 
MHz, rotameric) δ 155.6, 149.2, 147.2, 136.3, 132.6, 132.3, 128.2, 127.8, 119.7, 114.2, 
113.7, 116.9, 114.2, 113.7, 112.4, 95.3, 79.9, 79.0, 69.6, 60.3, 56.0, 48.4, 47.7, 34.4, 32.6, 
31.8, 28.4, 27.6, 25.7, 22.4, 20.9, 17.9, −4.8, −4.9; LRMS (EI) m/z (%) 312 (35), 268 
(72), 237 (28), 225 (17), 180 (24), 136 (57), 109 (30), 75 (77), 57 (57), 45 (100); HRMS 
(EI) calcd for C30H49NO6Si: 547.3329. Found 547.3323; Anal. Calcd for C30H49NO6Si: 
C, 65.78; H, 9.02. Found C, 65.52; H, 8.85. 
N-(2-((5S,6S)-5-((Tert-butyldimethylsilyl)oxy)-6-(2-(methoxymethoxy)-5-vinylphen-
oxy) cyclohex-1-en-1-yl)ethyl)-N,4-dimethylbenzenesulfonamide (409). 
 
To a suspension of Wittig salt CH3P
+
Ph3Br
–
(254 mg, 0.71 mmol) in THF (5 ml) at -78 
°C, n-BuLi (0.28 ml, 0.64 mmol) was added and the resulting yellow solution was stirred 
for 15 minutes. It was then warmed to 0 °C, and aldehyde 407 (215 mg, 0.36 mmol) in 
THF (5 ml) was cannulated into the reaction mixture, which was stirred for another 10 
minutes at 0 °C. The resulting yellow suspension was heated to reflux for 4 hours 
whereupon the solvent was evaporated under reduced pressure and column 
chromatography on silica gel using hexane/EtOAc (80:20) provided 409 (190 mg, 0.35 
mmol, 89%) as a colorless liquid.  
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409: Rf = 0.46 [hexane/EtOAc (70:30)]; [α]
  
 
 = –2.6 (c = 0.65, CHCl3); IR (CHCl3) ν 
2981, 2950, 2930, 2891, 2857, 1577, 1506, 1462, 1339, 1254, 1159, 1129 cm
-1
; 
1
H NMR 
(CDCl3, 300 MHz) δ 7.55 (d, J = 8.1 Hz, 1H), 7.26-7.21 (m, 3H), 7.07 (d, J = 8.4 Hz, 
1H), 6.95 (dd, J = 8.1, 1.5 Hz, 1H), 6.63 (d, J = 17.4, 10.8 Hz, 1H), 5.73 (s, 1H), 5.64 (d, 
J = 17.7 Hz, 1H), 5.17-5.12 (m, 3H), 4.62 (d, J = 3.9 Hz, 1H), 4.09-4.04 (m, 1H), 3.45 (s, 
3H), 3.15-3.05 (m, 1H), 2.95-2.86 (m, 1H), 2.62 (s, 3H), 2.51-2.42 (m, 1H), 2.38 (s, 3H), 
2.32-2.17 (m, 2H), 2.09-2.06 (m, 1H), 1.93-1.84 (m, 1H), 1.78-1.67 (m, 1H); 
13
C NMR 
(CDCl3, 75 MHz) δ 149.1, 147.3, 143.0, 136.2, 134.7, 132.4, 132.0, 129.5, 128.7, 127.3, 
119.8, 116.9, 114.2, 112.6, 95.4, 79.6, 69.6, 56.1, 49.3, 34.9, 32.6, 27.5, 25.8, 22.4, 21.5, 
18.0, −4.9, −5.0; LRMS (EI) m/z (%) 422 (18), 200 (11), 198 (100), 155 (72), 91 (68), 75 
(72), 45 (48); HRMS (EI) calcd for C32H47NO6SSi: 601.2893. Found 601.2877; Anal. 
Calcd for C32H47NO6SSi: C, 63.86; H, 7.87. Found C, 64.00; H, 7.95. 
(+)-tert-Butyl(2-((5S,6S)-5-((tert-butyldimethylsilyl)oxy)-6-(2-hydroxy-5-vinylpheno 
xy)cyclohex-1-en-1-yl)ethyl)(methyl)carbamate (13). 
 
 To a solution of 408 (1.3 g, 2.4 mmol) in CH2Cl2 (25 mL) at 0 °C was added ZnBr2 (0.59 
g, 2.6 mmol) followed by 1-dodecane thiol (1.1 mL, 4.8 mmol). Then the reaction 
mixture was stirred for 10 minutes, diluted with CH2Cl2 (60 mL), then NaHCO3 (sat) 
solution was added dropwise and the mixture was filtered through a pad of celite. The 
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aqueous layer was separated and further extracted with CH2Cl2. The combined organic 
solution was dried with Na2SO4, volatiles were removed in vacuo to provide crude 
product and column chromatography on silica gel using [hexane/EtOAc (90:10)] 
provided 13 (1.12 g, 2.22 mmol, 93%) as a clear liquid. 
13: Rf  = 0.27 [hexane/EtOAc (80:20)]; [α]
  
 
 = +1.0 (c = 3.15, CHCl3); IR (CHCl3)ν 
3535, 3297, 2955, 2930, 2858, 1684, 1605, 1508, 1396, 1268, 1161 cm
-1
; 
1
H NMR 
(CDCl3, 300 MHz, rotameric) δ 7.06 (s, 1H), 6.92-6.86 (m, 2H), 6.60 (dd, J = 17.4, 10.8 
Hz, 1H), 5.65 (s, 1H), 5.56 (d, J = 17.7 Hz, 1H), 5.09 (d, J = 10.8 Hz, 1H), 4.58 (s, 1H), 
4.10-4.06 (m, 1H), 3.71 (bs, 0.6H), 3.15 (bs, 0.8H), 2.95-2.91 (m, 0.6H), 2.75 (s, 3H), 
2.33-1.95 (m, 4H), 1.70-1.68 (m, 2H), 1.43 (s, 9H), 0.86 (s, 9H), 0.04 (s, 3H), 0.01 (s, 
3H); 
13
C NMR (CDCl3, 75 MHz, rotameric) δ 155.7, 146.8, 145.7, 136.7, 130.5, 129.2, 
119.7, 115.3, 111.0, 109.8, 79.2, 78.7, 69.6, 68.7, 48.6, 47.6, 44.1, 33.8, 33.1, 31.2, 31.4, 
29.6, 29.5, 29.3, 29.0, 28.4, 27.5, 26.7, 25.7, 22.7, 21.9, 17.9, −4.8; LRMS (EI) m/z (%) 
312 (14), 268 (15), 237 (17), 228 (17), 136 (42), 109 (15), 105 (240), 83 (34), 75 (56), 57 
(90), 44 (100); HRMS (EI) calcd for C28H45NO5Si: 503.3067. Found 503.3073; Anal. 
Calcd for C28H45NO5Si: C, 66.76; H, 9.00. Found C, 65.85; H, 9.07. 
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tert-Butyl (2-((3S,3aS)-3-((tert-butyldimethylsilyl)oxy)-4a-methoxy-5-oxo-1,2,3,3a, 
3a1,4a,4a1,5,9,9a-decahydrophenanthro[4,5-bcd]furan-3a1-yl)ethyl)(methyl)carba- 
mate (411).  
 
To a solution of 13 (110 mg, 0.22 mmol) in MeOH (5 ml) PIDA (84.4 mg, 0.26 mmol) in 
MeOH (5 ml) was added via a syringe pump over one hour. TLC analysis showed the 
complete consumption of starting material, then the reaction mixture was diluted with 
CH2Cl2, washed with NaHCO3 (sat.) solution, dried over Na2SO4 and solvent was 
evaporated in vacuo to provide crude product. It was dissolved in toluene (3 ml) and was 
heated to reflux in a sealed tube for 18 hours. Then the reaction mixture was directly 
loaded to a silica column, toluene was eluted using hexanes, and the product 411 (29 mg, 
0.05 mmol, 25%) was eluted using hexane/EtOAc (80:20).  
411: Rf  = 0.24 [hexane/EtOAc (70:30)]; [α]
  
 
 = +25 (c = 0.45, CHCl3); IR (CHCl3) ν 
2959, 2927, 2858, 1681, 1622, 1482, 1462, 1393, 1266 cm
-1
; 
1
H NMR (CDCl3, 300 
MHz) δ 7.07 (d, J = 9.9 Hz, 1H), 6.03 (t, J = 2.7 Hz, 1H), 5.95 (d, J = 9.9 Hz, 1H), 3.99-
3.89 (m, 2H), 3.61-3.51 (m, 1H), 3.37 (s, 3H), 3.09 (s, 1H), 2.94 (bs, 1H), 2.71 (s, 4H), 
2.25-2.02 (m, 3H), 1.84-1.72 (m, 3H), 1.42 (s, 9H), 1.25-1.12 (m, 2H), 0.89 (s, 9H), 0.12 
(s, 3H), 0.07 (s, 3H); 
13
C NMR (CDCl3, 75 MHz) δ 191.4, 155.4, 143.2, 132.1, 125.7, 
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100.1, 88.4, 79.5, 72.7, 52.5, 50.5, 49.9, 34.1, 33.2, 32.6, 29.3, 28.4, 25.8, 17.9, −4.3, 
−4.5.  
 (3S,3aS)-3a1-(2-(N-Methylacetamido)ethyl)-1,2,3,3a,3a1,9a-hexahydrophenanthro 
[4,5-bcd]furan-3,5-diyl diacetate (412).  
 
To a solution of 411 (5 mg, 0.01 mmol) in CH2Cl2 at room temperature Ac2O (0.1 ml) 
and TFA (0.1 ml) was added and was stirred for 18 hours. Then the reaction mixture was 
neutralised with NaHCO3 (sat) solution, organic layer was separated, dried over Na2SO4 
and solvent was evaporated in vacuo to provide crude product. It was then passed through 
a silica gel pipette column using EtOAc as eluent to yield (1.7 mg, 0.004 mmol, 40%) as 
an yellow liquid.  
412: Rf  = 0.19 [EtOAc]; IR (CHCl3) ν 3008, 2929, 2851, 2340, 1759, 1666, 1632 cm
-1
; 
1
H 
NMR (CDCl3, 300 MHz) δ 6.96-6.85 (m, 3H), 6.17-6.11 (m, 1H), 4.79 (d, J = 7.2 Hz, 
1H), 4.45-4.48 (m, 1H), 3.76-3.71 (m, 1H), 3.51-3.47 (m, 1H), 3.13 (s, 3H), 2.86 (s, 1H), 
2.62 (bs, 1H), 2.10 (s, 3H), 2.09 (s, 6H); LRMS (EI) m/z (%) 413 (2), 371 (5), 212 (14), 
211 (13), 149 (17), 101 (100); HRMS (EI) calcd for C23H27NO6: 413.1838. Found 
413.1837. 
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(+)-N-(2-((5S,6S)-5-((Tert-butyldimethylsilyl)oxy)-6-(5-(1-(dodecylthio)ethyl)-2-hy 
droxyphenoxy)cyclohex-1-en-1-yl)ethyl)-N,4-dimethylbenzenesulfonamide (413). 
 
To a solution of 409 (190 mg, 0.35 mmol) in CH2Cl2 (4 ml) at 0 °C was added ZnBr2 
(86.0 mg, 0.38 mmol) followed by 1-dodecane thiol (0.16 ml, 0.7 mmol). Then the 
reaction mixture was stirred for 10 minutes, diluted with CH2Cl2 (15 ml), then NaHCO3 
(sat) solution was added dropwise and the mixture was filtered through a pad of celite. 
The aqueous layer was separated and further extracted with CH2Cl2. The combined 
organic solution was dried with Na2SO4, volatiles were removed in vacuo to provide 
crude product and column chromatography on silica gel using [hexane/EtOAc 
(90:10)→hexane/EtOAc (70:30)] provided 413 (122 mg, 0.16 mmol, 46%)  and 414 (83 
mg, 0.13 mmol, 37%) as clear liquids. 
413: Rf  = 0.45 [hexane/EtOAc (70:30)]; [α]
  
 
= +7.02 (c = 0.87, CHCl3); IR (CHCl3) ν 
3536, 3456, 3030, 2923, 2853, 1686, 1598, 1505, 1436, 1341, 1305, 1152, 1115 cm
-1
; 
1
H 
NMR (CDCl3, 300 MHz) δ 7.60 (dd, J = 8.1, 1.8 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 7.05 
(d, J = 8.1 Hz, 1H), 6.86 (dd, J = 10.2, 8.1 Hz, 2H), 6.13-6.07 (m, 1H), 5.79 (s, 1H), 4.64-
4.60 (m, 1H), 4.08 (d, J = 2.1 Hz, 1H), 3.92-3.84 (m, 1H), 3.04 (t, J = 7.2 Hz, 2H), 2.62 
(s, 3H), 2.41 (s, 3H), 2.41-2.26 (m, 5H), 2.13-2.07 (m, 1H), 1.86-1.73 (m, 2H), 1.53-1.47 
(m, 5H), 1.26-1.25 (m, 20H), 0.87 (s, 9H), 0.07-0.04 (m, 6H); 
13
C NMR (CDCl3, 75 
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MHz) δ 145.5, 145.4, 145.2, 143.1, 136.2, 134.7, 131.1, 130.9, 129.6, 127.3, 120.6, 
120.5, 114.8, 114.7, 112.4, 112.3, 78.9, 69.3, 69.1, 49.3, 44.1, 34.7, 32.5, 32.4, 31.9, 31.4, 
29.6, 29.5, 29.4, 29.3, 29.0, 27.3, 27.1, 25.8, 23.2, 22.8, 22.7, 22.2, 22.1, 18.0, 14.1, −4.6, 
−4.7; HRMS (EI) calcd for C42H69NO5S2Si: 759.  
N-(2-((5S,6S)-6-(5-(1-(Dodecylthio)ethyl)-2-hydroxyphenoxy)-5-hydroxycyclohex-1-
en-1-yl)ethyl)-N,4-dimethylbenzenesulfonamide (414). 
 
 
 414: Rf  = 0.19 [hexane/EtOAc (70:30)]; [α]
  
 
 = +18.2 (c = 0.87, CHCl3); IR (CHCl3) ν 
3447, 2921, 2851, 1597, 1507, 1435, 1336, 1265, 1201, 1155, 1117, 1088, 1003 cm
-1
; 
1
H 
NMR (CDCl3, 300 MHz) δ 7.62 (dd, J = 8.1, 2.7 Hz, 2H), 7.30-7.27 (m, 2H), 7.12 (s, 
1H), 6.87 (s, 2H), 6.28 (bs, 1H), 5.81 (s, 1H), 4.77 (s, 1H), 4.16-4.11 (m, 1H), 3.90 (dd, J 
= 13.8, 6.9 Hz, 1H), 3.24-3.13 (m, 1H), 3.03-2.93 (m, 1H), 2.65 (s, 3H), 2.42 (s, 3H), 
2.36-2.22 (m, 5H), 1.90-1.79 (m, 2H), 1.55-1.47 (m, 5H), 1.26 (d, J = 4.2 Hz, 19H), 0.91-
0.87 (m, 3H); 
13
C NMR (CDCl3, 75 MHz) δ 145.4, 143.3, 136.3, 134.7, 131.0, 129.9, 
129.7, 127.3, 121.0, 115.1, 113.2, 113.1, 79.2, 68.9, 49.1, 43.8, 34.5, 31.9, 29.6, 29.5, 
29.4, 29.3, 29.2, 29.0, 26.4, 22.9, 22.7, 22.1, 21.5, 14.1; LRMS (EI) m/z (%) 202 (17), 
198 (100), 155 (76), 136 (26), 111 (16), 99 (19), 98 (36), 91 (80), 83 (50), 69 (56), 55 
(60), 43 (61); HRMS (EI) calcd for C36H55NO5S2: 645.3522. Found 645.3476. 
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 (–)-(4aS,4a1R,5S,7aR)-4a1-(2-((tert-Butoxycarbonyl)(methyl)amino)ethyl)-5-((tert-
butyldimethylsilyl)oxy)-3-oxo-3,3a,3a1,4a,4a1,5,6,7,7a,8-decahydrophenanthro[4,5-
bcd]furan-3a-yl acetate (416). 
 
A solution of lead tetraacetate (37.9 mg, 0.08 mmol) in DCE (1 mL) was added dropwise 
to a refluxing solution of 13 (43 mg, 0.08 mmol) in DCE (1 mL). The reaction mixture 
was stirred for another 4 hours, cooled to room temperature, and then passed through a 
plug of celite and solvent was evaporated under reduced pressure to obtain the crude 
product which was purified by column chromatography on silica gel using 
[hexane/EtOAc (90:10) → hexane/EtOAc (70:30)] as eluent to provide 416 (24 mg, 0.04 
mmol, 50%) as a colourless liquid.  
416: Rf = 0.46 [hexane/EtOAc (70:30)]; [α]
  
 
 = –22.0 (c = 1.2, CHCl3); IR (CHCl3) ν 
3024, 3009, 2951, 2931, 2858, 1730, 1686, 1625, 1462, 1368, 1252, 1161 cm
-1
; 
1
H NMR 
(300 MHz, CDCl3, rotameric) δ 7.06 (d, J = 9.9 Hz, 1H), 6.47 (bt, J = 3.6 Hz, 1H), 5.98 
(d, J = 9.9 Hz, 1H), 4.15-4.05 (m, 1H), 3.42-3.10 (m, 4H), 2.87 (s, 3H), 2.27-2.22 (m, 
2H), 2.16 (bs, 1H), 2.13 (s, 3H), 2.04-2.02 (m, 2H), 1.72 (bs, 1H), 1.53-1.51 (m, 1H), 
1.47 (s, 9H), 1.14-1.05 (m, 2H), 0.84 (s, 9H), −0.01 (s, 3H), −0.05 (s, 3H); 13C NMR (75 
MHz, CDCl3, rotameric) δ188.2, 170.9, 155.4, 144.5, 139.0, 134.2, 122.7, 103.9, 90.6, 
79.7, 74.2, 73.5, 52.0, 48.6, 45.9, 45.4, 40.7, 39.8, 38.6, 37.3, 34.4, 30.8, 29.4, 28.5, 25.8, 
188 
 
21.3, 20.6, 18.1, −4.6, −5.1; LRMS (EI) m/z (%) 388 (10), 345 (10), 313 (12), 287 (25), 
171 (15), 83 (12), 75 (23), 73 (45), 59 (34), 57 (87), 44 (100); HRMS (EI) calcd for 
C30H47NO7Si (M
+–C2H4O2): 501.2911. Found 501.2910; Anal. Calcd for C30H47NO7Si: 
C, 64.14; H, 8.43. Found C, 64.03; H, 8.45. 
 (–)-(4aS,4a1R,5S,7aR)-5-((tert-Butyldimethylsilyl)oxy)-4a1-(2-(N,4-dimethylphenyls 
ulfonamido)ethyl)-4a,4a1,5,6,7,7a-hexahydro phenanthro[4,5-bcd]furan-3-yl 4-
methylbenzenesulfonate (419).  
 
A solution of 416 (16 mg, 0.028 mmol) in CH2Cl2 (1.5 mL) was cooled in an ice bath and 
TFA (0.5 mL) was added dropwise. The reaction mixture was stirred for 10 minutes, 
diluted with CH2Cl2 (4.5 mL) and the pH of the reaction mixture was adjusted to ~7 using 
saturated Na2CO3 solution. The organic layer was separated, washed with water, dried 
over Na2SO4 and evaporated in vacuo to obtain the crude product (417) which was 
immediately taken to next step without further purification.  
A solution of 417 in CH2Cl2 was cooled in an ice bath, was added Et3N (6.3 µL, 0.045 
mmol) and TsCl (8.6 mg, 0.045 mmol) and the resulting reaction mixture was stirred for 
10 hours. The solvent was evaporated under reduced pressure and the crude product was 
purified by column chromatography on silica gel using [hexane/EtOAc (90:10) → 
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hexane/EtOAc (80:20)] as eluent to provide 419 (9 mg, 0.013 mmol, 46% over two steps) 
as a light yellow oil.  
419: Rf = 0.47 [hexane/EtOAc (70:30)]; [α]
  
 
 = –106.5 (c = 0.42, CHCl3); IR (CHCl3) ν 
3027, 2929, 2857, 1599, 1490, 1446, 1378, 1341, 1274, 1221, 1158 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ 7.78 (d, J = 8.4 Hz, 2H), 7.61 (d, J = 8.1 Hz, 2H), 7.31-7.26 (m, 4H), 
6.84 (d, J = 8.1 Hz, 1H), 6.59 (d, J = 8.1 Hz, 1H), 6.35 (d, J = 9.6 Hz, 1H), 5.92 (dd, J = 
9.6, 5.7 Hz, 1H), 4.36 (d, J = 6.9 Hz, 1H), 3.31-3.23 (m, 1H), 3.05-2.95 (m, 1H), 2.82-
2.72 (m, 1H), 2.59 (s, 3H), 2.44 (s, 3H), 2.40 (s, 3H), 2.36-2.34 (m, 1H), 1.77-1.68 (m, 
2H), 1.63-1.55 (m, 3H), 1.25-1.17 (m, 1H), 0.88 (s, 9H), 0.08 (s, 3H), −0.01 (s, 3H); 13C 
NMR (150 MHz, CDCl3) δ 148.2, 145.3, 143.3, 134.6, 133.0, 132.8, 132.7, 129.7, 129.6, 
129.2, 128.9, 128.8, 127.4, 124.1, 122.5, 117.7, 98.2, 73.9, 46.1, 44.7, 39.7, 35.8, 34.8, 
29.8, 29.7, 26.6, 25.8, 21.7, 21.5, 18.1, −4.6, −5.0; LRMS (EI) m/z (%) 653 (3), 198 (34), 
155 (12), 149 (19), 124 (28), 123 (13), 100 (42), 92 (17), 91 (58), 83 (16), 57 (35), 43 
(100); HRMS (EI) calcd for C37H47NO7S2Si (M
+–C4H9): 652.1859. Found 652.1852; 
Anal. Calcd for C37H47NO7S2Si: C, 62.59; H, 6.67. Found C, 62.52; H, 6.63. 
 (–)-(4aS,4a1R,5S,7aR)-4a1-(2-(N,4-Dimethylphenylsulfonamido)ethyl)-5-hydroxy-
4a,4a1,5,6,7,7a-hexahydrophenanthro[4,5-bcd]furan-3-yl 4-methylbenzenesulfonate 
(420). 
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To a mixture of 419 (141 mg, 0.19 mmol) and THF (5 mL) at room temperature was 
added tetrabutylammonium fluoride (TBAF) solution in THF (0.34 mL, 0.34 mmol). The 
resulting mixture was stirred for 6 hours and the solvent was evaporated under reduced 
pressure to provide the crude product, which was purified by column chromatography on 
silica gel using [hexane/EtOAc (70:30) → hexane/EtOAc (50:50)] as eluent to provide 
420 (101 mg, 0.17 mmol, 86%) as a clear oil. 
420: Rf = 0.29 [hexane/EtOAc (50:50)]; [α]
  
 
 = –20.4 (c = 0.55, CHCl3); IR (CHCl3) ν 
3518, 3033, 2926, 2861, 1597, 1489, 1445, 1335, 1191, 1177, 1088 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ 7.76 (d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.1 Hz, 2H), 7.33-7.26 (m, 4H), 
6.78 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.4 Hz, 1H), 6.35 (d, J = 9.6 Hz, 1H), 5.93 (dd, J = 
9.6, 5.7 Hz, 1H), 4.48 (d, J = 7.2 Hz, 1H), 3.08-2.98 (m, 2H), 2.84-2.74 (m, 1H), 2.57 (s, 
3H), 2.47-2.36 (m, 8H), 1.88-1.56 (m, 4H), 1.27-1.15 (m, 1H), 0.89-0.76 (m, 1H); 
13
C 
NMR (75 MHz, CDCl3) δ 147.9, 145.6, 143.4, 134.3, 133.0, 132.6, 129.7, 129.3, 129.1, 
128.7, 127.4, 123.8, 122.5, 117.9, 98.0, 76.7, 72.9, 46.1, 44.7, 39.3, 35.2, 34.8, 27.8, 26.9, 
21.7, 21.5; LRMS (EI) m/z (%) 595 (1), 440 (4), 384 (3), 229 (7), 198 (10), 155 (35), 139 
(13), 124 (20), 97 (13), 92 (18), 91 (100), 69 (21), 57 (30); HRMS (EI) calcd for 
C31H33NO7S2: 595. 1698. Found 595. 1693. 
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 (+)-(4S,4aS,7S,7aS,12bR)-7-((tert-Butyldimethylsilyl)oxy)-3-methyl-2,3,4,4a,5,6,7,7a-
octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol (421). 
 
To a mixture of tBuOH (64 µL, 0.62 mmol) and THF (2 mL) at −78 °C was added liquid 
NH3 (~15 mL) and Li wire (37 mg, 5.3 mmol). The resulted blue colour reaction mixture 
was stirred for five minutes and 419 (35 mg, 0.05 mmol) in THF (2 mL) was added 
dropwise. The reaction mixture was stirred for another 10 minutes while it remained blue 
in colour. Then 2 g of NH4Cl was added as a solid, followed by 10 mL of MeOH and 20 
mL of saturated NH4Cl solution. This mixture was then washed three times with CH2Cl2 
(20 mL), the combined organic layers were washed with saturated NaCl solution, and 
dried over Na2SO4. The solvent was evaporated under reduced pressure to provide the 
crude product, which was purified by column chromatography on silica gel using 
[CH2Cl2/MeOH (95:5) → CH2Cl2/MeOH (90:10)] as eluent to provide 421 (16 mg, 0.04 
mmol, 82%) as a colourless oil.  
421: Rf = 0.24 [CH2Cl2/MeOH (90:10)]; [α]
  
 
 = +70.5 (c = 0.8, CHCl3); IR (CHCl3)ν 
3688, 3586, 2953, 2931, 2858, 1624, 1604, 1505, 1455, 1220, 1119, 1098 cm
-1
; 
1
H NMR 
(600 MHz, CDCl3) δ 6.70 (d, J = 8.4 Hz, 1H), 6.58 (d, J = 7.8 Hz, 1H), 4.91 (bs, 1H), 
4.31 (d, J = 6.6 Hz, 1H), 3.39-3.35 (m, 1H), 3.25 (d, J = 2.4 Hz, 1H), 2.98 (d, J = 18.6 
Hz, 1H), 2.68 (dd, J = 12, 4.2 Hz, 1H), 2.46 (s, 3H), 2.44-2.43 (m, 1H), 2.28-2.22 (m, 
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2H), 2.03 (s, 1H), 1.95-1.90 (m, 1H), 1.67-1.65 (m, 2H), 1.53-1.50 (m, 1H), 1.39-1.32 
(m, 1H), 0.88 (s, 9H), 0.10 (s, 3H), 0.01 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 143.0, 
139.9, 129.9, 124.5, 119.2, 117.0, 97.3, 73.7, 59.5, 46.9, 42.9, 42.2, 41.7, 34.7, 31.6, 25.8, 
23.4, 20.4, 18.1, −4.5, −4.8; LRMS (EI) m/z (%) 401 (3), 120 (29), 118 (32), 87 (92), 85 
(80), 83 (76), 60 (30), 47 (100), 43 (44); HRMS (EI) calcd for C23H35NO3Si: 401.2386. 
Found 401.2375. 
 (+)-(4S,4aS,7S,7aS,12bR)-3-Methyl-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-
methanobenzofuro[3,2-e]isoquinoline-7,9-diol (422). 
 
To a mixture of tBuOH (35 µL, 0.34 mmol) and THF (2 mL) at −78 °C was added liquid 
NH3 (~15 mL) and Li wire (20 mg, 2.85 mmol). The resulted blue colour reaction 
mixture was stirred for five minutes and 420 (20 mg, 0.03 mmol) in THF (2 mL) was 
added dropwise. The reaction mixture was stirred for another 10 minutes while the 
reaction mixture remained blue in colour. Then 2 g NH4Cl was added as a solid, followed 
by 10 mL of MeOH and 20 mL of saturated NH4Cl solution. This mixture was then 
washed three times with CH2Cl2 (20 mL), the combined organic washes were washed 
with saturated NaCl solution and was further dried over Na2SO4. The solvent was 
evaporated under reduced pressure to provide the crude product, which was purified by 
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column chromatography on silica gel using [CH2Cl2/MeOH (90:10) → CH2Cl2/MeOH 
(80:20) → MeOH] as eluent to provide 422 (9.1 mg, 0.03 mmol, 93%) as a white solid.  
422: Rf = 0.15 [CH2Cl2/MeOH (80:20)]; mp >200 °C; [α]
  
 
 = +57.0 (c = 0.35, MeOH); 
IR (CHCl3)ν3311, 2923, 1599, 1462, 1313, 1255, 1084 cm
-1
; 
1
H NMR (600 MHz, 
MeOD) δ 6.71 (d, J = 7.8 Hz, 1H), 6.66 (d, J = 7.8 Hz, 1H), 4.33 (d, J = 6.6 Hz, 1H), 3.66 
(s, 1H), 3.16 (d, J = 19.2 Hz, 1H), 3.02 (d, J = 11.4 Hz, 1H), 2.78 (s, 3H), 2.64-2.60 (m, 
1H), 2.39 (d, J = 9.6 Hz, 1H), 2.10-2.05 (m, 1H), 1.81 (d, J = 10.6 Hz, 2H), 1.68-1.66 (m, 
1H), 1.43-1.31 (m, 2H), 1.03-0.97 (m, 1H), 0.93–0.90 (m, 1H); 13C NMR (150 MHz, 
MeOD) δ 142.9, 140.9, 128.5, 122.1, 119.3, 117.5, 95.5, 72.1, 60.9, 47.2, 42.1, 40.6, 
40.4, 33.2, 30.1, 22.9, 20.8; MS (EI) m/z (%) 287 (92), 286 (23), 230 (22), 228 (10), 164 
(17), 149 (15), 97 (17), 84 (26), 70 (32), 57 (53), 43 (100); HRMS (EI) calcd for 
C17H21NO3: 287.1521. Found 287.1519. 
(+)-(4S,4aS,7aS,12bR)-9-Hydroxy-3-methyl-2,3,4,4a,5,6-hexahydro-1H-4,12-methan-
obenzofuro[3,2-e]isoquinolin-7(7aH)-one (16). 
 
To a suspension of 422 (8.0 mg, 0.028 mmol) and benzophenone (10.2 mg, 0.056 mmol) 
in a mixture of toluene (1 mL) and DME (1 mL) was added potassium tert-butoxide (18 
mg, 0.16 mmol) at room temperature. The resulting reaction mixture was heated at 85 °C 
for 8 hours and then the solvent was evaporated under reduced pressure to obtain the 
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crude reaction mixture, which was purified by column chromatography on silica gel using 
[CH2Cl2/MeOH (95:5) → CH2Cl2/MeOH (90:10)] as eluent to provide 16 (3.5 mg, 0.012 
mmol, 44%) as a white solid along with unreacted starting material 422 (4 mg, 0.014 
mmol, 53%). The physical and spectral properties of 16 were matched with those given in 
the literature.
[3]
 
16: Rf = 0.41 [CH2Cl2/MeOH (80:20)]; mp >200 
o
C; [lit.
[3]
 m.p. 266-267 °C (ethanol)]; 
[α]  
 
 = +190.0 (c = 0.13, dioxane), [lit. [3] [α]  
 
 = –194 (c = 0.98, dioxane); 1H NMR (300 
MHz, MeOD) δ 6.70 (dd, J = 14.1, 8.4 Hz, 2H), 4.61 (s, 1H), 3.56 (bs, 1H), 3.14 (d, J = 
19.2 Hz, 1H), 2.95-2.89 (m, 1H), 2.77-2.72 (m, 4H), 2.60-2.52 (m, 1H), 2.36-2.32 (m, 
1H), 2.00-1.87 (m, 1H), 1.80 (dd, J = 13.2, 2.7 Hz, 1H), 1.68 (dd, J = 13.2, 2.4 Hz, 1H), 
1.45-1.40 (m, 1H), 1.14-1.05 (m, 1H), 0.92-0.89 (m, 1H). 
tert-Butyl (2-((5R,6R)-6-(5-formyl-2-(methoxymethoxy)phenoxy)-5-hydroxycyclohex 
-1-en-1-yl)ethyl)(methyl)carbamate (423). 
 
Potassium phenoxide (196 mg, 0.89 mmol) and epoxide 273 (75 mg, 0.30 mmol) were 
taken in a mixture of DMF (0.8 mL0 and DME (0.8 mL) in a sealed tube and was purged 
vigorously with argon. Then catalytic amount of 18-crown-6 was added and was heated 
at 80 °C for 24 hours. Then the reaction mixture was cooled to room temperature and 
Et2O (20mL) was added, washed with sat. Na2CO3 solution (5 mL), and with water (1 
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mLx6). The organic layer was dried over Na2SO4 and slvent was evaporated under 
reduced pressure to obtain 115 mg of crude product. Pure product was separated by 
column chromatography on silica gel with [hexane/EtOAc (90:10)  hexane/EtOAc 
(50:50)] as eluent to yield 423 (88 mg, 0.20 mmol, 68%) as light yellow oil. 
423: Rf  = 0.19 [hexane/EtOAc (70:30), three run]; [α]
  
 
 = –27.6 (c = 1.0, CHCl3); IR 
(neat) ν 3430, 3004, 2973, 2927, 2846, 2725, 1685, 1593, 1582, 1483, 1257, 1153 cm-1; 
1
H NMR (300 MHz, CDCl3, rotameric) δ 7.61 (bs, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.21 (d, 
J = 8.4 Hz, 1H), 5.84 (bs, 1H), 5.25 (s, 2H), 4.67 (d, J = 3 Hz, 1H), 4.11-4.04 (m, 1H), 
3.86-3.59 (m, 1H), 3.45 (s, 3H), 2.81 (s, 3H), 2.38-2.08 (m, 4H), 1.88-1.74 (m, 2H), 1.38 
(s, 9H); 
13
C NMR (75 MHz, CDCl3, rotameric) δ 190.8, 171.1, 156.8, 153.4, 153.0, 148.9, 
146.83, 131.1, 131.0, 130.4, 130.0, 127.5, 125.9, 117.4, 116.9, 115.8, 115.5, 94.9, 94.7, 
92.5, 79.8, 66.2, 60.4, 56.5, 46.4, 34.0, 32.6, 28.4, 24.6, 21.0, 14.2. 
3-Methoxy-4-(methoxymethoxy)benzaldehyde (427). 
 
A solution of vanillin (2.0 g, 13.14 mmol) in CH2Cl2 at 0 °C was added Hunig‟s base 
(2.75 mL, 15.8 mmol) followed by MOMCl (1.19 mL, 15.8 mmoml). The resulting 
reaction mixture was stirred for 12 h. It was then diluted with H2O (30 mL) and was 
extracted with CH2Cl2 (3x20 mL). Organic washes were combined and was washed with 
brine solution (20 mL), dried over Na2SO4 and solvent was evaporated under reduced 
pressure to provide crude product. Pure product was separated by column 
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chromatography on silica gel with hexane/EtOAc (80:20) as eluent to yield 427 (36 g, 
1:1.8 ratio, 0.07 mol, 65%) as an oil. 
427: Rf  = 0.31 [hexane/EtOAc (70:30)]; IR (neat) ν 2954, 2931, 2915, 2872, 2828, 1679, 
1585, 1505, 1466, 1420, 1395, 1258, 1150, 1124, 1081 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 9.67 (s, 1H), 7.24-7.21 (m, 1H), 7.07 (d, J = 8.7 Hz, 1H), 5.13 (s, 2H), 3.74 (s, 
3H), 3.33 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 190.7, 151.8, 149.9, 130.9, 126.0, 114.6, 
109.4, 94.8, 56.2, 55.7; LRMS (EI) m/z (%) 196 (100), 166 (34), 165 (20), 151 (17), 119 
(15), 105 (13), 95 (13), 79 (19), 77 (20), 76 (18), 51 (12); HRMS (EI) calcd for C10H12O4: 
196.0736. Found 196.0738.  
2-(3-Methoxy-4-(methoxymethoxy)phenyl)oxirane (429). 
 
A 50% NaOH(aq) solution (2 mL) was added to a solution of trimethysulfonium 
methylsulfate (585 mg, 3.1 mmol) in CH2Cl2 (2 mL). Then a solution of aldehyde (508 
mg, 2.8 mmol) in CH2Cl2 (2 mL) was added and the resulting yellow suspension was 
stirred for 18 hours. Then the reaction mixture was diluted with H2O (50 mL) and the 
product was extracted with CH2Cl2 (3x25 mL). Organic washes were combined and was 
washed with brine solution (20 mL), dried over Na2SO4 and solvent was evaporated under 
reduced pressure to provide product 429 (514 mg, 2.4 mmol, 87%) as a colorless oil.    
429: Rf  = 0.28 [hexane/EtOAc (70:30)]; IR (neat) ν 3050, 2991, 2937, 2902, 2828, 1607, 
1592, 1514, 1463, 1423, 1393, 1262, 1200, 1153, 1132, 1075, 1034 cm
-1
; 
1
H NMR (300 
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MHz, CDCl3) δ 7.06 (d, J = 8.1 Hz, 1H), 6.79 (dd, J = 8.4, 2.1 Hz, 1H), 6.73 (d, J = 2.1 
Hz, 1H), 5.16 (s, 2H), 3.81 (s, 3H), 3.76 (dd, J = 3.9, 2.4 Hz, 1H), 3.45 (s, 3H), 3.05 (dd, 
J = 5.4, 3.9 Hz, 1H), 2.71 (dd, J = 5.7, 2.7 Hz, 1H); 
13
C NMR (75 MHz, CDCl3) δ 150.0, 
146.4, 131.8, 118.3, 116.4, 108.4, 95.4, 56.1, 55.8, 52.2, 51.0; LRMS (EI) m/z (%) 210 
(100), 180 (19), 165 (11), 157 (10), 151 (87), 135 (14), 105 (18), 91 (17), 77 (22), 65 
(13); HRMS (EI) calcd for C1IH14O4: 210.0892. Found 210.0891.  
(E)-tert-Butyl 3-methoxy-4-(methoxymethoxy)styryl(methyl)carbamate (431). 
 
To a solution of MeNHBoc (129 mg, 0.98 mmol) in THF (4 mL) at –78 °C was added n-
BuLi (0.41 mL, 0.98 mmol) and was stirred for 15 minutes. A solution of epoxide (173 
mg, 0.82 mmol) in THF (4 mL) was cooled to –10 °C in a separate vessel and BF3.OEt2 
was added and the reaction mixture from the first vessel was cannulated to it after 5 
minutes. The resulting reaction mixture was stirred for 3 hours and was diluted with 
CH2Cl2 (25 mL), washed with H2O (3x5 mL). Organic layer was washed with brine 
solution (8 mL), dried over Na2SO4 and solvent was evaporated under reduced pressure to 
provide crude product. Pure product was separated by column chromatography on neutral 
alumina with hexane/EtOAc (95:5) as eluent to yield 431 (118 mg, 0.36 mmol, 45%) as a 
colorless oil. 
431: Rf  = 0.45 [hexane/EtOAc (70:30)]; IR (neat) ν 2954, 2931, 2915, 2872, 2828, 1679, 
1585, 1505, 1466, 1420, 1395, 1258, 1150, 1124, 1081 cm
-1
; 
1
H NMR (400 MHz, CDCl3, 
rotameric) δ 7.69 (d, J = 14.0 Hz, 0.5H), 7.47 (d, J = 13.6 Hz, 0.5H), 7.03 (d, J = 6.8 Hz, 
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1H), 6.88-6.78 (m, 2H), 5.70 (d, J = 14.8 Hz, 1H), 5.17 (s, 2H), 3.85 (s, 3H), 3.48 (s, 3H), 
3.10 (s, 3H), 1.50 (s, 9H); 
13
C NMR (100 MHz, CDCl3, rotameric) δ 156.6, 153.4, 152.8, 
149.9, 144.9, 132.1, 128.4, 128.0, 125.9, 121.9, 118.4, 117.6, 116.8, 116.7, 113.1, 109.2, 
108.4, 108.0, 95.6, 81.4, 56.1, 55.8, 31.3, 30.6, 29.7, 28.2; LRMS (EI) m/z (%) 210 (32), 
196 (27), 162 (16), 151 (37), 144 (11), 117 (27), 77 (12), 76 (16), 57 (100); HRMS (EI) 
calcd for C17H25NO5: 323.1733. Found 323.1722.  
(–)-(1R,6S)-2-(2-Bromoethyl)-6-((tert-butyldimethylsilyl)oxy)cyclohex-2-enol (12). 
 
To a solution of alcohol (3.05 g, 13.8 mmol) in CH2Cl2 (35 mL) at –78 °C was added 
TBSCl (2.29 g, 15.2 mmol) followed by imidazole (1.03 g, 15.2 mmol). The resulting 
reaction mixture was stirred for 18 hours while it was slowly warmed to room 
temperature. Then it was diluted with CH2Cl2 (100 mL), washed with 10% CuSO4 
solution (aq) (3x30 mL), H2O (30 mL), brine solution (20 mL), dried over Na2SO4 and 
solvent was evaporated under reduced pressure to provide crude product. Pure product 
was separated by column chromatography on silica gel with hexane/EtOAc (95:5) as 
eluent to yield 12 (3.7 g, 11.0 mmol, 80%) as a colorless oil. 
12: Rf  = 0.25 [hexane/EtOAc (95:5)]; [α]
  
 
 = –47.7 (c = 1.5, CHCl3); IR (neat) ν 3553, 
2951, 2928, 2883, 2856, 1470, 1462, 1387, 1252, 1080 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 5.62 (t, J = 3.6 Hz, 1H), 3.87 (s, 1H), 3.79 (dt, J = 10.5, 3.6 Hz, 1H), 3.57-3.42 
(m, 2H), 2.78-2.67 (m, 1H), 2.63 (s, 3H), 2.62-2.53 (m, 2H), 2.19-2.12 (m, 1H), 2.03-
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1.95 (m, 1H), 1.82-1.69 (m, 1H), 1.58-1.50 m, 1H), 0.89 (s, 9H), 0.09 (s, 6H); 
13
C NMR 
(75 MHz, CDCl3) δ 134.8, 127.8, 70.8, 68.7, 38.5, 32.0, 25.9, 25.5, 24.0, 18.1, –4.4, –4.8; 
LRMS (EI) m/z (%) 279 (15), 277 (15), 198 (28), 197 (100), 179 (13), 167 (19), 105 (29), 
103 (13), 91 (21), 81 (15), 77 (16), 75 (62), 73 (14), 59 (13), 55 (13); HRMS (EI) calcd 
for C14H27BrO2Si (M
+
-C4H9): 277.0260. Found 277.0255; Anal. Calcd for C14H27BrO2Si: 
C, 50.14; H, 8.12. Found C, 50.33; H, 8.20. 
(1R,6S)-6-((tert-Butyldimethylsilyl)oxy)-2-(2-hydroxyethyl)cyclohex-2-enol (432). 
 
To a solution of acetate (1.24g, 3.96 mmol) in MeOH (6 mL) was added NaOMe/MeOH 
and was stirred at room temperature for 30 minutes. Then acidic Dowex-50 resin was 
added until the pH of the reaction mixture was changed to approximately 6-7. Then the 
solids were filtered off and the solvent was evaporated in vacuo to provide the product 
432 (0.98 g, 3.62 mmol, 91%) as a colorless oil. 
 432: Rf  = 0.27 [hexane/EtOAc (60:40)]; [α]
  
 
 = –39.6 (c = 0.54, CHCl3); IR (CHCl3) ν 
3379, 2950, 2928, 2883, 2856, 1471, 1462, 1319, 1083 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 5. 60 (s, 1H), 3.82 (d, J = 3.6 Hz, 1H), 3.76-3.53 (m, 3H),  3.36 (s, 3H), 2.60-
2.50 (m, 1H), 2.41-2.33 (m, 1H), 2.22-1.87 (m, 4H), 1.79-1.65 (m, 1H), 1.52-1.48 (m, 
1H), 0.85 (s, 9H), 0.05 (s, 6H); 
13
C NMR (75 MHz, CDCl3, rotameric) δ 134.8, 133.4, 
128.3, 126.6, 71.0, 70.8, 69.3, 68.4, 62.0, 61.0, 50.3, 39.7, 36.1, 26.2, 25.8, 25.6, 24.9, 
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24.6, 21.5, 18.1, 18.0, −4.5, −4.9; Anal. Calcd for C14H28O3Si: C, 61.72; H, 10.36. Found 
C, 61.57; H, 10.39.  
2-((5S,6R)-5-((tert-Butyldimethylsilyl)oxy)-6-hydroxycyclohex-1-en-1-yl)ethyl 4-met 
hylbenzenesulfonate (433). 
 
A solution of 432 (900 mg, 3.3 mmol) in CH2Cl2 was cooled in an ice bath, was added 
pyridine (0.53 mL, 6.6 mmol) and TsCl (756 mg, 3.96 mmol) and the resulting reaction 
mixture was stirred for 18 hours. The solvent was evaporated under reduced pressure and 
the crude product was purified by column chromatography on silica gel using 
[hexane/EtOAc (90:10) → hexane/EtOAc (80:20)] as eluent to provide 433 (565 mg, 
1.33 mmol, 40%) as an yellow oil.  
433: Rf = 0.56 [hexane/EtOAc (60:40)]; [α]
  
 
 = –20.5 (c = 1.3, CHCl3); 
1
H NMR (300 
MHz, CDCl3, rotameric) δ 7.69 (d, J = 8.1 Hz, 2H), 7.26 (dd, J = 8.4, 2.4 Hz, 2 H), 5.45 
(d, J = 12.6 Hz, 1H), 4.17-3.95 (m, 4H), 2.43-2.32 (m, 5H), 2.02-1.82 (m, 2H), 1.63-1.43 
(m, 2H), 0.83 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H); 
13
C NMR (75 MHz, CDCl3, rotameric) δ 
144.6, 144.5, 133.3, 133.1, 132.3, 129.8, 129.7, 128.0, 127.8, 127.7, 70.8, 70.6, 69.3, 
69.2, 68.7, 67.9, 34.3, 32.3, 31.5, 26.1, 25.7, 25.4, 23.9, 21.5, 21.3, 18.0, 14.1, –4.4, –4.6; 
Anal. Calcd for C23H35BrO5Si: C, 59.12; H, 8.03. Found C, 59.26; H, 6.84. 
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(–)-3-(((1S,6S)-2-(2-Bromoethyl)-6-((tert-butyldimethylsilyl)oxy)cyclohex-2-en-1-yl) 
oxy)-4-(methoxymethoxy)benzaldehyde (434). 
 
To a solution of PBu3 (0.88 mL, 3.88 mmol) in THF (7 mL) at 0 °C was added TMAD 
(0.67 g, 3.88 mmol) and was stirred for 15 minutes. The orange solution formed was 
cannulated to a solution of alcohol 12 (1.00 g, 2.98 mmol) and phenol (0.71 g, 3.88 
mmol) at 0 °C and was stirred for 18 hours. Then solvent was evaporated to provide 
crude product and was dissolved in CH2Cl2 and was adsorbed in silica. Pure product was 
separated by column chromatography on silica gel with [hexane/EtOAc (95:5)  
hexane/EtOAc (80:20)] as eluent to yield 434 (0.67 g, 1.3 mmol, 45%) as colorless oil. 
434: Rf  = 0.18 [hexane/EtOAc (90:10)]; [α]
  
 
= –30.7 (c = 1.8, CHCl3); IR (neat) ν 2951, 
2927, 2895, 2854, 2724, 1690, 1594, 1582, 1502, 1432, 1253, 1080 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ 9.85 (s, 1H), 7.66 (d, J = 1.8 Hz, 1H), 7.45 (dd, J = 8.1, 1.8 Hz, 1H), 7.27 
(d, J = 8.1 Hz, 1H), 5.78 (t, J = 3.3 Hz, 1H), 5.31 (s, 2H), 4.64 (d, J = 4.5 Hz, 1H), 4.10-
4.05 (m, 1H), 3.50 (s, 3H), 3.48-3.26 (m, 2H), 2.82-2.72 (m, 1H), 2.61-2.51 (m, 1H), 
2.27-2.20 (m, 1H), 2.13-2.06 (m, 1H), 1.94-1.84 (m, 1H), 1.80-1.69 (m, 1H), 0.80 (s, 
9H), –0.02 (s, 3H), –0.12 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 190.7, 152.9, 149.3, 
132.5, 130.9, 129.6, 126.1, 115.3, 94.8, 80.1, 69.8, 56.5, 37.7, 31.7, 27.8, 25.7, 22.6, 17.9, 
–4.8, –4.9; LRMS (EI) m/z (%) 319 (41), 318 (11), 317 (40), 239 (11), 194 (12), 193 (14), 
202 
 
179 (20), 105 (41), 95 (22), 91 (24), 81 (12), 79 (19), 78 (11), 77 (30), 75 (100), 73 (98), 
57 (16), 56 (16); HRMS (EI) calcd for C23H35BrO5Si (M
+
-C4H9): 441.0733. Found 
441.0729; Anal. Calcd for C23H35BrO5Si: C, 55.30; H, 7.06. Found C, 55.15; H, 7.08. 
(–)-3-(((1S,6S)-6-((tert-Butyldimethylsilyl)oxy)-2-(2-hydroxyethyl)cyclohex-2-en-1-
yl)oxy)-4-(methoxymethoxy)benzaldehyde (435). 
 
To a solution of acetate (63 mg, 0.13 mmol) in MeOH (1 mL) was added NaOMe/MeOH 
and was stirred at room temperature for 3 h. Then acidic Dowex-50 resin was added until 
the pH of the reaction mixture was changed to approximately 6-7. Then the solids were 
filtered off and the solvent was evaporated in vacuo to provide the product 15 (49.4 mg, 
0.11 mmol, 86%) as a yellow liquid. 
435: Rf  = 0.36 [hexane/EtOAc (60:40)]; [α]
  
 
= –23.7 (c = 1.5, CHCl3); IR (CHCl3) ν 
3610, 2950, 2927, 2896, 2855, 1690, 1594, 1582, 1503, 1462, 1432, 1389, 1254, 1155 
cm
-1
; 
1
H NMR (300 MHz, CDCl3) δ 9.87 (s, 1H), 7.64 (d, J = 1.5 Hz, 1H), 7.46 (dd, J = 
8.1, 1.5 Hz, 1H), 7.27 (d, J = 8.4 Hz, 1H), 5.87 (bs, 1H), 5.30 (s, 2H), 4.62 (d, J = 3.9 Hz, 
1H), 4.16-4.12 (m, 2H), 3.51 (s, 3H), 3.50-3.49 (m, 1H), 2.52-2.46 (m, 1H), 2.32-2.23 
(m, 2H), 2.21-2.15 (m, 1H), 1.93-1.87 (m, 1H), 1.78-1.71 (m, 1H), 0.85 (s, 9H), 0.03 (s, 
3H), −0.01 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 190.7, 152.6, 148.8, 130.9, 130.8, 
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130.3, 126.0, 115.1, 113.8, 94.7, 78.9, 68.6, 61.3, 56.5, 37.9, 26.9, 25.7, 22.1, 17.9, −4.8, 
−4.9. 
(–)-2-((5S,6S)-5-((tert-Butyldimethylsilyl)oxy)-6-(5-formyl-2-(methoxymethoxy)phen 
olxy)cyclohex-1-en-1-yl)ethyl 4-methylbenzenesulfonate (436). 
 
To a solution of alcohol 435 (540 mg, 1.27 mmol) and phenol (300 mg, 1.65 mmol) in 
THF (10 mL) at −10 °C was added PBu3 (0.43 mL, 1.91 mmol) followed by 
tetramethylazodicarboxamide (TMAD) (328 mg, 1.91mmol). The reaction mixture was 
slowly warmed to room temperature and was stirred for 3 hours. Solvent was evaporated 
under reduced pressure and purified by flash column chromatography on silica gel using 
[hexane/EtOAc (90:10)hexane/EtOAc (80:20)] as eluent to isolate product 436 (337 
mg, 0.57 mmol, 45%) as an yellow oil.  
436: Rf  = 0.42 [hexane/EtOAc (60:40)]; [α]
  
 
 = –19.9 (c = 1.8, CHCl3); IR (CHCl3) ν 
2952, 2928, 2897, 2855, 1737, 1691, 1594, 1582, 1503, 1470, 1253 cm
-1
; 
1
H NMR (300 
MHz, CDCl3) δ 9.87 (s, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 1.5 Hz, 1H), 7.47 (dd, 
J = 8.4, 1.8 Hz, 1H), 7.32-7.26 (m, 3H),  5.70 (bs, 1H), 5.29 (s, 2H), 4.53 (d, J = 4.8 Hz , 
1H), 4.15-3.99 (m, 3H), 3.49 (s, 3H), 2.60-2.50 (m, 1H), 2.45-2.34 (m, 4H), 2.23-2.04 
(m, 2H), 1.90-1.81 (m, 1H), 1.74-1.63 (m, 1H), 0.80 (s, 9H), –0.01 (s, 3H), –0.14 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 190.7, 152.7, 49.2, 144.6, 133.2, 130.8, 130.0, 129.8, 
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129.8, 127.8, 125.8, 115.2, 115.1, 94.7, 80.4, 70.1, 69.3, 56.5, 33.3, 28.0, 25.7, 22.7, 21.6, 
17.9, −4.9, −5.0; Anal. Calcd for C30H42O8SSi: C, 60.99; H, 7.17. Found C, 61.29; H, 
6.98. 
 (+)-(((1S,2S)-3-(2-Bromoethyl)-2-(2-(methoxymethoxy)-5-(oxiran-2-yl)phenoxy)cycl 
ohex-3-en-1-yl)oxy)(tert-butyl)dimethylsilane (437). 
 
A 50% NaOH(aq) solution (2 mL) was added to a solution of trimethysulfonium 
methylsulfate (111 mg, 0.58 mmol) in CH2Cl2 (1 mL) and was stirred for 5 minutes. Then 
a solution of aldehyde 434 (240 mg, 0.48 mmol) in CH2Cl2 (3 mL) was added and the 
resulting suspension was stirred for 18 hours. Then the reaction mixture was diluted with 
H2O (10 mL) and the product was extracted with CH2Cl2 (4x8 mL). Organic washes were 
combined and was washed with brine solution (8 mL), dried over Na2SO4 and solvent 
was evaporated under reduced pressure to provide product 437 (215 mg, 0.42 mmol, 
87%) as a colorless oil.    
437: Rf  = 0.26 [hexane/EtOAc (90:10)]; [α]
  
 
= +5.3 (c = 1.2, CHCl3); IR (neat) ν 3046, 
2951, 2927, 2895, 2855, 1607, 1588, 1507, 1429, 1246, 1077 cm
-1
; 
1
H NMR (300 MHz, 
CDCl3) δ 1.12 (dd, J = 8.4, 1.5 Hz, 1H), 7.00 (dd, J = 6.0, 2.1 Hz, 1H), 6.89-6.83 (m, 
1H), 5.78 (s, 1H), 5.20 (d, J = 1.2 Hz, 1H), 4.45 (s, 1H), 4.09-4.04 (m, 1H), 3.79 (t, J = 
3.0 Hz, 1H), 3.49 (s, 3H), 3.47-3.30 (m, 2H), 3.11-3.07 (m, 1H), 2.84-2.71 (m, 2H), 2.63-
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2.53 (m, 1H), 2.26-2.20 (m, 1H), 2.10-2.02 (m, 1H), 1.94-1.83 (m, 1H), 1.76-1.66 (m, 
1H), 0.82 (s, 9H), –0.02 (d, J = 1.2 Hz, 3H), –0.08 (d, J = 3.6 Hz, 3H); 13C NMR (75 
MHz, CDCl3, rotameric) δ 149.0, 148.9, 147.7, 147.6, 132.4, 131.8, 131.7, 129.6, 129.5, 
119.3, 119.0, 116.9, 116.8, 114.2, 114.1, 95.3, 79.6, 79.5, 69.0, 68.9, 56.2, 52.2, 52.1, 
51.0, 38.0, 31.9, 27.0, 26.9, 25.7, 22.1, 18.0, –4.8, –4.9; LRMS (EI) m/z (%) 233 (27), 
231 (27), 210 (18), 197 (28), 193 (33), 179 (29), 165 (12), 160 (16), 158 (14), 151 (27), 
149 (24), 135 (15), 123 (13), 121 (14), 111 (14), 105 (29), 97 (22), 91 (19), 85 (19), 83 
(24), 77 (30), 75 (100), 69 (29), 57 (50); HRMS (EI) calcd for C24H37BrO5Si: 512.1594. 
Found 512.1572. 
tert-Butyl (E)-3-(((1S,6S)-2-(2-bromoethyl)-6-((tert-butyldimethylsilyl)oxy)cyclohex-
2-en-1-yl)oxy)-4-(methoxymethoxy)styryl(methyl)carbamate (439): 
 
To a solution of MeNHBoc (36 mg, 0.27 mmol) in THF (4 mL) at –78 °C was added n-
BuLi (0.14 mL, 0.26 mmol) and was stirred for 15 minutes. A solution of epoxide 437 
(126 mg, 0.25 mmol) in THF (4 mL) was cooled to –10 °C in a separate vessel and 
BF3.OEt2 (0.03 mL, 0.25 mmol) was added and the reaction mixture from the first vessel 
was cannulated to it after 5 minutes. The resulting reaction mixture was stirred for 3 
hours and was diluted with CH2Cl2 (25 mL), washed with H2O (3x5 mL). Organic layer 
was washed with brine solution (8 mL), dried over Na2SO4 and solvent was evaporated 
under reduced pressure to provide crude product. Pure product was separated by column 
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chromatography on neutral alumina with hexane/EtOAc (95:5) as eluent to yield 439 (14 
mg, 0.02 mmol, 9%) as colorless oil. 
439: Rf = 0.26 [hexane/EtOAc (90:10)]; IR (neat) ν 3089, 3045, 2951, 2927, 2895, 2855, 
1708, 1645, 1601, 1577, 1508, 1473, 1416, 1368, 1322, 1247, 1144 cm
-1
; 
1
H NMR (300 
MHz, CDCl3, rotameric) δ 7.70-7.46 (m, 1H), 7.08-7.03 (m, 2H), 6.91 (bs, 1H), 5.78 (s, 
1H), 5.68 (d, J = 14.4 Hz, 1H), 5.21-5.17 (m, 2H), 4.47 (bs, 1H), 4.11-4.06 (m, 1H), 3.50 
(s, 3H), 3.49-3.44 (m, 4H), 3.12 (s, 3H), 2.89-2.77 (m, 1H), 2.65-2.55 (m, 1H), 2.27-2.20 
(m, 1H), 2.11-2.03 (m, 1H), 1.94-1.88 (m, 1H), 1.76-1.68 (m, 1H), 1.53 (s, 9H), 0.83 (s, 
9H), –0.03 (s, 3H), –0.01 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.1, 158.4, 146.1, 
132.6, 132.1, 129.5, 128.4, 118.6, 117.2, 115.4, 95.5, 69.1, 56.2, 38.0, 32.0, 28.3, 27.1, 
25.8, 22.1, 18.0, –4.8, –4.9; LRMS (EI) m/z (%) 319 (19), 317 (19), 279 (13), 179 (15), 
178 (20), 167 (33), 149 (93), 129 (26), 105 (31), 95 (23), 91 (17), 83 (26), 77 (12), 57 
(100); HRMS (EI) calcd for C30H48BrNO6Si: 625.2434. Found 625.2449. 
 
 
 
 
 
 
 
207 
 
6. Selected Spectra 
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